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Introduction
Cardiovascular disease (CVD) is the principle cause of mortality in all developed 
countries. The prevalence will increase also in developing countries by their 
adoption of the “Western” lifestyle with accompanying risk factors like high-fat 
diet, smoking and lack of exercise. The results of the ‘Global burden of disease 
studies’ pointed out that in the coming decennia atherosclerotic disease will be 
the most common cause of death worldwide (1). In total 49.952 persons died as a 
consequence of CVD in the Netherlands in 2000, this corresponds with 36% of the 
total mortality. Hyperlipidemia is like hypertension, obesity, diabetes mellitus and 
smoking a well-known risk factor of CVD. 
Definition of FCH
Familial combined hyperlipidemia (FCH) is the most common heritable lipid 
disorder, with an estimated prevalence of 1 - 2% in the general population and 
10 - 20% in survivors of myocardial infarction (2). Recently, several studies have 
demonstrated that FCH is associated with a 2- to 5 fold increased risk of premature 
CVD (3-5). FCH was originally identified in the early 1970s as a new inherited 
lipid disorder, characterized by multiple lipoprotein phenotypes defined by the 
presence of elevations of plasma total cholesterol (TC) and/or triglyceride (TG) 
concentration in affected individuals and strongly associated with premature CVD 
(6-8). The lipoprotein phenotype can vary in time both in affected individuals 
and in their first-degree relatives, hence the description of this disorder by some 
as multiple type hyperlipidemia. Other major characteristics of FCH include 
elevated apolipoprotein B (apoB) levels (9-13), the preponderance of atherogenic 
small dense low density lipoprotein (sdLDL) particles (12-16) and a decreased 
high density lipoprotein cholesterol (HDL-chol) concentration (17). Furthermore 
subjects with FCH are frequently obese and insulin resistant (4,18-21). Despite 
more than 30 years of investigation, the genetic and metabolic backgrounds of this 
disorder have not been elucidated in detail (21-25). It seems to be a metabolically 
and genetically heterogeneous disorder (14). Because of the absence of a specific 
clinical or metabolic marker, and because of the characteristic variability in the 
presenting phenotype, family studies are necessary to establish the diagnosis of 
FCH in a single patient.
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Metabolic features of FCH
Several disturbances in metabolic pathways have been suggested to be 
pathophysiologically important for the FCH phenotype. In general, FCH is thought 
to be caused by hepatic overproduction of very low density lipoprotein (VLDL) 
particles (26,27) with or without an impaired physiological clearance of TG-rich 
lipoproteins both of exogenous and of endogenous origin (28,29). Over the past few 
years, several other metabolic mechanisms that may contribute to the pathogenesis 
of FCH have been proposed (24). These include an altered metabolism of fatty 
acids (FA) (18,30), increased plasma free fatty acids (FFA) (30-32), a reduced insulin 
sensitivity (18,20,33), a prolonged and exaggerated post-prandial lipaemia, an 
impaired hydrolytic capacity of lipoprotein lipase (LpL) (34), or elevated plasma 
levels of an inhibitor of LpL, apoCIII (35). 
Because no single metabolic defect detected thus far can fully account for the 
FCH phenotype, it is hypothesized that even with a strict definition, the group of 
FCH patients might turn out to manifest a mixture of various disease entities, with a 
number of metabolic defects and possible genetic markers. Therefore, FCH may be 
considered more like a syndrome showing overlapping characteristics with other 
entities, such as hyperapobetalipoproteinemia (36), the ‘atherogenic lipoprotein 
phenotype’(37), familial dyslipidemic hypertension (38,39) and the insulin 
resistance syndrome (40). 
Genetic origin of FCH
Genetic analysis so far did also not reveal a genetic marker specific for FCH. FCH 
was originally assumed to be an autosomal dominant trait (6). However, subsequent 
reanalysis of the original data of Goldstein et al. provided evidence consistent with 
a multigenic mode of inheritance. Since then, a number of segregation analyses 
with multiple sets of families have indicated complex inheritance. These studies 
have suggested major gene effects on serum TG levels (41), apoB levels (10-12), 
LDL subfraction profile (12,14,23) and insulin resistance (42). Genome wide 
linkage studies have indicated that several chromosomal regions harbor genes 
contributing to the lipid profile of FCH. In Finnish families with FCH, 5 loci on 
chromosome 1q21, 2q31, 10p11.2, 10q11.2-10qter and 21q21 were identified 
(43,44), whereas 4 loci on chromosome 2p, 11p, 16q and 19q were found in Dutch 
families with FCH (45,46). Two potentially new loci on 6q and 8p were identified in 
2 large cohorts of families with FCH from England (47). The loci on 1q21 have been 
confirmed in German and Chinese FCH families and in families from the NHLBI 
family heart study (48,49). Recently, a combined data analysis of Dutch and Finnish 
genome wide scans for FCH identified 3 regions, on chromosomes 16q24.1, 2p25.1 
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and 9p23 with maximum LOD scores of 3.6, 2.2 and 2.1, respectively, which most 
likely harbor allelic variants for FCH. The 2p25.1 region was detected for the FCH 
trait whereas the other 2 regions were detected for the low HDL-chol trait (50). In 
addition, regions on 2p, 8q, 16q and 20q have been detected for low HDL-chol in 
the Finnish families with FCH and a region on 1p has been detected for apoB in 
Dutch families with FCH (51). The current genetic model suggests that FCH may 
result from the combination of a dominant major gene(s) with a number of modifier 
genes influencing plasma lipid levels. The identification of such modifier genes may 
help in reducing the problem of genetic heterogeneity of FCH. Several candidate 
genes have been evaluated in their contribution to the FCH lipid phenotype. 
These include genes involved in lipid metabolism (LpL (52-54), hepatic lipase 
(HL) (55,56), apoAI/CIII/AIV (57-62) and apoAV (63)), adipose tissue metabolism 
(tumor necrosis factor (TNF) (64), hormone sensitive lipase (HSL) (65,66)), insulin 
resistance and fatty acid (FA) metabolism (intestinal fatty acid binding protein 
(FABP) (67), insulin receptor substrate gene and beta3-adrenergic receptor (68) and 
peroxisome proliferator activated receptor (PPAR)-gamma (68,69)). To summarize 
the results of these studies, only LPL and apoAI/CIII/AIV genes have been most 
consistently associated as modifier genes in FCH. 
To further unravel the genetics of FCH, animal models have been developed. 
In 1998 a locus (Hyperlip1) in a mutant strain, HcB-19/DEM (HcB-19), has been 
identified, which strongly links to the FCH features in these mice (70). A few years 
later it was shown that these mice had a decreased expression of the thioredoxin 
interacting protein (TXNIP). By sequencing, a spontaneous nonsense mutation 
(T97Z) in the TXNIP gene was identified (71). The TXNIP gene in mice is located on 
chromosome 3F2.2, which is synthetic to chromosome 1q21 in humans, a region to 
which a major contributor of the FCH phenotype was mapped in a Finnish, German 
and Chinese population (43,48). However, we (72) and others (73) did not find any 
sequence variants in the TXNIP gene in subjects with FCH, so the TXNIP gene is 
not involved as a major contributor to the FCH phenotype. Recently, Pajukanta et 
al. (73) showed that FCH is strongly linked and associated with the gene encoding 
upstream transcription factor 1 (USF1). This is an intriguing finding as USF1 is also 
located at chromosome 1q21 and regulates the expression of several genes involved 
in glucose and lipid metabolism. Therefore, it may be a potentially good candidate 
as a major gene involved in the pathogenesis of FCH. 
All these data indicate that FCH may develop from the additive effects of many 
genes, a high degree of genetic heterogeneity, and gene-gene and gene-environment 
interactions.
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Evaluation of diagnostic criteria
It is clear that FCH is complex and heterogeneous, emphasizing the need for a 
variety of approaches, both metabolic and genetic, and for studies of multiple 
populations. Before multiple populations can be compared there has to be 
agreement about the diagnostic criteria. FCH still lacks a consensus on diagnostic 
criteria. Traditionally, the diagnosis FCH in a single patient is based on the presence 
of plasma TC and/or TG levels >90th percentile adjusted for age and gender, in 
a family with multiple type hyperlipidemia and the presence of premature CVD. 
Although these internationally accepted diagnostic criteria have been formulated 
for FCH, not all research groups use the same criteria to establish the diagnosis as 
reviewed (74,75). For example the 95th percentiles or even absolute values for TC 
and /or TG levels, not adjusted for age and gender, are used in some studies (75-
77). But there are more fundamental problems. Amongst the most important is that 
the lipid phenotype can vary substantially within any individual (78,79). When the 
traditional lipid phenotype is variable and insufficient, accurate clinical diagnosis 
in individual subjects is not possible. Equally important genetic characterization 
becomes problematic and biologically correct hypothesis may be falsely rejected 
because of inaccurate diagnosis. Furthermore, the phenotype FCH based on TC 
and/or TG levels alone incompletely accounts for what is going on physiologically. 
It is obvious that there is a need for unequivocal diagnostic criteria to establish the 
diagnosis of FCH. This may facilitate comparisons of different populations as well as 
the search for the clue(s) underlying this most common lipid disorder.
Outline of the thesis
The main aim of this thesis was to evaluate the intra-individual variation in lipid 
phenotype over a period of 5 year (chapter 2) and to elucidate more consistent 
and unequivocal diagnostic criteria for FCH which can be used in clinical practice 
(chapter 3). Furthermore, we reviewed about several metabolic disturbances that may 
contribute to the pathogenesis of FCH (chapter 4) and investigated the contribution 
of some metabolic factors in relation to the FCH phenotype and its increased risk of 
CVD (chapter 5-8). 
Re-evaluation of the diagnostic criteria of FCH
The intra-individual variation in lipid phenotype is considered to be one important 
fundamental problem in the research for FCH. In chapter 2 we evaluate the 
variability in lipid phenotype expression, apoB level, and LDL subfraction profile 
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in a large cohort of 299 individuals of 32 well-defined FCH families over a period 
of 5 year. In addition the factors affecting the lipid phenotype expression are 
investigated. 
A still ongoing problem in the research of FCH is the lack of consistent and 
worldwide used diagnostic criteria. Until now, different research groups use 
different definitions of FCH (74,75). In chapter 3 we evaluate which diagnostic 
features most adequately predict FCH in our 5-year follow-up cohort. To facilitate 
the implementation of these new diagnostic criteria in clinical practice we provide 
a nomogram to simply and accurately diagnose FCH. 
Metabolic features of FCH and the increased risk of CVD
The exact pathophysiology of FCH is still unknown. Over the past few years 
evidence has emerged that a primary defect in adipose tissue metabolism may be 
the culprit of FCH, resulting in reduced FA trapping in adipose tissue and increased 
FA flux to the liver resulting in high apoB production and contributing to insulin 
resistance. In chapter 4 we present a review about the metabolic pathogenesis of 
FCH with emphasis on the role of insulin resistance, adipose tissue metabolism and 
FFA. 
Since FCH is accompanied by an increased risk of CVD, the most commonly used 
approach to estimate coronary heart disease risk is based on the assay of plasma 
TC, TG and HDL-chol, with calculation of LDL-chol by means of the Friedewald 
formula. ApoB measurement has been proposed as the first line risk estimator for 
coronary heart disease instead of the conventional lipid-oriented approach (80). 
In chapter 5 we compare in 506 members of families with FCH the validity of 
the lipid-based and apoB-based approaches in risk evaluation of coronary heart 
disease. 
The plasma lipid and lipoprotein levels are relatively moderately elevated 
in subjects with FCH and do not fully explain the increased risk of CVD. 
Hyperhomocysteinemia as a disorder of methionine metabolism is also a well-
known independent risk factor for CVD (81,82). In chapter 6 we investigate 
whether subjects with FCH have higher plasma homocysteine concentrations 
than controls, and whether homocysteine contributes to the increased risk of CVD 
in FCH. Furthermore, we evaluate whether parameters of lipid and lipoprotein 
metabolism are associated with the homocysteine level.
Insulin resistance coincides with alterations in lipid metabolism, such as 
hypertriglyceridemia, low HDL- chol, increased apoB levels and a predominance 
of sdLDL particles. Because all these features are also characteristics of FCH, 
the existence of insulin resistance may be an important factor modulating FCH 
phenotype. In chapter 7 we explore the role of insulin resistance in FCH subjects 
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with different lipid phenotypes. Moreover, we study the interdependence between 
insulin resistance and change in lipid phenotype expression over a 5-year period. 
In addition we investigate whether insulin resistance or obesity can explain the 
elevated apoB levels and the high concentration of sdLDL in FCH.
Leptin is a hormone increased in obese subjects (83). Elevated levels of leptin are 
also associated with insulin resistance (84). Both obesity and insulin resistance are 
characteristics of FCH and therefore leptin may be elevated in FCH subjects. So far, 
only two small studies have studied the relationship between leptin concentrations 
and FCH, with conflicting results (85,86). Leptin is an independent risk factor for 
CVD (87). In chapter 8 we investigate whether leptin levels in our large cohort of 
well-defined male and female subjects with FCH are elevated independent of their 
BMI, indicating that adipose tissue metabolism is disturbed in FCH. The second 
objective is to consider whether leptin levels contribute to the increased risk for 
CVD in FCH. 
The summary and conclusions are provided in chapter 9
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Abstract
Familial Combined Hyperlipidemia (FCH) is characterised by a variable expression 
of hypercholesterolemia and/or hypertriglyceridemia. We evaluated the variability 
in lipid phenotype expression over a 5-year period and studied factors affecting the 
lipid phenotype expression. A total of 32 families (299 subjects) were studied in 
1994 and in 1999. Subjects were classified as having FCH when total cholesterol 
and/or triglyceride levels exceeded the 90th percentile adjusted for age and sex. 
In 1994, 93 (31%) of the 299 subjects were affected, whereas 206 (69%) of the 
subjects were unaffected relatives. In 1999, the diagnosis of FCH was consistent 
in 69 (74%) of the 93 subjects. So, 26% of the FCH subjects in 1994 showed a 
sporadic normolipidemic pattern (i.e. total cholesterol and/or triglycerides <90th 
percentile) in 1999. Among the 206 non-affected relatives in 1994, 178 (86%) 
remained unaffected in 1999, and 28 (14%) developed an FCH lipid phenotype. 
Multiple regression analysis showed that sex (odds ratio 2.03 (CI 95% 1.09-3.87), 
p=0.03) and body mass index (odds ratio 1.14 (CI 95% 1.05-1.24), p<0.01) 
significantly contributed to the variability in lipid phenotype expression. Thus, 
the diagnosis FCH, based on plasma total cholesterol and/or triglyceride levels, is 
consistent in only 74% of the subjects over a 5-year period. 
Two other major characteristics in our FCH group, compared with the unaffected 
relatives, included elevated apolipoprotein B (apoB) levels and the presence of 
small dense low density lipoprotein (LDL), as reflected by a low value of parameter 
K; (apoB (mg/l) 1461 ± 305 versus 997 ± 249 (p<0.001); K-value –0.22 ± 0.19 versus 
–0.02 ± 0.19 (p<0.001), respectively). We now report that the apoB concentration 
and the K-value show less variability in time and are more consistently associated 
with FCH, inasmuch as affected FCH subjects, compared with the unaffected 
relatives, persistently show a higher apoB level and a lower value of parameter K, 
reflecting small dense LDL, even when they present a sporadic normolipidemic 
pattern.
In conclusion, our results emphasize the need for reevaluation of the diagnostic 
criteria for FCH. We demonstrate that apoB and small dense LDL are attractive new 
candidates for defining FCH. Further studies are indicated to evaluate the role of 
apoB and small dense LDL as diagnostic criteria for FCH.
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Introduction 
Familial Combined Hyperlipidemia (FCH) was first described as a new autosomal 
inherited lipid disorder in 1973 by Goldstein et al. (1). FCH is the most common 
form of heritable lipid disorder with an estimated prevalence of 1.0 to 2.0% in 
the general population and 10 to 20% in survivors of myocardial infarction (2). 
The hyperlipidemia is characterised by elevations of plasma total cholesterol (TC) 
and/or triglyceride (TG) concentration and is therefore also known as ‘multiple type 
hyperlipidemia’. Such a lipid profile is frequently associated with an unfavourable 
decrease in high-density lipoprotein cholesterol (HDL-C) concentration, an 
elevated apolipoprotein (apo) B concentration and a preponderance of atherogenic 
small dense low density lipoprotein (LDL) particles (3-7). In general, FCH is thought 
to be caused by hepatic very low density lipoprotein (VLDL) overproduction (8,9) 
with or without impaired clearance of TG-rich lipoproteins (10,11), of exogenous 
and of endogenous origin. Over the past few years several other different metabolic 
pathways in the pathogenesis of FCH have been proposed as recently reviewed 
(12). Other syndromes appear to exhibit overlapping aetiologies with FCH, such 
as hyperapobetalipoproteinemia, the atherogenic lipoprotein phenotype, familial 
dyslipidemic hypertension and syndrome X (13-15). 
FCH was originally assumed to be an autosomal dominant trait. However, 
subsequent reanalyses of the original data of Goldstein et al. (1) provided 
evidence consistent with a multigenic mode of inheritance. Since then, a number 
of segregation analyses with multiple sets of families have indicated complex 
inheritance. These studies have suggested major gene effects for serum TG levels 
(16) and apoB levels (17,18). Bivariate analysis has suggested common genetic 
mechanisms influencing LDL particle size and apoB levels (19). Despite extensive 
research in metabolic and genetic fields, there is still no specific metabolic or 
genetic marker for FCH. Therefore, family studies are still necessary to establish the 
diagnosis FCH in a single patient. 
One of the characteristic features of FCH is its variability in lipid and lipoprotein 
pattern among family members and even in the individual patient (4). To our 
knowledge, there are no data published about the variability in lipid phenotype 
expression over a period of several years. In this 5-year follow-up study, we evaluate 
the variability in lipid phenotype expression, apoB level and small dense LDL in 
a large cohort of 32 well-defined FCH families, and study the factors affecting the 
lipid phenotype expression. 
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Subjects and Methods
Study population
The study population consisted of kindreds and probands of families with known 
FCH, who were recruited in 1994 and followed up in 1999. The recruitment of 
FCH kindreds took place in 1994 via known affected probands who were attending 
the outpatient clinic as described previously (20). The probands exhibited a 
combined hyperlipidemia with both plasma TC and TG concentrations >90th 
percentile using the age- and gender-related 90th percentile upper levels of the 
prospective cardiovascular Munster (PROCAM) study (21), confirmed by repeated 
measurement; these subjects were on lipid-lowering diets but were taking no lipid-
lowering drugs. Families were included when a multiple type hyperlipidemia with 
elevated levels of plasma TC and/or TG was present in first-degree relatives. Thus, 
besides the proband presenting combined hyperlipidemia, the presence of at least 
one first-degree relative with hypertriglyceridemia (HTG), hypercholesterolemia 
(HC), or combined hyperlipidemia was obligatory. Furthermore, at least the 
proband or 1 of the first-degree relatives should have premature cardiovascular 
disease (CVD) before the age of 60 years. In addition, the 95th percentile for plasma 
TC and TG was used if the body mass index (BMI) exceeded 30 kg/m2, or an alcohol 
consumption of more than 2 units per day was present. Families were excluded 
when a secondary cause of the hyperlipidemia was diagnosed in the proband (i.e. 
diabetes mellitus, hypothyroidism and hepatic or renal impairment). None of the 
probands were homozygous for the apo e2 allele and none of the probands or 
first-degree relatives had tendon xanthomas. All relatives of probands above the 
age of 20 years in 1999 and who participated in 1994 and 1999 were included. 
In this study, all individuals were Caucasian. This resulted in a total of 32 families, 
providing 299 subjects (excluding spouses). At both points of measurement (1994 
and 1999), all subjects filled out a questionnaire about their previous medical 
histories, especially cardiovascular status, medication, smoking and drinking 
habits and, hormonal status in women. BMI was determined for all subjects. After 
withdrawal of lipid-lowering medication for 4 weeks and after an overnight fast, 
venous blood was drawn by venipuncture. The subjects were classified as having 
FCH when plasma TC and/or TG levels exceeded the 90th percentile, based on 
the PROCAM study (21). Note that these percentiles are adjusted for age and sex. 
Unaffected relatives were defined by TC and TG levels <90th percentile. The study 
protocol was approved by the ethics committee of the University Medical Center 
Nijmegen. 
Plasma lipid, lipoprotein and apolipoprotein analysis
Plasma TC and TG concentrations were determined by enzymatic, commercially 
available reagents (Boehringer-Mannheim, Germany, catalog. No. 237574 and Sera 
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Pak, Miles, Belgium, catalog. No. 6639, respectively). VLDL-cholesterol (VLDL-C) was 
isolated from whole plasma by ultracentrifugation at density (d)=1.006 g/ml for 16 h 
at 36,000 rpm in a fixed angle rotor (TFT 45.6 rotor, Kontron), in a Beckman L7-55 
ultracentrifuge. HDL-cholesterol (HDL-C) was determined by the polyethylene glycol 
6000 method (22). LDL-cholesterol (LDL-C) was calculated by subtraction of VLDL-
C and HDL-C from plasma TC. Total plasma apoB concentrations were determined 
by immunonephelometry as recently described in detail elsewhere (23,24). To 
achieve accurate results in relation to the Center for Disease Control Standardization 
Program, obtained values were recalculated on the basis of an exchange of sera with 
dr.Marcovina (Northwest Lipid Research Laboratory, Seattle, WA, USA). 
Low density lipoprotein subfraction profile analysis
LDL subfractions were sepa rated by single-spin density gradient ultracentrifugation 
(25). Each individual LDL subfraction profile was defined by a continous variable 
K, as described in detail previ ously (26). Briefly, after ultra centrifu gation, the LDL 
subfractions were visible as distinct bands in the middle of the tube. Up to five 
LDL subfracti ons could be distinguished i.e. LDL1 (d=1.030-1.033 g/ml), LDL2 
(d=1.033-1.040 g/ml), LDL3 (d=1.040-1.045 g/ml), LDL4 (d=1.045-1.049 g/ml) and 
LDL5 (d=1.049-1.054 g/ml). The subfractions were carefully aspirated by means 
of a pasteur pipette. The volumes were calculated by weighing after correction 
for the densities. Subsequently, cholesterol was determined in each fraction, the 
concentrati ons were corrected for dilution and incomplete recoveries. The relative 
cholesterol concentrations (%chol) in the LDL subfractions were used to calculate 
parameter K as a continu ous variable, which best describes each individual 
LDL subfraction profile (27). A negative value (K<0) reflects a more dense LDL 
subfracti on profile, and a positive K value (K>0) a more buoyant profile. 
Statistical analysis
Differences in baseline characteristics for anthropometric measurements, lifestyle 
variables including lipid lowering medication use (yes/no), smoking (yes/no), use 
of >2 alcoholic consumptions a day (yes/no), CVD (yes/no), lipid and lipoprotein 
parameters, apoB levels and the value of parameter K, between subjects with FCH 
and their non-affected relatives were tested for statistical significance by using the 
2-tailed Fisher exact test for dichotomous variables and the t-test for continuous 
variables. 
Before the final analyses, we were interested in determing whether changes in 
time in each group were different between men and women. We included sex in the 
linear mixed model for each dependent variable separately. We were particularly 
interested in the third-order interaction term among sex, time and group. We found 
that this item was never significant; therefore the sex variable was removed from 
the final model.
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A linear mixed model with repeated measurements was used to test differences in 
lipid and lipoprotein concentrations, apoB level, K-value and BMI for statistical 
significance between the points of measurement (1994 and 1999) and between 
the groups (I,II,III and IV) for each dependent variable separately. The interaction 
between time and group and time, group and sex was also included in the model. 
The dependent variables were TC, TG, LDL-C, HDL-C, apoB, parameter K and BMI. 
The independent variables were time (1994, 1999), and group (I, II, III and IV) and 
their interaction. Group I was defined by subjects who were affected (FCH) in 1994 
and showed a normolipidemic pattern (NL) in 1999, defined by TC and TG levels 
<90th percentile, corrected for age and sex. Group II was defined by subjects who 
were affected both in 1994 and 1999. Group III consisted of normolipidemic FCH 
relatives in 1994 who developed an FCH lipid phenotype in 1999 and group IV 
consisted of those subjects who were non-affected i.e. TC and TG <90th percentile 
in 1994 and in 1999. The mean levels by time and group were estimated using the 
appropriate least square means. Adjusted p-values according to Tukey-Kramer were 
presented, and a p-value less than 0.05 was considered to be significant.
Logistic regression was used to test differences in percentages for statistical 
significance between the points of measurement and between groups, with the 
appropriate likelihood ratio for each dependent variable assessed separately. The 
dependent variables were lipid-lowering medication use (yes/no), smoking (yes/no), 
use of >2 alcoholic consumptions a day (yes/no) and CVD (yes/no). The independent 
variables were identical to those described in the linear mixed model.
Multiple variable logistic regression with forward selection procedures was used 
to select the variables that contributed independently to a switch in lipid phenotype. 
A switch (yes/no) was here defined as change for any reason from FCH in 1994 to 
NL in 1999, or the reverse. The independent variables were sex, age, BMI, smoking, 
alcoholic consumption, CVD and the use of lipid-lowering medication.
Statistical analysis was performed by using procedures available in the Statistical 
Analysis System software package (1996, SAS Institute Inc.).
Results
A total of 32 families (299 subjects) were studied in 1994 and in 1999. In 1994, 
93 (31%) of the 299 subjects were affected (FCH), whereas 206 (69%) of the 
subjects were unaffected, with TC and TG levels <90th percentile. Table 1 shows 
the anthropometric measurements, life style variables, including smoking habits, 
use of alcohol and lipid-lowering medication and lipid and lipoprotein variables, 
apoB levels and parameter K values for FCH and non-FCH (unaffected) relatives 
in 1994. The ratio of women to men was not statistically significant different 
between the affected and unaffected FCH family members. The mean age of the 
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group of affected subjects, compared with the group of unaffected FCH family 
members, was significantly higher, and they had also a higher BMI. This group also 
had more subjects with CVD, and the consumption of more than two alcoholic 
beverages per day was more frequent. In contrast, smoking habits and the use of 
oral contraceptives , including postmenopausal estrogen replacement therapy, was 
not significantly different between the affected and unaffected subjects. In 1994, 
106 (68%) of the women were premenopausal and 23 (22%) had FCH, whereas 
83 (78%) were unaffected. In 1994, among the 50 (32%) postmenopausal women, 
27 (54%) had FCH and 23 (46%) were unaffected. Fifteen (14%) premenopausal 
women in 1994 were postmenopausal in 1999; this finding was associated with a 
switch from unaffected to an affected FCH lipid phenotype expression in 3 women. 
Twelve women did not show a change in lipid phenotype expression (7 women were 
unaffected, and 5 women had FCH in 1994 and also in 1999). Thus, 20% of the 
women who were premenopausal in 1994 and postmenopausal in 1999 showed a 
switch in lipid phenotype expression, which was not significantly different from the 
percentage of lipid phenotype switchers (18%) observed among the postmenopausal 
women in 1994 and 1999. Therefore, the change to postmenopausal status is not 
the only reason for the switch in lipid phenotype expression.
All affected FCH subjects with CVD used lipid-lowering medication, whereas 
8 subjects used lipid-lowering medication for primary prevention of CVD. In the 
group of the unaffected subjects, 10 subjects used lipid-lowering medication; 4 
of these subjects used it for secondary prevention, whereas the other 6 subjects 
without a history of CVD and without increased TC and/or TG levels used lipid-
lowering medication. In total 5, unaffected subjects with CVD did not use lipid-
lowering medication. 
In 1994, 3 (1%) of the relatives had diabetes mellitus. Of these 3 relatives, 2 had 
diabetes mellitus type II and were classified as having FCH, and 1 relative had 
diabetes mellitus type I and was unaffected. In 1999, 6 subjects had developed 
diabetes mellitus type II (de novo), which was not associated with a change in lipid 
phenotype expression; 2 subjects remained unaffected in 1994 and also in 1999, 
whereas 4 subjects had FCH in 1994 and also in 1999. Note that TC and TG values 
of these 6 subjects were well within the range of the unaffected and affected FCH 
group, respectively. 
By definition the FCH group had significantly higher TC and TG concentrations. 
The FCH group exhibited also significantly higher concentrations of VLDL-C, 
VLDL-triglycerides (VLDL-TG) and LDL-C and lower concentrations of HDL-C. 
Furthermore, significantly higher levels of apoB and lower values of parameter K, 
reflecting small dense LDL, were found in the FCH group compared to the group of 
unaffected relatives (Table 1). 
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Table 1  Anthropometric measurements, lifestyle variables, lipid and (apo)lipoprotein concentrations, 
and value of parameter K, reflecting LDL heterogeneity, in 32 FCH families (299 subjects)
FCH
Subjects
unaffected
subjects p*
Subjects, n (%) 93 (31%) 206 (69%) <0.001
Women/men, n 50 / 43 106 / 100 NS
Age, y 46.6 ± 14.8 38.4 ± 15.2 <0.001
BMI, kg/m2 26.9 ± 3.5 23.3 ± 3.2 <0.001
CVD, n (%)  14 (15)  9 (4) <0.001
Lipid-lowering medication, n (%)  23 (25)  10 (5) <0.001
Smoking (≥1 cigarette/d), n (%)  24 (26)  50 (24) NS
Alcohol (>2U/d), n (%)  10 (11)  7 (3)      0.013
OAC, n (%)  12 (13)  38 (18) NS
TC, mmol/L 7.04 ± 1.19 5.30 ± 1.03 <0.001
TG, mmol/L 3.26 ± 2.30 1.16 ± 0.51 <0.001
VLDL-C, mmol/L 1.44 ± 1.01 0.41 ± 0.26 <0.001
VLDL-TG, mmol/L 2.30 ± 1.89 0.66 ± 0.43 <0.001
HDL-C, mmol/L 1.03 ± 0.31 1.25 ± 0.32 <0.001
LDL-C, mmol/L 4.59 ± 1.28 3.65 ± 0.96 <0.001
ApoB, mg/L 1461 ± 305 997 ± 249 <0.001
K-value -0.22± 0.19 -0.02± 0.19 <0.001
OAC indicates oral contraceptives, including postmenopausal estrogen replacement therapy; K-value 
<0, small dense LDL; K-value >0,buoyant LDL; NS, not statistically significant (p>0.05). Because 
of technical errors and/or plasma unavailability, apoB levels and the value of parameter K were 
determined in 88and 85 FCH subjects, respectively, and 205 and 201 unaffected subjects, respectively. 
Results are presented as total number (percentages) or mean ± SD. 
*Fisher exact test for dichotomous variables (numbers) and t-test for numeric variables (means).
FCH diagnosis in 1994 versus 1999
In 1994, 93 (31%) of the 299 subjects were affected (FCH). These affected subjects 
presented with hypercholesterolemia (HC), (n=26, 28%), hypertriglyceridemia 
(HTG), (n=31, 33%) or HC + HTG (n=36, 39%) (Table 2). In 1999 the diagnosis 
FCH was consistent with the diagnosis in 1994 in only 69 (74%) of the 93 subjects. 
These subjects were affected in both 1994 and 1999 based on HC (n=9), HTG 
(n=20) or combined HC+HTG (n=10) levels, and 30 subjects remained affected by 
FCH but changed in lipid phenotype, as shown in Table 2.
Table 2  Number of subjects in 32 FCH families (299 subjects), stratified by lipid phenotype 
expression in 1994 and in 1999
           1999
1994 HC HTG HC+HTG NL Total
HC   9   6    3     8   26
HTG   1 20    4     6   31
HC+HTG   2 14  10   10   36
NL   1 26    1 178 206
Total 13 66  18 202 299
HC indicates FCH based on TC >90th percentile, HTG, FCH based on TG >90th percentile and NL, 
FCH relatives with TC and TG levels ≤90th percentile adjusted for age and sex. Values are absolute 
number of subjects.
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However, most important, a total 24 subjects (26%) with FCH in 1994 according to 
HC (n=8), HTG (n=6) or HC+HTG (n=10) levels showed a normolipidemic pattern 
in 1999. Of the 206 non-affected relatives in 1994, 178 (86%) of them remained 
unaffected in 1999; however, 28 (14%) of the normolipidemic subjects (ie TC and 
TG levels <90th percentile in 1994 were affected (FCH) in 1999 according to HC 
(n=1), HTG (n=26) and HC+HTG (n=1) levels. Figure 1 shows the pedigree of 
one FCH family at both points of measurement (1994 and 1999), indicating the 
individual change in lipid phenotype expression. 
Figure 1 The pedigree of 1 FCH family in 1994 and 1999, indicating the individual change in lipid 
phenotype expression.
In total, 83 (28%) of the 299 subjects showed a switch in lipid phenotype for any 
reason (Table 2). The numbers of switches in lipid phenotype that were due to change 
in only TC concentration (n=27) were not significantly different from the number 
of switches in lipid phenotype that were due to change in only TG concentration 
(n=37) (test of Mc Nemar, p>0.05). The cholesterol level of 45 participants in the 
present study fell above the cut-off point (90th percentile) in 1994 and below this 
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point in 1999, or vice versa. So, they underwent a switch in phenotype according to 
the cholesterol level. The mean change in the cholesterol level of these subjects was 
1.10 ± 0.66 mmol/L. Fifty-six participants switched in phenotype according to the 
TG level (mean change: 1.49 ± 1.15 mmol/L). These results show that the switch in 
lipid phenotype is based on significant TC and/or TG changes that cannot be simply 
explained by the intra-individual and analytical variation. Therefore, we studied 
in 4 subgroups (group I, II, III and IV) defined by the switch in lipid phenotype as 
described in Statistical Analysis. 
Anthropometric measurements and lipid and lipoprotein concentrations in 
1994 versus 1999
Table 3 shows the anthropometric measurements and mean values of lipid and 
lipoprotein concentration by the 4 subgroups, each defined by lipid phenotype 
expression in 1994 versus 1999. Note that a normolipidemic lipid profile is defined 
by TC and TG levels <90th percentile, corrected for age and sex. The mean age of 
the unaffected subjects in 1994 and 1999 (group IV) was statistically significantly 
lower than the mean age of the other groups. The results of the linear mixed model 
showed that there was a statistical significant difference in each of the lipids and 
lipoprotein values and of the BMI between 1994 and 1999 and between the groups 
and that the time differences were different between the groups (ie, interaction). This 
result indicates that the variability in lipid and lipoprotein concentration observed, 
especially among FCH subjects (group I, II, and III), is not simply the result of either 
random biological or analytical variation, or a time effect.
The BMI of the subjects who were affected in 1994 and had a normolipidemic 
pattern in 1999 (group I) did not change, whereas the BMI of the subjects of the 
other groups increased significantly from 1994 to 1999 (group II, III, IV).
For TC, a significant decrease was observed in the subjects who were affected 
in 1994 but had a normolipidemic pattern in 1999 (group I). The decrease in TC 
concentration of the subjects who remained affected (group II) or unaffected (group 
IV) and the increase in TC concentration of the subjects who had a normolipidemic 
pattern in 1994 but were affected in 1999 (group III) did not reach statistical 
significance. The TG concentration decreased significantly in the subjects who were 
affected in 1994 but had a normolipidemic pattern in 1999 (group I), whereas the 
subjects who remained affected (group II) and who had a normolipidemic pattern 
in 1994 and a FCH phenotype in 1999 (group III) showed a significant increase, 
most likely reflecting progression of the disease. The unaffected subjects (group 
IV) showed no significant change in TG concentration. The LDL-C concentration 
showed a decrease in all 4 groups, reaching statistical significance in the subjects 
who were affected in 1994 and had a normolipidemic pattern in 1999 (group I) and 
in the group of subjects who remained affected in both 1994 and 1999 (group II). 
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Table 3  Anthropometric measurement, lipid and (apo)lipoprotein concentrations and value of 
parameter K, reflecting LDL heterogeneity, in 299 subjects from 32 FCH families, stratified 
by switch in lipid phenotype expression in 1994 versus 1999. 
1994 → 1999
FCH → NL
Group I (n=24)
FCH → FCH
Group II (n=69)
NL → FCH
Group III (n=28)
NL → NL
Group IV (n=178)
Male/female,* 16 / 8 27 / 42 17 / 11 83 / 95
Age (1994) † y   47.1 (41.1–53.1)     46.5 (42.9–50.0) 44.0 (38.4–49.6)  37.5|| (35.3–39.8)
BMI,‡ kg/m2
   1994
   1999 
  26.7 (25.2–28.1)
  26.5 (25.0–27.9)
   27.1  (26.3–27.9)
  28.6|| (27.7–29.4)
 25.4  (24.1–26.7)
28.0|| (26.7–29.3)
  23.0  (22.5–23.5)
24.2|| (23.7–24.7)
TC,‡ mmol/L
   1994
   1999
7.04   (6.61–7.48)
6.03||  (5.60–6.47)
   7.05   (6.79–7.30)
   6.93   (6.68–7.19)
5.75   (5.35–6.16)
5.93   (5.53–6.33)
5.23   (5.07–5.39)
5.09   (4.93–5.25)
TG,‡ mmol/L
   1994
   1999
 2.85  (2.19–3.50)
1.86|| (1.20–2.52)
   3.40  (3.02–3.79)
  4.27|| (3.88–4.66)
 1.55  (0.93–2.16)
2.89|| (2.28–3.51)
1.10   (0.85–1.34)
1.20   (0.96–1.45)
LDL-C,‡ mmol/L
   1994
   1999
 4.70  (4.28–5.12)
4.21|| (3.78–4.63)
   4.55  (4.30–4.80)
  4.13|| (3.87–4.38)
 4.11  (3.72–4.50)
 3.73  (3.34–4.06)
 3.58  (3.43–3.74)
 3.44  (3.29–3.60)
HDL-C,‡ mmol/L
   1994
   1999
0.97 (0.85–1.10)
1.0    (0.88–1.12)
    1.05 (0.98–1.12)
  0.92|| (0.85–0.99)
  1.03 (0.92–1.15)
 0.93  (0.81–1.04)
1.29 (1.24–1.33)
1.23|| (1.18–1.27)
ApoB,§ mg/L
   1994
   1999
 1434 (1331–1536)
1271|| (1169–1374)
    1477 (1415–1539)
    1452 (1390–1514)
  1174 (1078–1269)
1285|| (1190–1380)
      973 (935–1011)
    1006 (969–1044)
K-value§
   1994
   1999
-0.25 (-0.34– -0.17)
-0.13 (-0.21– -0.04)
  -0.21 (-0.26– -0.15)
-0.31|| (-0.36– -0.26)
-0.14 (-0.22– -0.06)
-0.26 (-0.34– -0.19)
     0.0 (-0.04–0.03)
   0.05 ( 0.02–0.08)
Values are estimated mean (95% CI) and absolute numbers for sex distribution.
* =  χ2-test (p<0.05).
† =  ANOVA (p<0.05), indicating that only the mean age is significanlyt lower in group IV compared 
with all other groups, 
‡ Statistically significant effect for each of the following, (1) time, (2) group and (3) time-group 
interaction with use of a linear mixed model (p<0.05). 
§ In 1994 and 1999, the mean value in groups I, II, III is significantly different compared with that in 
group IV (p<0.05 by adjusted Tukey-Kramer test).
|| p-value <0.05 by adjusted Tukey-Kramer for differences between 1994 and 1999. 
The HDL-C concentration in the subjects who were affected FCH in 1994 and had 
a normolipidemic pattern in 1999 (group I) did not change. In all the other groups 
(II, III and IV) the HDL-C concentration decreased, reaching statistical significance 
in the subjects consistently had FCH and in those who were consistently unaffected 
(groups II and IV, respectively). 
These results show that, on average, the subjects who switch from affected to 
a normolipidemic pattern (group I) improve on all parameters (although less for 
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HDL-C). Most likely, the healthier lifestyle in 1999, as indicated by the stable 
BMI, contributed to the improved lipid and lipoprotein profile. However, the lipid 
phenotype remained more atherogenic: TC, TG and LDL-C were significantly 
higher and HDL-C was significant lower than in the unaffected relatives, suggesting 
that these subjects are genetically predisposed to FCH. Also, on average, the 
subjects with a normolipidemic pattern in 1994 but with FCH in 1999 (group III) 
deteriorated. Although the deterioration was not more than that in the unaffected 
subjects (group IV) for all parameters, the assumption that these subjects already 
had a predisposition to FCH is more likely because these subjects already had 
higher baseline levels in 1994.
 Because the change in lipid and lipoprotein parameters, as described above, 
is not simply the result of a random effect (including biological and analytical 
variation), further statistical analysis was performed to identify whether sex, age, use 
of lipid-lowering medication and BMI contribute to the change in lipid phenotype 
expression (ie, from FCH to a normolipidemic pattern or from a normolipidemic 
pattern to FCH). The final model, in which we used selection procedures with 
multivariate logistic regression analyses, showed that only sex (adjusted odds 
ratio 2.03 (95% CI 1.09-3.87), p=0.03) and BMI (adjusted odds ratio 1.14 (95% CI 
1.05-1.24), p<0.01) independently contributed to the change in lipid phenotype 
expression between 1994 and 1999. Thus, the estimated adjusted relative risk for 
switch in lipid phenotype is 1.13 times higher per unit (kg/m2 ) gain in BMI and 2.03 
times higher in men compared to women, (ie adjusted for the other variable in this 
model). This is in line with the general observation that men with a high BMI are 
most likely to vary in lipid phenotype.
ApoB and LDL heterogeneity in 1994 versus 1999
ApoB levels and values of parameter K, reflecting LDL heterogeneity, are shown 
in Table 3, stratified by 4 groups, defined by switch in lipid phenotype expression 
in 1994 versus 1999. In contrast to the lipid and lipoprotein levels, the difference 
between time points (1994-1999) in the values of apoB and parameter K among 
FCH subjects (group I, II and III) was not significantly different from that observed 
among the group of non-affected relatives (group IV). This result indicates that apoB 
and parameter K are less variable in time than are TC and TG levels. Although 
variability in apoB levels and the value of parameter K is present, it is most intriguing 
to observe that, on average, subjects with an affected FCH phenotype in 1994 and/
or 1999 (group I, II and III) have significantly higher apoB concentrations and lower 
values of parameter K, reflecting small, dense LDL, than do the unaffected relatives 
(group IV), even when they have a sporadic normolipidemic phenotype (group I in 
1999 and group III in 1994, Table 3).
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Presence of CVD, use of lipid-lowering medication and smoking/drinking 
habits in 1994 versus 1999
Table 4 shows the use of lipid-lowering medication smoking and drinking habits 
and the presence of CVD by group (I, II, III and IV) in 1994 and 1999. 
The percentage those consuming >2 alcoholic beverages per day and smokers was 
not statistical significantly different between points of measurement (1994 and 
1999). The percentage users of those consuming >2 alcoholic beverages per day 
was significantly higher in the group of subjects who remained affected (group II) 
compared with the subjects who remained normolipidemic between 1994 and 1999 
(group IV). The percentage of smokers in the group of subjects who were affected in 
1994 but had a normolipidemic pattern in 1999 (group I) was significantly higher 
than the percentage of smokers in the group of subjects who remained affected 
(group II) and in the group of subjects who remained normolipidemic (group IV). 
The percentage of subjects using lipid-lowering medication significantly increased 
(odds ratio 3.28, CI 95% 1.96-5.5, p<0.001) in 1999 compared to 1994, and this 
was similar for all groups. The use of lipid-lowering medication of the subjects 
who remained affected in 1994 and also in 1999 (group II) was significantly higher 
than in all other groups (group I, III, IV). This percentage increased from 29 to 61% 
between 1994 and 1999. In group IV (the unaffected subjects), the use of lipid-
lowering medication was significantly lower than in the other groups (group I, II, 
III), as expected. 
Table 4  Smoking and drinking habits, the use of lipid-lowering medication and the presence of CVD
in 299 subjects from 32 FCH families stratified by switch in lipid phenotype expression in 
1994 versus 1999. 
                           1994 → 199
FCH → NL
Group I (n=24)
FCH → FCH
Group II (n=69)
NL → FCH
Group III (n=28)
NL → NL
Group IV (n=178)
Alcohol >2U/d, †
   1994
   1999
   3  (13)
 1  (4)
   7  (10)
 5  (7)
 2 (7)
 0 (0)
 5 (3)
 9 (5)
Smoking >1/d ‡
   1994
   1999
    8  (33)
 11  (46)
 16  (23)
 14  (20)
   8 (29)
   7 (25)
 42 (24)
 44 (25)
LL med *
   1994
   1999
   3  (13)
 11  (46)
 20  (29)
 42  (61)
   6 (21)
 10 (36)
  4 (2)
  8 (4)
CVD *
   1994
   1999
   4  (17)
   6  (25)
 10 (14)
 17 (25)
   4 (14)
   8 (29)
  5 (3)
 11 (6)
LL med indicates lipid-lowering medication, Values are absolute number (percentages),
† the use of alcohol is significantly higher in group II compared with group IV, by multivariate logistic 
regression. ‡ smoking is significanlyt higher in group I compared with groups II and IV, by multivariate 
logistic regression. *Statistically significant (p<0.05) increase in 1999 compared with 1994 for all 
groups, by multivariate logistic regression.
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The percentage of subjects with CVD increased significantly between 1994 and 1999 
(odds ratio 2.05, CI 95% 1.18-3.56, p=0.011), but the increase was not significantly 
different between the 4 groups. However, the total percentage of subjects with CVD 
was significantly lower in the subjects who remained normolipidemic (group IV) 
than in each of the other groups (group I, II, III), as expected, and there were no 
significant differences between group I, II and III.
Discussion
This is the first long-term follow-up study of a large cohort of FCH families. This 
study shows that the diagnosis FCH, based on internationally accepted criteria 
(including plasma TC and/or TG level above the 90th percentile adjusted for age 
and sex), is consistent in only 74% of the subjects over a 5-year period. So most 
important, 26% of the subjects with FCH in 1994 had a sporadic normolipidemic 
pattern in 1999, defined by TC and TG levels below the 90th percentile, corrected 
for age and sex. The literature shows that variability in lipid phenotype expression 
is a characteristic of FCH (1,2,4). However, this variability is usually determined 
as a change from HTG to HC or vice versa. Indeed, in our large cohort of FCH 
families, 32% of the affected subjects showed such a change in lipid phenotype 
over a period of 5 years, but the change was still consistent with the diagnosis of 
FCH. Our present results show that this variability in lipid phenotype may also lead 
to a sporadic “normolipidemic” pattern, because 26% of the affected subjects in 
1994 showed a normolipidemic pattern in 1999, 5 years after the initial diagnosis 
FCH (Table 2). 
The switch from affected FCH to a normolipidemic phenotype was due to a 
significant decrease in plasma TC, LDL-C and TG level (Table 3), which could not 
be explained by a random effect, including biological and analytical variation. 
Further statistical analysis revealed that BMI contributes to a change in lipid 
phenotype expression. Indeed, these subjects who switched from FCH to a sporadic 
normolipidemic pattern did not change in body weight, whereas the subjects who 
remained affected increased in body weight. Knowledge of the presence of FCH in 
1994 might have resulted in the patients leading a healthier lifestyle, contributing 
to a stable body weight and a reduction in lipid and lipoprotein levels. However, 
this knowledge of having FCH did not affect BMI and lipid and lipoprotein levels 
in subjects who remained affected in 1994 and also in 1999. From the present 
study, we cannot deduce which other factors contribute to the confounding effect 
of knowledge of the presence of FCH. 
The subjects who developed an FCH phenotype between 1994 and 1999 showed 
a significant increase in BMI, which was associated with a significant increase in 
TG level, whereas TC, LDL-C and HDL-C levels did not change significantly. As 
13_Mario Veerkamp_BOEK_DEF   37 18-10-2004, 14:01:08
CHAPTER 238
discussed above, BMI influences the FCH lipid phenotype expression. Thus, our 
data suggest that body weight control in FCH subjects should be an important 
issue in lifestyle intervention programs. However, the significant increase in BMI 
among the unaffected subjects in 1994 and 1999 is not associated with expression 
of FCH phenotype, suggesting that these subjects are most likely not genetically 
predisposed to develop FCH. The expression of FCH has been suggested to be age-
dependent (1) with increased prevalence in adolescence. However, in the present 
study, the mean age of the subjects who developed an FCH phenotype between 
1994 and 1999 was 42.9 years. In additional statistical analysis, age was not an 
independent variable contributing to FCH expression. Also Porkka et al. (28) did not 
find clear signs of age dependence with TC and/or TG criteria. 
With aging, the plasma TC and TG levels usually increase, so it may be surprising 
that in our cohort after 5 years, the TC concentration did not change and even 
decreased in some groups (Table 3). The change in TC concentration in our FCH 
cohort reflects the total Dutch population in which the plasma TC concentration 
had decreased with 0.5 mmol/L between 1987 and 1997 (29). 
Thus, we demonstrate that the lipid profiles in FCH families are highly variable 
in time, leading to misclassification in diagnosis. Our results help to explain 
why, despite extensive research, until now no single diagnostic marker has been 
identified for FCH. For example, until now, 3 genome screens have been reported 
in an attempt to locate the genetic region for FCH (30-32) but no unique locus has 
been found in the different family sets. To be able to delineate the metabolic and 
genetic factors contributing to the aetiology of FCH, it is essential to have consistent 
diagnostic tools to establish the diagnosis of FCH. Although internationally accepted 
diagnostic criteria are formulated for FCH, not all research groups use the same 
criteria to establish the diagnosis as recently reviewed (28,33). For example, in 
some studies the 95th percentiles or even absolute values for TC and /or TG levels, 
not adjusted for age and sex, are used, whereas in other studies apoB also served as 
a diagnostic criterion (11). However, a change in threshold or cut-off points for TC 
and TG levels will not improve the diagnosis of FCH because of the considerable 
intraindividual variability in lipid phenotype expression in time, as demonstrated by 
our results: with use of the 90th percentile cut point for TC and/or TG level adjusted 
for age and sex, 26% of the FCH subjects in our cohort had a normolipidemic 
pattern after a 5-year period, leading to a false-negative disease status at that point 
of time. So, for the diagnosis FCH, the inclusion of only plasma TC and TG levels is 
insufficient due to this considerable variability in time. 
Literature has shown that FCH is associated with other traits that may contribute 
to the increased risk of CVD, including unfavourable increases in plasma apoB and 
an increased prevalence of atherogenic small dense LDL. Previously, we reported 
that in FCH, apoB is as effective as lipid levels in classifying subjects at increased 
risk for CVD (24). In the present study, a significant higher apoB level and a lower 
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value of parameter K, reflecting small dense LDL, was found in the affected FCH 
group. Most important, we show that the variabilities in the plasma levels of apoB 
and in the value of parameter K in time is considerably less than those for TC and 
TG levels and not different from those for unaffected relatives. Most intriguingly, 
we demonstrate that compared with unaffected subjects, subjects with FCH have 
significantly higher apoB levels and increased prevalence of small dense LDL (ie, 
lower value of parameter K), even when they present a normolipidemic phenotype. 
So, even the affected FCH subjects in 1994 who showed a normolipidemic lipid 
profile in 1999 had significantly higher levels of apoB and more small dense 
LDL in 1994 and 1999. Similarly, the subjects who were unaffected in 1994 
but who developed the FCH phenotype in 1999 showed a significantly higher 
apoB concentration and a lower value of K in 1994 and 1999. These data suggest 
that subjects genetically predisposed to FCH have increased levels of apoB and 
increased prevalence of small dense LDL, independent of the lipid profile. Together 
with less variability in time, apoB and small dense LDL, compared with TC and TGs, 
could potentially contribute to more consistent diagnostic criteria for FCH with a 
better discriminant power to separate affected from unaffected relatives.   
FCH is accompanied with an increased risk of CVD (1). The total percentage 
of subjects with CVD increased significantly between 1994 and 1999, but the 
increase was not significantly different between the 4 groups. However, the 
total percentage of subjects with CVD in the group of subjects who had an FCH 
phenotype in 1994 and also in 1999 was significantly higher than in each of the 
other groups; in the group of subjects who were normolipidemic in 1994 and also 
in 1999, the percentage subjects with CVD was significantly lower than in each 
of the other groups. It might appear somewhat surprising that the percentage of 
subjects who develop CVD was similar among FCH subjects despite the switch 
to a normolipidemic phenotype in 20% of the subjects versus a switch to an FCH 
phenotype in 23% of the subjects. The explanation to this apparent contradiction 
is most likely that once a subject shows an FCH lipid phenotype, he or she is 
genetically predisposed to FCH, associated with an increased risk of CVD. In FCH, 
several potential risk factors have been suggested in literature to contribute to its 
increased atherogenicity, including small dense LDL, an increase in apoB, low 
HDL levels, and insulin resistance (12). We show that affected FCH subjects (group 
I, II and III) have an increased apoB level and more small dense LDL (low value 
of parameter K), independent of the lipid phenotype expression. So, even when 
a relative with FCH shows a sporadic normolipidemic pattern, increased levels of 
apoB and lower values of parameter K are found, most likely contributing to an 
increased risk of CVD and, thus, contributing to the explanation for the similar 
increase in the percentage of subjects who develop CVD within 5 years. 
In 1994, only 23 of the 93 affected subjects used lipid-lowering medication. Thus, 
<25% of the subjects were treated properly. In 1999, 53% of the affected subjects 
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used lipid-lowering medication, showing that FCH, (most likely due to relatively 
mild hyperlipidemia) is still not treated properly. The recommendations for treating 
subjects with mild hyperlipidemia in a family with FCH must be stricter than the 
recommendations for treating subjects with mild hyperlipidemia in a family without 
FCH, because a positive family history is an independent risk factor for CVD (34). 
Besides lipid- lowering medication, lifestyle intervention programs should reinforce 
a cessation of smoking, because, unfortunately >20% of all the subjects were still 
smoking in 1999, despite their known FCH status in 1994.
A major problem in clinical medicine, contributing to the undertreatment of FCH 
patients, is the difficulty in diagnosing FCH, because with the present diagnostic 
criteria (TC and TG levels), the diagnosis cannot be made in a single patient without 
family screening. Therefore, a major effort should be undertaken to redefine the 
diagnostic criteria of FCH by 1 standardized parameter, which, measured at 1 
time point, discriminates between affected and unaffected relatives. We now 
demonstrate that apoB and small dense LDL are potentially attractive parameters 
for improving the diagnostic criteria for FCH. 
This unique study of a large cohort of FCH families with 5-year follow-up 
indicates that the diagnosis FCH, based on plasma TC and/or TG levels above the 
90th percentile adjusted for age and sex, is consistent in only 74% of the subjects. 
Twenty-six percent of the affected subjects showed a normolipidemic pattern after 
5 years. Therefore, our results emphasize the need for reevaluation of the diagnostic 
criteria. Furthermore, we demonstrate that plasma apoB and small dense LDL are 
potentially valuable diagnostic criteria for FCH. Further studies are indicated to 
determine the role of apoB and the presence of small dense LDL and, thus, to 
improve the diagnostic criteria for FCH.
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Abstract
Background: Familial combined hyperlipidemia (FCH) is traditionally diagnosed 
by total plasma cholesterol and/or triglyceride levels above the 90th percentile 
adjusted for age and gender. In a recent study we showed that the diagnosis FCH 
based on these diagnostic criteria was inconsistent in 26% of the subjects over a 
5-year period. This results emphasizes the need for re-evaluation of the diagnostic 
criteria for FCH. 
Methods and Results: A total of 32 families (299 subjects) were studied in 1994 
and in 1999. A subject was defined ‘truly’-FCH, when diagnosed FCH in 1994 
and/or 1999 based on the traditional plasma lipid criteria. Additional lipid and 
lipoprotein parameters, including apolipoprotein B (apoB) and small dense LDL, 
were measured at both time points. In total, 121 subjects (40%) were defined as 
truly FCH. Multivariate analysis revealed that absolute apoB values combined with 
triglyceride and total cholesterol levels adjusted for age and gender best predicted 
truly FCH. A nomogram including these parameters is provided to simply and 
accurately calculate the probability to be affected by FCH. Furthermore, it is shown 
that when percentiles of triglyceride and total cholesterol adjusted for age and 
gender are not available in a population, the definition of FCH can be established 
based on hypertriglyceridemia (>1.5 mmol/l) and hyperapoB (>1200 mg/l). 
Conclusions: The diagnosis of FCH is best predicted by absolute apoB levels 
combined with triglyceride and total cholesterol levels adjusted for age and gender 
and can accurately be calculated by a nomogram. This definition is also a good 
predictor of cardiovascular risk in FCH. 
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Introduction
Familial Combined Hyperlipidemia (FCH) was first described in 1973 as a common 
familial disorder characterized by multiple lipoprotein phenotypes and increased 
risk of premature cardiovascular disease (CVD) (1) . In the 30 years ago since it was 
described, the genetic basis for FCH has remained elusive; indeed even the mode of 
inheritance remains controversial. Obviously, no genetic hypothesis can be reliably 
tested when there is no consistent phenotype to establish the diagnosis FCH. 
FCH is characterized by several phenotypes, including increased total cholesterol 
(TC), increased triglycerides (TG), decreased high-density lipoprotein cholesterol 
(HDL-C), increased apolipoprotein B (apoB) and the presence of small dense low-
density lipoprotein (LDL). Not all research groups use the same criteria to establish 
the diagnosis of FCH (2,3). There are even more fundamental problems. Amongst 
the most important is that the lipid phenotype can vary substantially within any 
individual. Recently, we showed in a 5-year follow-up study (1994 to 1999) of 
32 families that the diagnosis of FCH, based on plasma TC and/or TG level above 
the 90th percentile (pTC or pTG >90th) adjusted for age and gender is consistent 
in only 74% of the subjects (4). Most importantly, 26% of the subjects with FCH 
in 1994 had a sporadic normolipidemic pattern in 1999 defined by pTC and pTG 
levels <90th corrected for age and gender. Thus, the classical lipid phenotypes are 
not only variable amongst family members, but also within individuals. This has 
previously been suspected, but has now been convincingly demonstrated by our 
data, and by recent data of Mc Neely et al (5). 
Although the genetic origin of FCH has remained obscure, much has been 
learned about its pathophysiology. The characteristic abnormality is an increased 
production of very low density lipoprotein (VLDL) with or without impaired 
clearance of TG-rich lipoproteins in the majority of patients (6) that results in the 
generation of increased numbers of small dense LDL particles. This suggests that 
just as a variable lipid phenotype is the hallmark of FCH within a family, an elevated 
plasma apoB might be the common hallmark of FCH within an individual. Indeed, 
this was a principal finding of our previous study (4), which demonstrated that 
subjects affected FCH in 1994 and/or 1999 had significantly higher apoB levels and 
an increased amount of small dense LDL compared with nonaffected subjects, even 
when they presented a normolipidemic phenotype. Together with less variability in 
time, measurements of apoB and small dense LDL in plasma could potentially lead 
to more consistent diagnostic criteria for FCH with a better discriminant power to 
separate affected from nonaffected relatives compared to TC and TG levels alone. 
The objective of the present study is to evaluate several diagnostic features of FCH 
and to provide a nomogram that can simply and accurately predict FCH in clinical 
practice. 
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Subjects and Methods
Study population
The study population consisted of kindreds and probands of families with 
known FCH, who were recruited in 1994 and followed up in 1999 as recently 
described elsewhere (4). At both time points of investigation all subjects filled out 
a questionnaire about their medical history, especially cardiovascular status. Body 
mass index (BMI) was determined in all subjects. After withdrawal of lipid-lowering 
medication for four weeks and after an overnight fast, venous blood was drawn by 
venipuncture. The subjects were classified affected FCH when plasma pTC and/or 
pTG >90th on the basis of the PROCAM study (7). These percentiles are adjusted 
for age and gender. Nonaffected relatives were defined by TC and TG levels <90th 
percentile (pTC and pTG <90th). The ethics committee of the University Medical 
Center Nijmegen approved the study protocol. 
In total, 32 families, including 299 subjects, were studied in both 1994 and 
1999. In 1994, 93 of the 299 subjects (31%) were affected by FCH. The diagnosis 
of FCH in 1999 was consistent with the diagnosis in 1994 in only 69 of the 93 
subjects (74%). Most importantly, however, 24 subjects (26%) with FCH in 1994 
showed a normolipidemic pattern in 1999 and 28 (14%) of the normolipidemic 
subjects i.e. pTC and pTG levels <90th, in 1994 were affected in 1999. Of the 206 
nonaffected relatives in 1994, 178 (86%) remained nonaffected in 1999 (4). In the 
present study we define all subjects who were diagnosed FCH in 1994 and/or 1999, 
on the basis of the traditional lipid criteria (pTC and/or pTG >90th), as affected by 
FCH. Thus, this definition also includes the subjects with FCH in 1994 who show a 
normolipidemic pattern in 1999 (Table 1). We refer to these affected FCH subjects 
further as ‘truly’-FCH. 
Table 1 Subjects in 32 families defined affected by familial combined hyperlipidemia (FCH) or 
normolipidemic relatives (NL) in 1994 and 1999.
1999, n (%)
1994 FCH NL Total
FCH  69 (74) *  24 (26) *  93 (31) 
NL  28 (14) *  178 (86)  206 (69)
Total  97 (32)  202 (68)  299 (100)
NL indicates normolipidemic relatives defined by pTC and pTG levels <90th. FCH was based on pTC 
and/or pTG levels >90th. 
*Subjects classified as truly FCH defined by affected FCH based on pTC and/or pTG>90th in 1994 
and/or 1999. In total, 121 subjects (40%) of the study population were defined as truly FCH.
13_Mario Veerkamp_BOEK_DEF   47 18-10-2004, 14:01:11
CHAPTER 348
Plasma lipid, lipoprotein and apolipoprotein analysis
Plasma TC and TG concentrations were determined by enzymatic, commercially 
available reagents (Boehringer-Mannheim, Germany, catalog. No. 237574 and 
Sera Pak, Miles, Belgium, catalog. No.6639, respectively). HDL-cholesterol (HDL-
C) was determined by the polyethylene glycol 6000 method (8). LDL-cholesterol 
(LDL-C) was calculated by subtraction of VLDL-C and HDL-C from plasma TC. 
Total plasma apoB concentrations were determined by immunonephelometry (9). 
Coefficient of variation estimates of the analytical and biological variation of apoB 
in our laboratory were <7%.
LDL subfractions were sepa rated by single spin density gradient ultracentrifugation 
(10). Each individual LDL subfraction profile was defined by a continuous variable K, 
as described in detail previ ously (11). A negative value (K<0) reflects a more dense 
LDL subfracti on profile, and a positive K value (K>0) a more buoyant profile. 
Statistical analyses 
The Mann-Whitney-test was used to test differences at baseline between truly FCH 
subjects and their nonaffected relatives for statistical significance in the case of 
quantitative variables and the 2-tailed Fisher exact test in the case of qualitative 
variables. 
Univariate logistic regression was used to evaluate the prognostic ability of 
the variables, separately, to discriminate between truly FCH subjects and their 
nonaffected relatives. Because the apoB level, K-value and TC and TG levels in 
particular were expected to be non-linearly related in the logistic model, reasonable 
cut-off values for these variables to discriminate truly FCH subjects from their 
unaffected relatives were constructed. At this point the condition of equal ‘costs’ of 
misclassification of cases and noncases was used. In other words, the optimal cut-
off value for a particular variable was chosen so that the sum of the sensitivity and 
the specificity to discriminate truly FCH subjects from their unaffected relatives was 
maximal. Crude ORs with 95% CIs are presented.
Multivariate logistic regression analysis with selection procedures was used 
to determine the variables, that were sufficient and complete to contribute 
independently to the prediction of truly FCH. Because forward selection procedures 
do not identify other important variables, probability values for entry into the model 
were considered to find close alternatives to the variables selected. Adjusted ORs 
with 95% CIs are presented. With the multivariable prognostic model, a boundary 
value of the probability to be truly FCH, given the values of the prognostic variables 
only, was constructed again under the condition of equal ‘costs’ of misclassification 
of cases and noncases. In case of a two variable prognostic model a straight line 
dissociates cases (i.e. truly FCH with high probability) and noncases. In case of a 
three (or more) variable prognostic model a nomogram is constructed.
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Finally, univariate logistic regression was used to evaluate the prognostic ability of 
variables, separately, to identify patients with CVD compared to normal. Statistical 
analysis was performed by using procedures available in SAS (software package 
2000, SAS Institute Inc).
Results
In total, 32 families, comprising 299 subjects, were studied in both 1994 and 1999. 
One hundred and twenty one subjects were defined truly FCH, based on plasma 
pTC and/or pTG >90th adjusted for age and gender in 1994 and/or 1999 (Table 1). 
Thus, 40% of the study population was ‘truly’-FCH, whereas 31% in 1994 and 32% 
in 1999 were affected by FCH. Table 2 shows the anthropometric measurements, 
lipid and (apo)lipoprotein concentrations and value of parameter K, reflecting LDL 
heterogeneity, in truly FCH subjects and nonaffected relatives in 1994. 
Table 2 Anthropometric measurements, lipid and (apo)lipoprotein concentrations and value of 
parameter K, in truly FCH subjects and normolipidemic relatives in 1994.
Truly FCH
(n=121)
Normolipidemic relatives
(n=178)
Age, y  48  (19-73) *  34  (13-71)
BMI, kg/m2  26  (18-37) *  23  (15-35)
CVD, n (%)  18  (15%) #  5  (3%)
TC, mmol/L  6.9  (3.7-9.0) *  5.2  (2.4-7.5)
TG, mmol/L  2.4  (0.2-15.0) *  1.0  (0.3-2.9)
LDL-C, mmol/L  4.48  (1.67-6.63) *  3.47  (1.25-5.71)
HDL-C, mmol/L  0.98  (0.53-2.56) *  1.25  (0.55-2.47)
Apo B, mg/L  1374  (604-2640) *  914  (467-1640)
K-value  -0.23  (-0.58-0.59) *  0.03  (-0.48-0.41)
BMI indicates body mass index. Values are median (minimum-maximum). Values of K<0 reflect small, 
dense LDL.
* p<0.001 Mann-Whitney test, #: p<0.001 Fisher’s exact test. 
Truly FCH subjects were significantly older and had a higher BMI than 
normolipidemic relatives. As expected, among subjects with FCH, CVD was more 
prevalent. By definition, the truly FCH group had higher TC and TG concentrations. 
The truly FCH group also exhibited significantly higher concentrations of LDL-C 
and lower concentrations of HDL-C. Furthermore, significantly higher levels of apo 
B and lower values of parameter K, reflecting small dense LDL, were found in the 
truly FCH group compared with the unaffected relatives. 
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Crude ORs to predict truly FCH are indicated in Table 3; all variables except gender, 
contributed independently to the diagnosis truly FCH. 
Table 3 Crude ORs to predict truly FCH with univariate logistic regression
Independent variables OR 95% CI R2 ,(%) AUC,(%)
Gender (m vs f)  1.13  0.71–1.79  1 52
Age, y  1.20  1.11–1.30  7 65
BMI, kg/m2  1.41  1.29–1.55  31 79
TC absolute, mmol/L  3.08  2.36– 4.02  40 82
pTC  2.32  1.88–2.85  37 79
TC>6.0 mmol/L  7.19  4.29–12.07  25 73
TG absolute, mmol/L  11.51  6.43–20.61  58 89
pTG  3.24  2.48–4.24  54 87
TG>1.5 mmol/L  15.19  8.53–27.03  41 80
ApoB absolute (per 100 mg/L)  1.76  1.54–2.01  49 86
ApoB>1200 mg/L  12.31  6.99–21.69  37 78
K-value absolute (per 0.1)  0.60  0.51–0.69  27 78
K-value <-0.1  9.62  5.50–16.82  31 76
AUC indicates area under the curve as a measure of predictive discrimination (ie 50% is equivalent to 
random guessing and 100% is the perfect prediction); CI: confidence interval; R2: rescaled R-square, 
indicating the percentage explained variance; BMI: body mass index. 
ROC analysis shows that the K-value, reflecting LDL heterogeneity, and apoB levels 
are nearly as good predictive for truly FCH as the traditional lipid criteria including 
TC and TG levels. Next the variables were dichotomized by determining the optimal 
cut-off values of apoB, TC, TG and K-value for prediction of truly FCH (Table 4). In 
our cohort cut-off values of apoB >1200 mg/l, parameter K <-0.10, TG levels >1.5 
mmol/l (pTG ≥6) and TC levels >6.0 mmol/l (pTC ≥7) were found. 
Table 4 Otimal cutoff values with receiver-operating curve parameters for apoB, parameter K, 
absolute TG and TC, pTG and pTC for prediction of truly FCH with univariate logistic 
regression under the condition of equal cost of misclassification.
Cut-off point Probability Maximum J Sensitivity Specificity
ApoB, mg/L  >1200 0.44 0.55 0.77 0.79
K-value  <-0.10 0.40 0.51 0.77 0.74
TG, mmol/L    >1.5 0.35 0.59 0.81 0.78
TC, mmol/L  >6.0 0.42 0.46 0.70 0.75
PTG  ≥6 0.58 0.61 0.77 0.84
PTC  ≥7 0.74 0.51 0.51 1.00
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To evaluate which (combination of) phenotype(s) best predicted truly FCH, we 
included all the variables presented in Table 3 in a multivariate logistic regression 
model. This analysis revealed that the absolute apoB value in combination with 
pTG and pTC best predicted truly FCH with an R2 = 69%. pTG was the strongest 
independent predictor of truly FCH (R2=58%); when percentiles are not available, 
TG concentrations >1.5 mmol/l can be used to predict truly FCH. When TG levels 
in percentiles were included in the model, the K-value did not provide additional 
information. In the next step of the regression analysis, apoB was the second most 
important predictor of FCH. Including apoB levels besides pTG in the model 
improved R2 to 68%. Finally pTC contributed significantly to truly FCH, although 
the R2 did not increase substantially. The R-square (i.e. the amount of variation) with 
the combination of these three variables was 69%. 
By logistic regression the probability of classification affected FCH based on 
absolute apoB values and pTG and pTC was assessed at 60%. In Figure 1, the two 
most informative variables in predicting truly FCH, including apoB levels and the 
pTG levels, are plotted for all individuals. 
Figure 1 Probability of classification of affected by truly FCH on the basis of absolute apoB 
concentration and TG levels adjusted for age and gender.
  Shaded area indicates probability of truly FCH of >0.52 on the basis of absolute apoB 
concentration and TG levels adjusted for age and gender. This area was optimal to 
discriminate those truly FCH from unaffected subjects under condition of equal costs of 
misclassification. For ease of presentation, unaffected subjects are shifted upward, truly FCH 
subjects are shifted downward, and cutoff point of pTG (90th percentile) is presented at 6.5.
  For pTG and pTC; 1= 0-5%; 2= 6-10%; 3= 11-25%; 4= 26-50%; 5= 51-75%; 6= 76-90%; 
7= 91-95%; 8= 96-100%. ° indicates truly FCH subjects; •, unaffected subjects.
 
13_Mario Veerkamp_BOEK_DEF   51 18-10-2004, 14:01:13
CHAPTER 352
The optimal cut-off value to predict truly FCH based on the combination of absolute 
apoB with pTG is 0.52. The shaded area indicates high probability of predicting 
truly FCH, using the observed apoB and pTG values. This figure shows that the 
prediction area makes a fairly good distinction between truly FCH subjects and 
nonaffected subjects. 
Finally, a nomogram was constructed to calculate the probability of affected by 
FCH (Figure 2). For each of the three variables (pTG, pTC and absolute apoB levels), 
the corresponding number of points is read from the scale below. These are then 
summed to give a total points score, which can be translated into a probability of 
being affected by FCH by using the 2 scales at the bottom. The optimal cutoff point 
for the probability of affected FCH was determined under the condition of equal 
costs of misclassification according to sensitivity and specificity. When having a 
probability >60% the subject is defined as affected by FCH when also at least 1 
other family member also exhibits the FCH phenotype and at least 1 individual in 
the family has premature CVD. For example, a subject with a pTG of 7 (between 91 
and 95%, 8 points), a pTC of 6 (between 76 and 90%, 2.8 points) and an apoB level 
of 1600 mg/l (4.3 points) will receive a total amount of 15.1 points. The probability 
of being affected by FCH is then 0.92. Thus, according to this test, this individual 
subject (if a member of a FCH family) is being affected by FCH.
Diagnosis FCH as predictor for CVD
In 1999, 41 subjects (14%) had a history of CVD. To define the ability of the different 
FCH definitions to predict CVD, sensitivity and specificity were determined. FCH 
diagnosis based on traditional lipid criteria, including pTC and/or pTG >90th 
adjusted for age and gender, showed a sensitivity and specificity to predict CVD 
of 45% and 27% respectively. The proposed new FCH diagnosis based on pTG, 
pTC and absolute apoB had a sensitivity and specificity for CVD risk prediction 
of 59% and 72%, respectively. In literature, the diagnosis FCH has also recently 
been defined as hyper-TG (TG >1.5 mmol/l) and hyper-apoB (apoB >1200 mg/l). 
In our cohort, the diagnosis of FCH on the basis of these criteria (hyperTG plus 
hyperapoB) had corresponding values of sensitivity and specificity to predict FCH 
(64% and 72%, respectively). Thus, both new definitions of FCH improved CVD risk 
prediction compared with the FCH diagnosis based on traditional lipid criteria. 
The predictive value of the nomogram for CVD analyzed as a quantitative trait 
shows that the median probability of being affected by FCH is >3.5 times higher in 
patients with CVD (median (95% CI): 0.71 (0.54 to 0.80)) compared with patients 
without CVD (median (95% CI): 0.20 (0.28 to 0.38)) (p<0.001; t-test using angular 
transformed data). 
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Discussion
We propose a new definition of FCH based on absolute apoB levels and TG and 
TC levels, both adjusted for age and gender. A nomogram is provided to simply and 
reliably read the probability to be affected FCH in clinical practice (Figure 2). This 
nomogram has been constructed using data from our large FCH cohort including 
299 subjects with 5-year follow-up. This new definition of FCH also reflects 
increased CVD risk in contrast to the traditional criteria of FCH.
Until now, different research groups used different definitions of FCH (1-3). In 
a recent follow-up study we showed that for the diagnosis FCH, only plasma TC 
and TG levels adjusted for age and gender, is insufficient (4). Furthermore, the 
phenotype FCH based on TC and/or TG levels alone is physiologically incoherent 
(12). When the traditional lipid phenotype is variable and insufficient, accurate 
clinical diagnosis in individual subjects is not possible. Equally important, genetic 
characterization becomes problematic and biologically correct hypotheses may be 
falsely rejected because of inaccurate diagnosis. For all these reasons, it is necessary 
to come to unequivocal standardized diagnostic criteria of FCH. The present study 
shows that absolute apoB levels combined with pTG and pTC are most informative 
to predict FCH. 
ApoB as a diagnostic feature of FCH
In our previous study, subjects with FCH had significantly higher apoB 
concentrations compared to nonaffected relatives, even when they had a sporadic 
normolipidemic phenotype (4). Additionally, in the follow-up study of Mc Neely et 
al. (5) apoB levels were highest among individuals who were consistently affected 
by FCH, intermediate among those who switched phenotypes, and lowest among 
individuals who were consistently normolipidemic. In addition, several other 
studies have shown that apoB is an important phenotypic measure in FCH (4,13-
16). ApoB fits with the most important pathophysiological feature of FCH, increased 
VLDL secretion and impaired clearance of postprandial lipoproteins, resulting 
in hypertriglyceridemia, elevated plasma apoB and small dense LDL. Another 
practical advantage of including apoB level as a new diagnostic criterion of FCH is 
diagnosing FCH at a younger age. A number of studies have shown that in teenaged 
children, apoB may be elevated, whereas lipids are not (2,17). A limitation in 
using apoB as a diagnostic criteria for FCH is the need for an apo B measurement 
standardized according to the WHO-IFCC standardization program. ApoB can be 
measured with the same precision and accuracy as the lipoprotein lipids (18). All 
these data encourage the inclusion of apoB in the phenotypic definition of FCH. 
The present study shows in a large FCH cohort with 5-year follow-up that the optimal 
cutoff point for apoB to predict FCH is >1200 mg/L. Subjects with an apoB level 
>1200 mg/L have an increased probability to be affected by FCH (OR, 12.3 (95% 
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CI: 6.99 to 21.69)) compared with subjects with an apoB level <1200 mg/L. The 
level of apoB >1200 mg/L has been suggested in previous studies. It corresponds to 
roughly the 75th percentile in men (results of the Framingham Offspring study) (19), 
and subjects with apoB concentrations >1200 mg/L were significantly more likely 
to have CVD than subjects with apoB levels <1200 mg/L (20). Thus, our data now 
show convincingly that the measurement of apoB concentration is imperative for 
the diagnosis of FCH.
Small dense LDL and TG levels as diagnostic feature of FCH
Small dense LDL, reflected by the parameter K, is also an important feature in FCH 
(16,21-23). We previously showed that subjects with FCH had significantly lower 
levels of parameter K, reflecting atherogenic small dense LDL, compared with 
nonaffected relatives, even when they had a sporadic normolipidemic phenotype 
(4). However, this was not shown in the follow-up study of Mc. Neely et al. (5), 
maybe because different methods were used to determine small dense LDL. The 
present study shows that the optimal cutoff point for K-value to predict FCH is <-
0.10, reflecting small dense LDL. 
However, although small dense LDL is an important feature of FCH, it is of interest 
that in multivariate analysis, parameter K, reflecting LDL heterogeneity, did not 
provide additional information in predicting FCH after inclusion of TG, which is the 
most important predictor of truly FCH, most likely because of the strong correlation 
between LDL heterogeneity and TG levels (r=-0.68). Serum TG concentration has 
been suggested to be the most important predictor of LDL size in FCH patients (23). 
In both in earlier studies (9,24) and this study, we have confirmed that plasma TG 
levels >1.5 mmol/L distinguish optimally between atherogenic small dense LDL 
and a large buoyant LDL subfraction profile. 
Hyper-TG and hyper-apoB as diagnostic feature of FCH
In an international forum on FCH in 2001, a proposal to redefine FCH was made 
that was based on hypertriglyceridemia and elevated plasma apoB (hyperTG 
hyperapoB) (12). The cutoff points proposed were >1200 mg/L for apoB and >1.5 
mmol/L for plasma TG. The choice of these cutoff points was tentative and based on 
the reports mentioned earlier. We show here for the first time that cutoff points of 
>1200 mg/L for apoB and >1.5 mmol/L for TG are justified on the basis of our large 
FCH cohort with 5-year follow-up. 
Comparing the absolute apoB value combined with pTG and pTC as diagnostic 
criteria for FCH with hyperTG and hyperapoB reveals that the diagnosis based on these 
combined values better predicted truly FCH (R2 =69% versus 50% respectively). 
The disadvantage of using percentiles of lipid levels in the definition of FCH is that 
these levels vary substantially across the world and therefore will affect decisions 
on cutoff levels. Lipid levels are changing, and up-to-date, accurate information 
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on lipid levels and threshold values is not available in many populations. An 
advantage of using percentiles is the correction for age and gender, but assignment 
of percentiles still depends on the population. 
To take into account the great interindividual variability in apoB and TG levels, we 
recommend using apoB and TG levels as quantitative traits instead of a dichotomy 
i.e. apoB>1200 mg/L and TG>1.5 mmol/L. Much information is lost because we 
do not know whether an individual is close to or far from the threshold. Moreover, 
where family data are used, quantitative traits of relatives are often more informative 
than their affected status. As a clinical tool, a nomogram was constructed to simply 
and reliably calculate the probability of FCH in an individual subject on the basis 
of quantitative apoB, pTG and pTC values. In case pTC and pTG are not available, 
we show that it is acceptable to define FCH by TG levels >1.5 mmol/L and apoB 
values >1200 mg/L.
Finally, we found that our new definition of FCH is of value in predicting CVD risk. 
Subjects fulfilling the new FCH definition have an increased risk of CVD (OR=3.8 
(95%CI: 7.0 to 21.7)). Subjects fulfilling the definition hyperTG and hyperapoB, 
have a comparable OR (4.6, 95% CI: 2.3 to 9.2) in contrast to the diagnosis of FCH 
based on traditional lipid criteria (pTC and/or pTG >90th), which had an OR of 
only 0.3 (95% CI: 0.2 to 0.6). Similar results have been reported for intima-media 
thickness, a surrogate end point of CVD (25).
Using the proposed new diagnostic criteria, included in a nomogram will make 
it easier to identify patients and test relatives to diagnose FCH. Still, the diagnostic 
phenotype has to be present in >1 family member, and ≥1 individual in the family 
must have premature CVD to diagnose FCH. Confirmation of the relevance of 
this new definition of FCH in other large FCH cohorts is warranted to confirm the 
unequivocal diagnostic criteria for FCH. 
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Introduction
Familial combined hyperlipidemia (FCH) was originally identified by Goldstein et 
al, Rose et al, and Nikkila et al in the early 1970s as a new inherited lipid disorder, 
characterized by multiple lipoprotein phenotypes and strongly associated with 
premature cardiovascular disease (1-3). At present, FCH is the most common 
inherited hyperlipidemia in humans, affecting 1% to 3% of the population and 
up to 20% of patients with premature myocardial infarction. The genetic and 
metabolic basis of the disorder has not yet been defined (4-6). This review discusses 
the different metabolic pathways with emphasis on the role of insulin resistance, 
adipose tissue metabolism and free fatty acids (FFA).
Definition of FCH
Individuals with FCH are characterized by variable expression of elevated cholesterol 
and/or triglyceride (TG) levels, defined by concentrations above the 90th percentile 
for age and gender. Within a family, multiple type hyperlipidemia in first-degree 
relatives comprising hypertriglyceridemia, hypercholesterolemia and/or combined 
hyperlipidemia is obligatory, in addition to the presence of atherosclerosis before 
the age of 60 years. Because of the absence of a specific clinical or metabolic 
marker for the disorder, and because of characteristic variability in the presenting 
lipid phenotype, family studies are necessary to establish the diagnosis of FCH 
in a single patient (4,5). Recently, we evaluated the variability in lipid phenotype 
expression over a 5-year period in 32 FCH families, comprising 299 subjects (7). 
We demonstrated that the diagnosis of FCH, based on plasma total cholesterol 
and/or TG levels, is consistent in only 74% of the subjects over a 5-year period, 
suggesting that inaccurate diagnosis of FCH contributes to heterogeneity in 
FCH populations in the literature (4,5). Characterization of our FCH cohort was 
substantially more consistent when using two other major characteristics of FCH: 
elevated apolipoprotein B  (apoB) levels and the presence of small dense low-
density lipoprotein (sdLDL). Further studies are necessary to evaluate the role of 
apoB and sdLDL as potential new diagnostic criteria for FCH (7,8).
Cardiovascular risk factors in FCH
In FCH, total cholesterol and TG levels are frequently elevated only mildly. In 
our large cohort of 42 FCH families, comprising 161 FCH patients and 401 
normolipidemic relatives, mean total cholesterol and TG levels among FCH 
patients and non-affected relatives were 6.4 ± 1.4 mmol/L and 3.6 ± 2.9 mmol/L 
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versus 4.9 ± 1.0 mmol/L and 1.2 ± 0.5 mmmol/L, respectively. This FCH lipid profile 
is often associated with an unfavourable decrease in high-density lipoprotein (HDL) 
cholesterol concentration and elevated apoB concentrati on (4,5,7). In addition, 
other traits in FCH have been proposed to contribute to accelerated atherosclerosis 
in vivo, including the presence of increased numbers of sdLDL, increased oxidative 
stress, low-grade inflammation, genetic heterogeneity, insulin resistance and 
impaired metabolism of fatty acids (4-6). 
Metabolic pathogenesis of FCH 
Abnormalities in several metabo lic pathways have been suggested to be important 
in causing the FCH phenotype (Figure 1).
FCH and metabolism of apo-b100 containing lipopro teins
In general, FCH is thought to be caused by [1] hepatic very low-density 
lipoprotein (VLDL) overproducti on either with or without [2] impaired clearance 
of TG-rich lipoproteins from plasma. These TG-rich lipoproteins, of exogenous and 
endogenous origin, result in an increase in the pool of apoB100 containing TG-rich 
lipoprotein (9). Although apoB overproduction is a well-establis hed feature of FCH, 
the underlying mechanism is not known. ApoB gene defects have been ruled out 
by linkage analysis in FCH kindreds (10). The most likely contribution to increased 
VLDL apoB production is increased concentrations of plasma FFA; their role is 
discussed in more detail below. 
FCH and lipoprotein lipase 
The enzyme lipoprotein lipase (LPL), activated by the cofactor apoCII, liberates 
FFA from TG-rich lipoproteins of both exogenous (chylomicrons) and endogenous 
(VLDL) origin. FA then pass into adipose tissue or skeletal muscle cells to be 
oxidized or stored (11). During this process, LPL converts VLDL into smaller 
apoB100-containing VLDL remnants, intermediate-density lipoprotein (IDL) and 
LDL (12). 
Of patients with FCH, 36% have diminished postheparin LPL activity and mass 
values (13). Redu ced LPL activity due to LPL gene mutations has been reported 
repeatedly in subsets of FCH populations. Our data confirm that previous studies 
have shown that LPL mutations have significant additional effects on lipid and 
lipoprotein phenotype expression in FCH (14). However, although linkage analysis 
ruled out LPL as a major gene in FCH, it may act as a modifier gene (15). 
Another possible explanation for the reduced LPL activity and mass found in 
some FCH families may be an adaptation to changes in the transport of FFA in 
plasma, as increased concentrations of FFA decrease LPL activity (16). Furthermore, 
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insulin is the principal hormone that regulates LPL, i.e. stimulating expression and 
activity of adipocyte LPL (17). FCH is associated with insulin resistance, which 
also contributes to decreased LPL activity. Finally, increased apoCIII levels are 
associated with impaired clearance of TG-rich lipoprotein due to direct inhibition 
of LPL by apoCIII (18).
Figure 1 Different metabolic pathways in Familial Combined Hyperlipidemia
  (I) Hepatic very low-density lipoprotein (VLDL) overproduction may result from an 
increased supply of fatty acids (FFA) to the liver. (II) Impaired clearance of triglyceride-rich 
lipoproteins may be caused by diminished lipoprotein lipase (LPL) activity resulting from 
a. LPL mutations; b. increased FFA concentrations; c. increased apoCIII concentrati ons; 
d. insulin resistance. (III) Small dense LDL may be present due to a. increased cholesteryl 
ester transfer protein (CETP) activity; b. major gene effect - genetic defect c. increased 
concentrations of precursor molecule VLDL; d. change in hepatic lipase (HL) and/or LPL 
activity. (IV) Insulin resistance may be caused by a. genetic defect; b. obesity; c. defects in 
fatty acid metabolism; d. activation of TNF system; e. increased leptin concentration. Insulin 
resistance itself results in impaired suppression of HSL (V), increased FFA concentrations 
(VI) and diminished LPL activity (II). (V) Defects in adipose tissue metabolism may result 
from a. decreased activity of acylation stimulatory protein (ASP); b. decreased activity of 
hormone sensitive lipase (HSL); c. increased leptin concentration. These defects contribute 
to insulin resistance (IV) and increased plasma FFA concentration (VI) which results in 
increased supply of FFA to the liver (I). (VI) Increased FFA concentrations may be induced by 
a. (genetic) defects in HSL, ASP or leptin (V); b. insulin resistan ce (IV); c. genetic defects; d. 
resistance to lipolytic hormones; e. TNF activation. Increased concentration of plasma FFA 
results in increased supply of FFA to the liver (I), insulin resistance (IV) and decreased LPL 
activity (II).
Metabolics pathways  
in familial combined  
hyperlipidemia
I
VLDL overproduction  
in liver
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↓ 
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↓
VLDL overproduction
VI
Increased FFA  
concentration
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c. Genetic defects
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II 
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lipase activity
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III 
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IV 
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FCH and insulin resistance
Resistance to the normal action of insulin is related to alterations in lipid 
metabolism, such as hypertriglyceridemia, low HDL cholesterol and an excessive 
postprandial release of FFA. An increased supply of FFA to liver cells is associated 
with VLDL overproduction. Furthermore, the normal insulin-mediated activation of 
LPL is diminished resulting in a reduced clearance of TG-rich lipopro teins (19). In 
addition, insulin resistance may coincide with a predomi nance of sdLDL particles 
(20). Since all these features are also characteristics of FCH, the existence of insulin 
resistance may be an important factor modula ting FCH phenotypes. 
Impaired insulin action in FCH patients, both on the suppression of serum FFA and 
the stimulation of glucose disposal, has been demonstra ted directly by several groups 
using the euglyce mic hyperinsulinemic clamp technique (21-24). 
In 1997, we demonstrated that in male FCH patients, who presented with 
combined hyperlipidemia, mean whole-body glucose uptake was lower compared 
with the non-affected relatives (21). Most importantly, these observations were not 
confounded by gender/age and were found in the absence of obesity, as measured 
by body mass index (BMI), hypertension or impaired glucose tolerance. A similar 
study was reported by Aitman et al (22), who also used the clamp technique to study 
insulin action on both carbohydrate and fatty acid metabolism in 8 FCH patients with 
combined hyperlipidemia compared with 6 normolipidemic relatives and 2 non-
related controls. FCH patients showed impaired insulin- mediated glucose uptake in 
peripheral tissues, which was dependent on increased upper- body fat, as measured 
by dual-energy X-ray absorptiometry scan. Furthermore, impaired insulin mediated 
suppression of serum nonesterified fatty acids (NEFA) was found, although this was 
independent of BMI or fat distribution. This is consistent with elevated fasting and 
postprandial NEFA in hypertriglyceridemic FCH patients (25). These findings suggest 
that a defect in insulin-mediated suppression of NEFA in patients with FCH may play 
a primary role in the development of FCH phenotype.  These results were confirmed 
and extended by a study of Karjalainen et al (23) who studied 28 FCH patients with 
combined hyperlipidemia, 30 non-affected relatives and 72 non-related controls. 
Their data also showed that defects in both glucose oxidation and FFA suppression 
were also observed in relatives without dyslipidemia. 
In conclusion, the suppressive effect of insulin on FFA levels is impaired in both 
patients with FCH and their first-degree relatives. This impairment may precede 
dyslipidaemia in FCH. 
Several pathophysiological mechanisms may contribute to insulin resistance in 
FCH i.e., increased upper body-fat, decreased insulin-induced vasodilatation in 
skeletal muscle (21) or impaired post-prandial FA metabolism, as discussed below. 
Another potential mechanism contributing to insulin resistance is the activation of 
the tumor necrosis factor (TNF) / TNFreceptor axis. TNF has the ability to modulate 
the binding of insulin receptor substrate 1  (IRS-1) to the insulin receptor, thus 
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contributing to reduced insulin sensitivity (26). Activation of the TNF-TNFR axis also 
causes increased secretion of VLDL from the liver (27), an important characteristic 
of FCH. Other effects of TNF include induction of de novo  FA synthesis in 
adipocytes and hepatocytes and reduction of LPL expression on the endothelium 
(28). Finally, the increased leptin concentration reported in FCH (29) may also result 
in insulin resistance, due to the effect of leptin on pancreatic insulin secretion and 
on peripheral insulin action and sensitivity. 
FCH lipid phenotype and insulin resistance
All studies on insulin resistance in FCH have been performed in patients who 
exhibit a  combined hyperlipidemia. The reported defect in the ability of insulin to 
suppress FFA release results in elevated serum FFA concentration, and in peripheral 
tissues, particularly skeletal muscle, high FFA levels block glucose oxidation, 
causing insulin resistance (30). In the liver, high flux of FAA is the most likely driver 
of hepatic overproduction of TG and apoB, thereby contributing to an elevation in 
the concentration of VLDL (31). Insulin resistance is associated with a combined or 
hypertriglyceridemic lipid phenotype. However, this does not explain (isolated) high 
LDL-cholesterol in FCH, and the question arises as to the role of insulin resistance is 
in FCH patients with high LDL choleserol in the absence of hypertriglyceridemia.
This question was addressed by Pihlajamaki et al (24), who studied insulin action in 
55 FCH patients, including 19 subjects with hypercholesterolemia only, 22 subjects 
with combined hyperlipidemia, 14 subjects with isolated hypertriglyceridemia, and 
50 non-affected relatives compared with 110 non-related controls. All FCH family 
members, irrespective of their lipid profile, had higher FFA levels than controls. 
In contrast, insulin-stimulated glucose uptake was impaired only in patients with 
hypertriglyceridemia or combined hyperlipidemia. This is the first study to report 
that insulin action is selectively  impaired only in hypertriglyceridemic/combined 
hyperlipidemic subjects.  In 1998, Vakkilainen et al (32) also investigated whether 
glucose tolerance/insulin resistance is an inherant feature of FCH, independent of 
lipid phenotype or secondary to existing hypertriglyceridemia. In 253 FCH patients, 
an oral glucose tolerance test was performed. Among controls 94% had a normal 
glucose tolerance versus 80% of the hypercholesterolemic FCH patients (type IIA). 
In FCH patients with hypertriglyceridemia or combined hyperlipidemia, glucose 
tolerance was impaired, with a prevalence of 58.3% and 54.3%, respectively. In 
our large FCH cohort, including 23 patients with only hypercholesterolemia, 96 
patients with hypertriglyceridemia and 30 patients with combined hyperlipidemia, 
we evaluated insulin sensitivity using the homeostasis model assessment (HOMA, 
fasting insulin x fasting glucose / 22.5), which correlates closely with the glucose 
clamp technique in the assessment of insulin sensitivity. The HOMA index in 
patients who presented with hypertriglyceridemia or combined hyperlipidemia was 
significantly higher compared to patients with isolated hypercholesterolemia and 
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normolipidemic relatives (3.89 ± 3.04 and 4.42 ± 2.67 versus 2.67 ± 1.28 and 2.37 
± 1.41, unpublished data).
However, a major concern in all these studies is that a change in lipid phenotype, 
which is considered an important characteristic of FCH, is not taken into account. 
We reported that 43% of the FCH patients showed a change in lipid phenotype 
expression after 5 years (7). The effect of these intra-individual changes in lipid 
phenotype expression with time on insulin resistance has not been addressed in 
literature. It would be of great interest to study the interdependence of  insulin 
resistance on change in lipid phenotype expression with time to reveal further the 
role of insulin resistance in FCH.  
FCH and insulin resistance and visceral obesity
A  tempting hypothesis that potentially explains the presence of insulin resistance 
in hypertriglyceridemia alone, with or without hypercholesterolemia, is the 
frequent presence of visceral obesity in hypertriglyceridemic subjects (33). The 
interdependence of insulin resistance and visceral obesity was studied by Purnell 
et al (34). Insulin action was studied using the intravenous glucose tolerance test 
in 11 male FCH patients with combined hyperlipidemia, and visceral obesity 
was measured by computed tomography (CT) scan. In the FCH group, insulin 
sensitivity was associated inversely with intra-abdominal fat and BMI but not with 
subcutaneous fat. Therefore, insulin resistance was present in patients with FCH who 
were viscerally obese. The degree of insulin resistance was related to their degree of 
visceral obesity. In our FCH cohort, the HOMA index, used as a measure of insulin 
sensitivity, was also related to BMI  (r=0.43, p<0.001, unpublished data). Insulin 
resistance was also present in non-obese FCH patients (obesity measured by BMI) 
(21). However, it has been suggested that intra-abdominal fat levels, as measured by 
CT-scan, can vary up to 10-fold in non-obese subjects. The most sensitive parameter 
for predicting insulin resistance (e.g. BMI- reflecting degree of adiposity, waist-hip-
ratio (WHR)- reflecting abdominal obesity, or CT-scan measuring intra-abdominal 
fat) remains to be determined.
Can insulin resistance and/or visceral obesity explain the FCH lipid 
phenotype?
It is well-known that insulin resistance and visceral obesity are both associated with 
a number of metabolic abnormalities, including increased TG levels, lower HDL 
cholesterol, more sdLDL particles, and increased apoB production rates. These 
abnormalities are all characteristics of FCH (19). 
The main question of whether insulin resistance / visceral obesity can explain 
the FCH lipid phenotype remains unanswered. Purnell et al (34) examined the 
relationship between insulin resistance / visceral obesity and increased apoB levels 
in 11 FCH patients. For any level of insulin sensitivity or intra-abdominal fat, apoB 
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levels remained higher in FCH patients than controls. In our FCH cohort, including 
all subjects with different lipid phenotypes, the majority of the FCH patients had 
increased apoB levels and more sdLDL at any level of HOMA (unpublished data). 
Therefore, visceral obesity and/or insulin resistance, do not account fully for the 
elevated levels of apoB or high prevalence of sdLDL in FCH. These results support 
the physiological concept of separate, but additive, genetic determinants in the 
aetiology of the FCH lipid phenotype. We have reported previously that in our FCH 
families, a major gene influences apoB levels and sdLDL (35), although, this gene 
has not yet been found.
FCH and adipose tissue metabolism
So, FCH is associated with reduced insulin-mediated NEFA suppression, which 
is consistent with elevated fasting and postprandial FFA in hypertriglyceridemic 
FCH patients (25). Why are FFA suppressed poorly by insulin in FCH patients? It is 
hypothesized that a defect in FA metabolism is a primary defect in FCH, which is 
likely to be localized in the adipocyte: adipose tissue is the major site for storage 
and mobilizati on of FFA within the body.
A simplified scheme of adipose tissue metabolism is shown in figure 2. The FFA 
liberated by the continuous hydrolysis of core TG by LPL in VLDL  and chylomicrons 
are stored in adipocytes by intracellular re-esterifi cation to TG, a process that is 
mediated by the action of a basic protein called acylation stimulatory protein (ASP) 
and modulated by insulin (36). In the adipocyte re-esterification of FFA results in TG 
that can be hydrolysed again by hormone sensitive lipase (HSL), releasing FFA from 
the fat cell. While the most important lipolytic hormones are cathecholamines, 
insulin is important in the inhibition of HSL (37). 
Figure 2 Potential defects in adipose tissue metabolism in Familial Combined Hyperlipidemia, see 
figure 1 for key to abbreviations
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FCH and the role of ASP in adipose tissue metabolism
ASP was first characterized by Cianflone et al in 1989 (38). Adipocytes are able to 
secrete complement factors, including C3, from which ASP is generated through 
activation of the alternative complement pathway. The ASP pathway modulates 
the rate at which FA are trapped by adipocytes and converted to TG. ASP also 
influences the rate at which FA are released by adipocytes. In vivo evidence on the 
role of the ASP pathway in determining the effectiveness of FA trapping and storage 
by adipocytes has recently been reviewed extensively (39). 
Resistance of adipocytes to the effects of ASP and/or impaired ASP activity may 
contribute to reduced FFA uptake into adipocytes, potentially resulting in an 
increased flux of FFA to the liver and consequently in an increased hepatic VLDL 
synthesis, characteristic of FCH. For example, impaired ASP activity has been 
reported in hyperapobetalipoproteinemia, a condition apparently related to FCH 
(40,41). However, no elevation of apoB lipids were found in ASP-knock-out- mice 
(42). It is possible that species variations may account for this difference. In contrast, 
Cianflone et al (43) reported increased ASP levels in patients with coronary heart 
disease (CHD) and speculated that elevated ASP levels would counteract the 
reduced number (or impaired function) of the putative ASP receptor. Recently, 
Ylitalo et al (44) studied plasma ASP levels in 66 hypertriglyceridemic FCH patients 
compared with 84 normotriglyceridemic relatives. No differences in plasma ASP 
levels  was found. A key step in the ASP concept is that chylomicrons will promote 
ASP production. However, no response in plasma ASP after a fatty meal was found 
in FCH subjects (44) or in healthy controls (45). However, Cianflone et al (46) 
did report increased ASP levels after oral fat load. It has been suggested that ASP 
is generated only locally in adipose tissue and cannot be detected in peripheral 
plasma. Indeed, the work of Saleh et al (47) demonstrated that ASP generation in 
adipose tissue was accentuated postprandially in vivo. Although no significant 
difference in plasma ASP levels were found in FCH patients compared with their 
normolipidemic relatives, FCH patients were found to have significantly elevated 
serum levels of C3 (44). It remains to be determined whether C3 is an independent 
risk factor or a surrogate marker of vascular inflammation and atherosclerosis.  
FCH and the role of HSL in adipose tissue metabolism 
The release of FFA from visceral adipocytes is mediated by the action of the enzyme 
HSL. This lipolytic effect of HSL is inhibited by postprandial hyperinsu linemia. 
As discussed above, FCH is associated with increased insulin resistance, which 
accounts for the increased VLDL production via increasing supply of FFA to liver 
cells. 
Cathecholamines are the most important lipolytic hormones, and they activate 
HSL. In FCH patients from Sweden a marked resistance to the lipolytic effect of 
cathecholamines in fat cells has been demonstrated, predominantly due to a defect 
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in HSL (48). The maximum enzymatic activity of HSL was decreased by 40%. This 
lipolytic defect correlated with the serum lipid abnorma lities typical for FCH. 
However, in FCH patients from Finland, no difference in adipose tissue  HSL activity 
was found (49). In addition, in the genetically homogene ous Finnish population the 
HSL gene was not a major locus responsible for the expression of the FCH phenoty pe 
(50). The most likely explanation for the discrepancy in HSL activity results between 
the Swedish and Finnish FCH populations is the heterogeneity and background 
of FCH between the two populations. For example, a substantial number of the 
Finnish FCH patients had only hypercholesterolemia and a number of the patients 
with hypertriglyceridemia had normal apoB levels. Therefore, many of the Finnish 
patients would not have been expected to have impaired FFA trapping.  
Recently, the putative role of adipose tissue in the pathogenesis of FCH has been 
reviewed (51). Although more evidence-based arguments are needed, the current 
hypothesis suggests that a combined defect in lipid storage (as a result of reduced 
ASP and insulin action) and in lipolysis (following decreased HSL activity) results in 
adipose tissue that is metabolically inactive. As a result, FFA are shunted directly to 
the liver which drives apoB synthesis and increases VLDL levels (Figure 2).  
FCH and increased free fatty acid concentration
In vivo evidence has been provided suggesting a pivotal role for increased FFA in 
insulin resistance (22,31,52): FFA activate gluconeogenesis by supplying acetyl 
CoA which stimula tes one of the enzymes involved in hepatic gluconeogenesis, 
namely pyruvate carboxylase. Increased glucose production acts as a trigger to 
stimulate insulin secretion from the pancreas in order to maintain normoglycemia. 
Therefore, this can result in an increased fasting plasma insulin concentra tion. In 
FCH, increased fasting plasma insulin concentrations associated with the insulin 
resistan ce syndrome may be secondary to impaired postprandial FA metabolism. 
High FFA levels may lead to both a decrease in insulin-stimulated glucose uptake in 
adipose tissue and skeletal muscle, according to the scheme proposed by Randle et 
al (30), and to an increase in the synthesis of lipoproteins in the liver (31).
Recently, in vivo evidence of defective postprandial and postabsorptive FFA 
metabolism in FCH was demonstrated (53). 24 hr oral fat loading tests were 
performed with 7 FCH patients with combined hyperlipidemia and 7 non-related 
controls. Changes in FFA and ketone bodies, which represent hepatic products of 
FFA metabolism, were studied. The post-prandial (0-8hr) increase in ketone bodies 
was almost 4 times higher in FCH patients compared with controls, suggesting 
an increased flux of FFA to the liver, possibly due to inadequate FFA trapping in 
the adipocyte. In the post-absorptive period (8-24hr), FFA and ketone bodies were 
decreased significantly in FCH patients compared with controls, in whom ketone 
bodies increased. This may represent a diminished release of FFA from adipocytes 
by HSL.
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Why is the metabolism of FFA altered in FCH? Potential mechanisms include 
altered activity of ASP and/or HSL. Furthermore, insulin resistance has been 
associated with impaired inhibition of HSL, resulting in increased FFA release from 
adipocytes. In addition, genetic defects, resistance to lipolytic hormones, increased 
leptin levels and TNF activation may contribute to increased FFA concentrations in 
FCH (26-29). 
Conclusions
Studies aiming to solve the complex metabolic background of FCH have been going 
on for nearly 25 years. Several metabolic abnormalities have been suggested, but the 
exact cause of these metabolic disturbances is unknown. The abnormal metabolism 
of FA may be a primary defect in FCH which provides a pathophy siological link to 
the hepatic apoB overproduction, partial LPL deficiency and the insulin resistance 
sydrome, all of which are characteristic features of FCH (Figure 3). 
Figure 3 Possible central role of fatty acids in the pathogenesis of FCH 
  Free fatty acids (FFA) activate hepatic gluconeo genesis. Increased production of glucose 
is a trigger to the pancreas to secrete insulin in order to maintain normoglyce mia and can 
thus result in increased fasting plasma insulin concen tration, which is associa ted with 
the syndro me of insulin resistance. A defect in insulin action at the level of the adipocyte 
reduces FFA trapping, resulting directly in elevated plasma FFAs. Increased hepatic 
availability of FFA stimulates VLDL-apoB and triglyceride producti on. Furthermore, increase 
of FFA in plasma inhibits lipoprotein lipase (LPL) and promotes the release of LPL from 
the endothelial cells resulting in increased uptake of LPL by the liver which could result 
in slower clearance of TG-rich particles from plasma. So, an abnormal metabolism of fatty 
acids provides a pathophysio logical link to the hepatic apoB overproduction, partial LPL 
deficiency and insulin resistance syndrome, all characteristic features of FCH. The defect 
in fatty acid metabo lism could be in the acylation stimulatory protein (ASP) or hormone 
sensitive lipase (HSL) pathway, or due to resistance to lipolytic hormo nes, increased leptin 
concentration or activation of the TNF/TNFR axis. 
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To further delineate the pathogenesis of FCH, it is essential to simplify and 
standardize the diagnosis of FCH (7,8). In this respect, both  the aetiology of 
the increased pool of apo B100 containing TG-rich lipoproteins and that of the 
preponderance of sdLDL particles in FCH patients have to be elucidated. 
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Abstract
We compared in 506 members of families with familial combined hyperlipidaemia 
(FCH), two approaches to select subjects with an apparent increased risk for 
coronary heart disease: assay of only apolipoprotein (apo) B versus measurement 
of plasma lipids and lipoproteins. When comparing both criteria, there was an 
overlap of 81.2% at apo B levels ≤1250 mg/l and of 86.9% at apo B levels >1250 
mg/l. At apo B ≤1250 mg/l all subjects were normolipidemic. However, 18.8% of 
these subjects had sub-normal HDL-cholesterol concentrations (<0.9 mmol/l) who 
were not considered to have an increased risk because of very low LDL-cholesterol 
levels (<2.5 mmol/l). At apo B concentrations >1250 mg/l we observed a group 
with normal plasma lipid levels (13.1%). This group was defined as normolipidemic 
hyperapobetalipoproteinemia who are considered to have an increased risk for 
coronary heart disease. In this group, apo B determination was thus most informative. 
The selection of the subgroup with “normolipidemic hyperapobetalipoproteinemia” 
on the basis of the conventional approach could be refined using a cut off limit for 
plasma triglycerides <1.5 mmol/l. This limit distinguished optimally between an 
atherogenic very dense LDL pattern versus a dense and buoyant pattern.
Thus, based on the results of our study, the determination of apo B appeared to 
be, if not superior, at least as effective as the conventional lipid and lipoprotein 
parameters in classifying subjects at increased risk for coronary heart disease.
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Introduction
At present, the most commonly used approach to estimate coronary heart disease 
risk is based on the measurement of plasma cholesterol, triglycerides and high-
density lipoprotein cholesterol (HDL-chol) with calculation of low-density 
lipoprotein cholesterol (LDL-chol) by means of the Friedewald formula (1-4). The 
variable fasting conditions of the examined patients constitute the major limitation 
of this approach. In addition, the information that dense LDL is more atherogenic 
than buoyant LDL is not included (5). There is consensus that apoprotein (apo) B of 
LDL is a more accurate clinical measure of atherogenic risk than is total cholesterol 
or LDL-chol (6-10), but it is doubtful whether this is also true when risk estimation 
includes plasma lipids and HDL-chol. Sniderman and Cianflone (11) recently 
proposed apo B measurement as the first line risk estimator for coronary heart 
disease in stead of the conventional lipoprotein-oriented approach. 
This proposal prompted us to review our results on measurement of lipids, 
lipoproteins, LDL-subfractions and apo B measurement in 40 families with familial 
combined hyperlipidemia (FCH). FCH is the most common form of heritable lipid 
disorder accompanied by an increased incidence of cardiovascular disease (12). 
In these families, the occurrence of dense LDL is typical (13) and normolipidemic 
hyperapobetalipoproteinemia is more frequent (14). Thus, this sample group 
provides interesting study material to compare the validity of the lipoprotein-based 
and apoprotein B-based approaches in risk evaluation of coronary heart disease.
Subjects and Methods
Design
The recruitment of FCH families took place through probands exhibiting a 
combined hyperlipidemia with both plasma cholesterol and triglycerides above 
the 90th percentile, adjusted for age and gender, as derived from the Prospective 
Cardiovascular Munster (PROCAM) study (15). These values were consistent over 
several measurements in which the probands had not been given any lipid-lowering 
drug. Families were included when a multiple type hyperlipidemia with levels of 
total plasma cholesterol and/or triglycerides above the 90th percentile was present. 
Besides a proband presenting a combined hyperlipidemia, the presence of at 
least one first-degree relative with hypertriglyceridemia or hypercholesterolemia 
was obligatory. Furthermore, at least one of the first-degree relatives should have 
cardiovascular disease before the age of 60 years. All probands were tested for an 
underlying cause of hyperlipidemia (i.e., diabetes mellitus, hypothyroidism and 
hepatic or renal impairment). The presence of one of these causes excluded them 
and their families from further analyses. None of the probands in these families was 
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homozygous for the apo E2 allele and none of the first-degree relatives had tendon 
xanthoma. In addition, to refine the selection procedure, the 95th percentile for 
plasma cholesterol and triglycerides was used if the body mass index exceeded 30 
kg/m2, or an alcohol consumption of more than two units per day was present. In 
total 506 members including the probands were studied from multigenerational 
families. All individuals were Caucasian above the age of 12 years. Everyone filled 
out a questionnaire in order to collect information on medical status, medication 
use, alcohol intake and smoking habits. The ethical committee of the University 
Hospital of Nijmegen approved the study protocol. Details about the study 
population have been described elsewhere (13,14).
Blood sampling procedure
Patients did not taken lipid-lowering medication for at least four weeks. After an 
overnight fast blood was drawn by venipuncture into EDTA-containing vacutainer 
tubes. Non-local participants were visited at their homes, and blood was transported 
immediately to the laboratory. Plasma was isolated within 3 hours for determination 
of the lipid, lipoprotein, apolipoprotein B levels and the LDL subfraction profile.
Analytical methods
Plasma cholesterol and triglycerides were measured on the Hitachi 747 analyser 
with enzymatic, commercially available reagents (Boehringer-Mannheim, 
Germany). HDL-chol was determined by the PEG-6000 method (16), LDL-chol was 
calculated by the Friedewald formula (4). For other purposes, not reported here, 
VLDL-chol and LDL-chol were determined by ultracentrifugation (17). Both series 
of LDL values obtained with different methods agreed well (Pearson correlation 
coefficient r = 0.97, n = 506) and were used in the risk estimation study. For risk 
evaluation, the upper limits for total cholesterol, LDL-chol, and triglycerides were 
6.5, 4.5 and 2.0 mmol/l, respectively; as normal limits for HDLchol we used ≥0.90 
mmol/l (18). Subjects were defined to have abnormal plasma lipids or lipoproteins 
when at least one of the values was abnormal.
Total plasma apo B concentrations were determined by immunonephelometry 
following modifications of a previously reported approach (19). As antigen we used 
LDL (d 1.025 – 1.038 g/ml). The antiserum appeared monospecific and did not react 
with purified apo A-I, apo A-II, apo C-II, apo C-III, apo E or human albumin as tested 
by immunodiffusion. The analyses were performed on the Behring Nephelometer II 
(Behringwerke AG, Marburg). Before use, the antiserum was treated with 7.5% (w/
v) PEG-4000 1:2 (v/v). After incubating overnight at room temperature, the mixture 
was centrifuged and filtered through a 0.20 um filter. Sample (30 uL), diluted 20 
or 100 times with saline, was incubated with 40 uL of antibody solution for 20 
min followed by immunonephelometry. Results of both dilutions had to be within 
5% and, after acceptance, were averaged. The assay was calibrated against freshly 
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isolated LDL. The LDL protein content was determined by the method of Lowry 
et al. (20) with chloroform extraction of the coloured solution before reading the 
absorbance. To evaluate the standardisation of the measurements, two sets of fresh-
frozen plasma samples were shipped in dry ice to the Northwest Lipid Research 
Laboratories at the University of Washington, Seattle. One set was composed by 
14 untreated plasma samples while the other set was composed by 14 samples to 
which we added 600 mg/L of saccharose prior to being frozen at -80º C. Multiple 
apo B analyses were performed on these samples at the Northwest Lipid Research 
Laboratories using a standardised nephelometric approach calibrated by the use 
of the World Health Organisation International Federation of Clinical Chemistry 
(WHO-IFCC) First International Reference preparation for apo B (21).
LDL subfractions were detected by single spin density gradient ultracentrifugation, 
according to a method described in detail elsewhere (22). Up to five LDL 
subfractions could be distinguished concentrated in the following density ranges: 
LDL1 (1.030-1.033 g/ml), LDL2 (1.033-1.040 g/ml), LDL3 (1.040-1.045 g/ml), 
LDL4 (1.045-1.049 g/ml) and LDL5 (1.049-1.054 g/ml). The ultacentrifugation 
tubes, containing the LDL subfractions stained with Coomassie Briljant Blue 
R, were placed in a specially designed rack and photographed (23). Accurate 
documentation of the different LDL subfraction patterns was obtained by scanning 
the obtained slides in triplicate on a LKB 2202 ultrascan laser densitometer gel 
scan program (Pharmacia-LKB, Upsala, Sweden), The mean peak heights (h1-h5) 
of the LDL subfractions (LDL1-LDL5) on the three scans were used to calculate 
the parameter K as a continuous parameter, that best describes each individual 
LDL subfraction pattern (24). The relative contribution of each LDL subfraction, 
expressed by its peak height (%hl -%h5), relative to the total LDL subfraction profile 
(total LDL [100%] = %hl+%h2+%h3+%h4+%h5) was calculated. The relative peak 
heights of LDL3 and the less frequently occurring LDL4 and/or LDL5 were added to 
give %h3’ = (%h3+%h4+%h5), where LDL (100%) = LDL 1 [%h 1] + LDL2 [%h2] 
+LDL3 [%h3’], When a subfraction profile was characterised by a predominance 
of buoyant LDL particles (h1-h3 >0), parameter K was calculated by K=(%h1-%h3’ 
)/(%h2-%h3’ + 1). In the case of a predominance of dense LDL subfraction (h1-h3 
<0), parameter K was calculated by: K=(%h1-%h3)/(%h2-%h1 + 1). A buoyant LDL 
subfraction profile was defined by values of K≥0, whereas a dense LDL subfraction 
profile was reflected by parameter K<0 (24). In those subjects with predominantly 
dense LDL subfractions LDL3, LDL4 and LDL5, parameter K was <-0.25. So, the 
dense LDL subfraction profile (K<0) was subdivided into 2 groups: dense (-0.25≤ K≤ 
0) and very dense (K<-0.25) LDL subfraction profile.
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Statistics
A one-way analysis of variance (ANOVA) was used to analyse the differences in 
plasma lipid and lipoprotein levels between subjects stratified by three different 
LDL subfraction profiles. The student t-test was used to analyse the differences in 
mean values between the distinctive groups. Pearson correlation coefficients were 
computed to determine the correlation between LDL values calculated by Friedewald 
formula and determined by ultracentrifugation. The correlation between apo B values 
obtained in our laboratory and these obtained at the Northwest Lipid Research 
Laboratories (NWLRL) in Seattle was also determined by computing Pearson 
correlation coefficients. All values are presented as mean ± S.D.. Statistical analysis 
were performed with procedures available in SPSS/PC software (Statistical Package for 
the Social Sciences) Software package version 4.0 (SPSS Inc., Chicago, IL, USA).
Results
Standardisation of apo B measurements
To evaluate the accuracy of the apo B measurements, we prepared two sets of fresh-
frozen samples, encompassing a large range of apo B values. Saccharose was added 
as a cryopreservative to one set of samples while the other set did not contain any 
additive. Multiple apo B analyses were performed on each sample, in our laboratory 
and at the Northwest Lipid Research Laboratories (NWLRL) in Seattle. The NWLRL 
has been the leading laboratory of the IFCC International Standardisation of apo A-1 
and apo B and consequently these parameters are measured by a highly standardised 
nephelometric approach calibrated against the WHO-IFCC International Reference 
Materials with accuracy-based target values assigned as previously described in 
details (21,25). An excellent agreement was found between the apo B values obtained 
in our laboratory and those obtained at the NWLRL with a correlation coefficient of 
0.995 for the untreated samples and a correlation coefficient of 0.998 for the samples 
containing saccharose. However, there was a systematic bias between the apo B 
values obtained in our laboratory and those obtained at the NWLRL and this bias 
was practically identical in the two sets of data. The following equation, y=0.73x + 
49, where x represents the Nijmegen data, provides the magnitude of the bias and 
this equation was used to harmonise our data to those traceable to the WHO-IFCC 
International Reference Material. When corrected, the average bias and the absolute 
bias for apo B measurements were 0.5% and 2.7%, respectively. These biases were 
independent of the plasma triglyceride concentration up to a value of 8.0 mmol/l. 
Considering the excellent correlation between the two methods, the inaccuracy of 
our data, prior to correction, was most likely related to the assay calibration due to 
differences in the method used for LDL purification and/or in the Lowry method used 
to assign a target value to our primary calibrator. 
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The diagnostic power of apolipoprotein B versus lipid and lipoprotein 
profile
We compared the validity of apo B assay as a selection criterion for coronary heart 
disease versus conventional risk estimation on the basis of measurement of lipids 
and lipoproteins. Subjects were grouped according to the cut off limits for total 
cholesterol, LDL-chol, and triglycerides (6.5, 4.5, and 2.0 mmol/l, respectively) (18), 
and stratified as having an increased risk of coronary heart disease when a value 
was outside the normal range. In total 246 subjects had an elevated total cholesterol 
and/or triglycerides and/or LDL-chol level and were defined as subjects at risk. In all 
these subjects the apo B level was >1250 mg/l. So, values of apo B above 1250 mg/l 
were considered to identify subjects at risk for coronary heart disease.
In table 1 we show the comparison of both diagnostic criteria for selecting subjects 
with an apparent increased risk for coronary heart disease. 
Table 1 Comparison of both diagnostic criteria (apolipoprotein B values versus lipid and lipoprotein 
profile) for selecting subjects with an apparent increased risk for coronary heart disease.
Apo B ≤ 
1250 mg/l
Apo B >
1250 mg/l
Total group (n=506)  223  283
Normal lipids  181  37
Elevated TC and/or TG and/or LDL-chol *  0  246
Decreased HDL-chol only **  42  0
TC = total cholesterol, TG = triglycerides
* defined as TC >6.5 mmol/l and/or TG >2.0 mmol/l and/or LDL-chol >4.5 mmol/l
** defined as HDL-chol<0.9 mmol/l without other abnormal lipid concentrations
Within the group of subjects with apo B concentration ≤1250 mg/l no subject had 
elevated total cholesterol or triglyceride concentrations. A subgroup of 42 subjects 
(18.8%) was found with HDL-chol <0.9 mmol/l without other abnormal lipid 
levels, apparently not being at an increased risk because of the concomitant sub-
normal total cholesterol and low LDL-chol concentrations (<2.5 mmol/l). Thus, at 
an apo B concentration ≤1250 mg/L, there was an overlap between both diagnostic 
criteria in 81.2% of the subjects. With inclusion of a second risk estimator of the 
lipid/lipoprotein approach, there was complete identity between both selection 
criteria. On the other hand, the group with apo B >1250 mg/L included 37 subjects 
(13.1%) with normal plasma lipid and lipoprotein parameters (Table 1). This 
subgroup is referred to normolipidemic hyperapobetalipoproteinemia in whom 
the risk estimation on the basis of apo B appears thus more accurate. At an apo B 
concentration >1250 mg/L, there was an overlap between both diagnostic criteria 
in 86.9% of the subjects.
The phenomenon of normolipidemic hyperapobetalipoproteinemie subjects 
(n=37) was studied further with regard to their triglyceride concentrations. All 
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these 37 subjects had a plasma triglyceride concentration between 1.5 and 2.0 
mmol/l. When the cut off limit for normal triglycerides was lowered to 1.5 mmol/l, 
the overlap between both selection criteria in the subjects with apo B>1250 mg/l 
increased from 86.9 to 97.8%. Decreasing the cut off limit for plasma triglycerides 
from 2 mmol/l to 1.5 mmol/l could thus enhance the selection power. To underscore 
this, we re-analysed, subjects with a plasma triglyceride concentration between 1.5 
and 2 mmol/l (n=76). Of the 76 subjects, only 9 had a normal apo B concentration 
which stresses the additional power of lowering the cut-off limit for normal 
triglycerides from 2.0 to 1.5 mmol/l for inclusion of the patients with normal versus 
hyperlipidemic hyperapobetalipoproteinemia.
Dense LDL as another risk estimator
The total group of 506 subjects was subdivided according to their LDL-subfraction 
profile defined by parameter K. In 132 subjects a buoyant LDL subfraction profile 
(K>0, group 1) was found. A dense LDL subfraction profile, defined by parameter 
K≥-0.25 and K≤0, was found in 151 subjects (group 2), whereas 223 subjects 
showed a very dense LDL subfraction profile (K<-0.25, group 3). As expected, in 
FCH a very dense LDL subfraction profile was frequently observed (Table 2). 
Table 2 Plasma lipids, lipoproteins and apolipoprotein B concentrations in subjects stratified 
according to their LDL-subfraction profile.
Buoyant LDL Dense LDL Very dense LDL
Parameter Ka K>0 -0.25≤K≤0 K<-0.25
Group 1 Group 2 Group 3
Total group (n) 132 151 223
Age (years) 36.5 ± 16.3 37.7 ± 16.6 46.4 ± 15.9c
Plasma cholesterol 5.23 ± 1.13 5.48 ± 1.35 6.40 ± 1.30c
Plasma triglyceridesd 0.88 ± 0.51 1.42 ± 1.42b 2.69 ± 1.84c 
HDL-chold 1.45 ± 0.33 1.24 ± 0.33b 0. 99 ± 0.25c
LDL-chold 3.40 ± 1.04 3.68 ± 1.26b 4.27 ± 1.09c
Plasma apo Bd 1050 ± 272 1218 ± 338b 1616 ± 378c
LDL-chol/plasma apoBd 3.31 ± 0.40 3.06 ± 0.50b 2.65 ± 0.57c
Plasma concentrations of lipids and lipoproteins are given in mmol/L and of apo B in mg/L.
a) parameter K is defined in Materials and Methods section
b) dense LDL versus buoyant LDL p<0.05, student’s t-test 
c) very dense LDL versus dense LDL p<0.05, student’s t-test
d) significant difference for the presented variable ANOVA p<0.005
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Table 2 shows the concentrations of plasma lipids, lipoproteins and apolipoprotein 
B stratified by LDL-subfraction profile. A significant difference for all parameters 
was found (ANOVA, p<0.05). A very dense LDL subfraction profile was associated 
with significantly increased levels of total cholesterol, triglycerides, LDL-chol, apo 
B and decreased concentration of HDL-chol and ratio LDL-chol/plasma apo B 
compared to a dense and buoyant LDL subfraction profile (Table 2). 
In Figure 1 we show that a triglyceride concentration of 1.5 mmol/l is a sharp cut 
off limit for segregating subjects with a very dense LDL versus dense and buoyant 
LDL confirming the rationale to lower the threshold for normal triglyceride value 
from 2 to 1.5 mmol/l. In addition figure 2 shows that an apo B value of 1370 mg/l, 
near to the cut off limit of 1250 mg/l used in the present evaluation, can optimally 
distinguish subjects with very dense versus dense and buoyant LDL.
Figure 1 Cumulative frequency distribution of plasma triglycerides in the groups with very dense 
versus dense and buoyant LDL. Note: the frequency distribution for the dense and buoyant 
group is combined and reversed for better establishing the cut off limit that optimally 
distinguishes both groups. The intercept of both curves is at a triglyceride concentration of 
1.5 mmol/l.
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Figure 2 Cumulative frequency distribution of plasma apo B in the groups with very dense versus 
dense and buoyant LDL. For explanation see figure 1. The intercept of both curves lays at an 
apoB concentration of 1370 mg/l.
Discussion
In this study, using subjects with familial combined hyperlipidemia and their 
relatives, we show that assay of apo B results in almost the same selection of 
subjects with an increased risk for coronary heart disease as measurement of 
lipids and lipoproteins. Thus, on the basis of one single deviating parameter 
(apolipoprotein B) we obtained 81.2% of agreement between both criteria in the 
subjects with normal apo B concentrations (<1250 mg/l) and 86.9% agreement in 
the subjects with increased apo B concentrations (>1250 mg/l). With inclusion of a 
second parameter, we obtained 100% agreement in the first group, whereas, in the 
group with increased apo B concentration, an additional 10.9% of subjects with 
normal lipid concentrations could be included if the upper limit for triglycerides 
was decreased to 1.5 mmol/l. Thus, irrespective of knowing the coronary heart 
disease conditions assessed by invasive techniques we were able to show that the 
claim of Sniderman and Cianflone (11) about the predictive value of total apo B 
measurement in plasma is indeed justified. The predictive value of apo B is slightly 
superior to that obtained with the conventional risk estimation for which a fasting 
condition is needed and three different parameters should be measured according 
to strict quality control criteria in combination with calculation of LDL-cholesterol. 
Evaluation of treatment by diet or drugs would be less problematic if only the 
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change in one parameter has to be taken into account instead of positive and/or 
negative changes in three to four different parameters. The additional value of apo 
B measurement is especially relevant in subjects with the so called normolipidemic 
hyperapobetalipoproteinemia (6). Patients with this phenotype are characterised 
by a typical LDL-subfraction pattern with a predominance of very dense LDL; the 
protein to cholesterol content of this LDL is increased (13,14,26) This explains their 
preferential selection on the basis of apo B versus LDL-chol. A dense LDL subfraction 
is usually associated with an increased plasma triglyceride concentration (22-24). 
It is surprising that we were able to detect a group of normolipidemic subjects with 
a plasma triglyceride concentration in the upper part of the normal range (between 
1.5 and 2.0 mmol/l). lt is likely that the subjects participating in our family study 
strictly adhered to the prescriptions for fasting. 
Regarding the large biological variation of the fasting plasma triglyceride 
concentration (27), it cannot be excluded that these patients have temporary 
episodes of hypertriglyceridemia throughout the year. The half-life of VLDL, the 
main triglyceride carrier is several hours (28,29); while that of LDL is several 
days (29,30). In addition, the parameter LDL-apo B is independent of typical lipid 
exchange reactions, in contrast to LDL-chol. Apo B is thus a more stable metabolic 
estimate of the lipoprotein status similarly as HbA1c which is a long term metabolic 
control of glucose homeostasis. Consequently, strict fasting conditions on the day 
preceding the blood sampling procedure or an increased physical activity in the 
evening or morning before blood sampling can normalise plasma triglycerides in 
contrast to LDL-chol and especially to LDL-apo B. The fact that fasting conditions are 
mandatory for the lipid-oriented approach makes it more attractive to concentrate 
on apo B measurements. On the other hand, increased apo B concentrations 
are the result of quantitative changes in LDL rather than qualitative changes. 
Indeed, only 10.9% of our subjects with increased apo B concentrations belong 
to the last group with mainly qualitative changes in LDL. The apo B approach is 
thus primarily directed towards the atherogenic LDL particle. Consequently, this 
approach diminishes the significance of an altered triglyceride mechanism as a 
risk factor for coronary heart disease. On the basis of epidemiological and case 
control studies, hypertriglyceridemia in combination with slightly decreased HDL-
chol level is considered atherogenic (15). However, the group with normolipidemic 
hyperapobetalipoproteinemia had, in our study, apo B values that were lower than 
those in the group with hypertriglyceridemia and decreased HDL-chol levels. That 
decreasing the cut off limit for normal triglycerides to 1.5 mmol/l results in the 
inclusion of this group, could mean that normolipidemic hyperapobetalipoprotein
emia is a marginal problem within two valid diagnostic approaches. Nevertheless, 
these patients have a very dense LDL pattern. On the basis of this it is tempting to 
decrease, in the classical lipid approach, the normal limit for plasma triglycerides to 
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1.5 mmol/l. A similar approach was followed by Austin et al (27). This cut off value 
could have relevance for the metabolic control of VLDL secretion.
In our study, the apo B value appeared to be, if not superior, at least as effective 
as lipid and lipoprotein values in identifying subjects at increased risk for coronary 
artery disease. However, to reach uniformity across the studies, it is imperative that 
apo B is measured by standardized methods that are documented to be traceable 
to the WHO-IFCC International Reference Material. Recently, population-based 
reference values for apo B obtained by WHO-IFCC standardised methods 
showed an excellent agreement between the apo B cut-off values obtained in the 
different populations (31-33). Another potential problem in the accuracy of apo B 
measurements may be related to improper storage of the samples, which may result 
in denaturation of apo B (34). In this study, we show that the storage at -80º C does 
not affect the apo B assay and that addition of saccharose to fresh-frozen quality 
control samples is not needed. However, in lyophilized samples used as assay 
calibrator or quality control, saccharose addition may be important to prevent LDL 
denaturation (35).
In conclusion, we have shown that apo B values obtained on accurate assay 
are if not superior at least as effective as the conventional lipid and lipoprotein 
parameters in classifying subjects at increased risk for coronary artery disease.
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Abstract
Familial Combined Hyperlipidemia (FCH) is characterised by hypercholesterolemia 
and/or hypertriglyceridemia and associated with an increased risk of cardiovascular 
disease (CVD). The plasma lipid and lipoprotein levels in subjects with FCH are 
relatively moderately elevated and do not fully explain the increased risk of CVD. 
Hyperhomocysteinemia is a disorder of methionine metabolism and also a well-
known independent risk factor for CVD. We investigated whether subjects with 
FCH have higher plasma homocysteine concentrations than controls, and whether 
homocysteine contributes to the increased risk of CVD in FCH. Furthermore we 
evaluated whether parameters of lipid and lipoprotein metabolism and/or insulin 
resistance are associated with the homocysteine level.
In total 667 subjects, including 161 subjects with FCH, 109 spouses who 
referenced as control group and 397 normolipidemic relatives were studied. FCH 
was defined by the presence of plasma total cholesterol and/or triglyceride levels 
above the 90th percentile adjusted for age and gender. The mean homocysteine 
concentration of the FCH group did not significantly differ from the control group. 
The risk for CVD due to hyperhomocysteinemia in subjects with FCH was not higher 
than in subjects without FCH. No associations were observed between plasma 
homocysteine concentration and plasma lipid and lipoprotein levels, including 
small dense LDL, nor between homocysteine concentration and insulin resistance.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common form of heritable lipid 
disorder with an estimated prevalence of 1.0 to 2.0% in the general population and 
10 to 20% in survivors of premature myocardial infarction (1). The hyperlipidemia 
is characterised by elevations of plasma total cholesterol (TC) and/or triglyceride 
(TG) concentration and therefore known as ‘multiple type hyperlipidemia’. Features 
of FCH include an increased production and decreased clearance of very low 
density lipoproteins (VLDL), an elevated apolipoprotein B (apo B) concentration 
and a preponderance of atherogenic small dense low density lipoprotein (LDL) 
subfractions (2,3). In addition, FCH is associated with insulin resistance. The lipids 
and lipoprotein levels in FCH are relatively moderately elevated and do not fully 
explain the total increased risk of cardiovascular disease (CVD). 
Hyperhomocysteinemia is a disorder of methionine metabolism. Several studies 
reported that even moderate hyperhomocysteinemia is an independent risk factor 
for CVD (4-6). An increase of 5 µmol/L homocysteine may increase the risk of CVD 
by as much as does an increase in cholesterol level of 0.5 mmol/L (7). It is estimated 
that approximately 10% of the CVD in the general population could be attributed 
to hyperhomocysteinemia (7). However the results of some population-based 
prospective cohort studies have reported no association between homocysteine 
level and risk of CVD (8-10) or only in subpopulations (11,12). 
The aim of this study was to investigate whether subjects with FCH have higher 
plasma homocysteine levels than controls and whether this metabolic factor 
contributes to the increased risk of CVD in FCH. Furthermore, we studied whether 
parameters of lipid and lipoprotein metabolism, including apo B and small dense 
LDL, and/or insulin resistance are related to the homocysteine level.
Subjects and Methods
Study population
Recently, we performed a large family study (n=667 individuals) to investigate the 
metabolic and genetic aspects of FCH. For the current study plasma homocysteine 
levels were measured in all subjects with FCH (probands and relatives) and 
compared with homocysteine levels of spouses, who referenced as control group. 
Furthermore, the normolipidemic relatives were included to evaluate which factors 
are related to the homocysteine level. The relatives and spouses in this study were 
ascertained through probands exhibiting a combined hyperlipidemia, with both 
plasma TC and TG concentrations above the 90th percentile, adjusted for age 
and gender, as obtained from the Prospective Cardiovascular Munster (PROCAM) 
study (13). These values were confirmed by repeated measurement, on a lipid 
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lowering diet and without lipid-lowering drugs. At least one first-degree relative 
of the proband had a multiple type hyperlipidemia with elevated levels of plasma 
TC and/or TG. Furthermore, at least the proband or one of the first-degree relatives 
should have premature CVD before the age of 60 years. All probands were tested 
for an underlying cause of hyperlipidemia (i.e., diabetes mellitus, hypothyroidism, 
and hepatic or renal impairment). The presence of one of these causes excluded 
the proband and his/her family from further analysis. None of the probands in 
these families were homozygous for the apo E2 allele and none of them and their 
first-degree relatives had tendon xanthoma. Relatives were included in this study in 
the FCH group when affected by FCH (having a plasma TC and/or TG level above 
the 90th percentile adjusted for age and gender (PROCAM)). The spouses of these 
probands and relatives referenced as control group. All individuals were Caucasian 
above the age of 12 years. All subjects filled out a questionnaire about their previous 
medical history, especially cardiovascular status, medication, and smoking habits. 
Body mass index (BMI), waist/hip ratio (WHR) and blood pressure were determined 
in all subjects. After a withdrawal of four weeks of lipid-lowering medication and 
an overnight fast, venous blood was drawn by venipuncture. Samples were put on 
ice immediately and transported to the laboratory. The ethical committee of the 
University Medical Center Nijmegen approved the study protocol. 
Laboratory measurements
Serum levels of plasma TC, TG, and high density lipoprotein cholesterol (HDL-
C) were determined enzymatically on a Hitachi 747 analyser. LDL-C levels 
were calculated according to the Friedewald method (14). ApoB concentrations 
were determined by immunonephelometry (15,16). LDL subfraction analysis 
was performed by density gradient ultracentrifugation (17). Each individual LDL 
subfraction profile was defined by a continuous parameter K, as described in detail 
previously (18), recently modified by using the relative cholesterol concentrations in 
the LDL subfractions to calculate parameter K. K>0 reflects a light LDL subfraction 
profile and K≤0 a small dense LDL subfraction profile (19).
The total homocysteine concentration in plasma was measured by an automated 
high-performance liquid chromatography method with reverse phase separation 
and fluorescence detection (Gilson 232-401 sample processor, Spectra Physics 
8800 solvent delivery system and Spectra Physics LC 304 fluormeter), essentially 
according to the method by Fiskerstrand et al.(20). Glucose concentrations were 
measured using the oxidation method (Beckman, Glucose Analyser2, Beckman 
Instruments Inc., Fullerton, CA 92634 USA). Plasma insulin concentrations were 
determined using a double antibody method with an interassay variability of 6%. 
Insulin resistance was assessed by the Homeostasis Model Assessment index 
(HOMA). The HOMA index was calculated by following formula as described by 
Matthews et al.: fasting insulin x fasting glucose / 22.5 (21). The methylenetetra-
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hydrofolate reductase (MTHFR) genotype was tested by polymerase-chain reaction 
(PCR) essentially according to Frosst et al. (22).
Statistical analysis
Descriptive values were expressed as mean ± SD or absolute numbers with 
percentages. Differences in characteristics between subjects with FCH, controls and 
normolipidemic relatives were tested by means of Generalized Estimating Equations 
(GEE) because of possible correlated values within families. Also odds ratios as an 
estimate of risk of cardiovascular disease were calculated using GEE. Correlations 
between plasma homocysteine level (log transformed) and variables were analysed 
using Pearson’s correlation coefficients. Multiple linear regression test was used to 
select the variables that contributed independently to homocysteine level. P-values 
<0.05 were considered statistically significant.
Results
In total 667 subjects, including 161 subjects with FCH, 109 spouses, who 
referenced as control group and 397 normolipidemic relatives from 37 families, 
were included in the study. Table 1 shows the anthropometric measurements, 
life style variables, including smoking and biochemical variables by subjects 
with FCH, controls and normolipidemic relatives. The ratio women/men was not 
significantly different between the groups. The mean age of the group of subjects 
with FCH was significantly younger compared to controls and significantly older 
compared to the normolipidemic relatives. As expected, the group of subjects with 
FCH had a higher prevalence of CVD compared to controls and normolipidemic 
relatives. Smoking habits did not differ between the studied groups. The BMI and 
WHR were significantly higher in the FCH group compared to the control group 
and normolipidemic relatives. Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were not significantly different between the FCH group and controls, 
but were significantly higher in the FCH group compared to the normolipidemic 
relatives. By definition the FCH group had significantly higher plasma TC and TG 
concentrations compared to controls and normolipidemic relatives. In addition, the 
subjects with FCH had a more atherogenic lipid and lipoprotein profile as reflected 
by decreased HDL-C-, increased LDL-C- and increased apo B-concentrations. 
The subjects with FCH also had a more dense LDL subfraction profile as reflected 
by a more negative value of parameter K compared to the control group and 
normolipidemic relatives. 
Subjects with FCH appeared to be more insulin resistant as assessed by the HOMA 
index, which was significantly higher, compared to controls and normolipidemic 
relatives. The glucose concentration was not significantly different between the FCH 
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group and control group whereas the subjects with FCH had significantly higher 
insulin levels comparing to both other groups. The prevalence of 677 TT genotype 
was not significantly different between the groups. The differences between the 
control group and normolipidemic relatives are indicated in Table 1.
Table 1 Anthropometric and biochemical parameters in subjects with familial combined 
hyperlipidemia (FCH) compared to controls and normolipidemic relatives (NL)
FCH 
n=161
Controls 
n=109
NL 
N=397
M/F 71/90 50/59 188/209
Age (years) 47 ± 16 # * 53 ± 13 ‡ 39 ± 16
CVD (y/n) 34 (21%) # * 4 (4%) 24 (6%)
Smoking (y/n) 35 (22%) 19 (17%) 95 (24%)
BMI (kg/m2) 27.6 ± 4.1 # * 26.3 ± 3.8 ‡ 24.1 ± 3.7
WHR 0.88 ± 0.09 # * 0.86 ± 0.09 ‡ 0.83 ± 0.08
SBP (mmHg) 138 ± 17 * 135 ± 16 ‡ 128 ± 16
DBP (mmHg) 86 ± 8 * 84 ± 9 ‡ 80 ± 10
TC (mmol/l) 6.4 ± 1.4 # * 5.4 ± 1.0 ‡ 4.9 ± 1.0
TG (mmol/l) 3.6 ± 2.9 # * 1.4 ± 0.9 ‡ 1.2 ± 0.5
HDL-C (mmol/l) 0.95 ± 0.28 # * 1.27 ± 0.36 1.22 ± 0.32
LDL-C (mmol/l) 3.92 ± 1.33 # * 3.62 ± 0.96 ‡ 3.30 ± 0.91
Apo B (mg/l) 1341 ± 292 # * 1057 ± 232 ‡ 983 ± 240
K-value -0.26 ± 0.28 # * 0.03 ± 0.24 0.04 ± 0.20
Glucose (mmol/l) 5.5 ± 1.5 * 5.3 ± 0.8 ‡ 5.0 ± 0.6
Insulin (mU/ml) 15.1 ± 8.4 # * 11.5 ± 5.3 10.6 ± 5.6
HOMA 3.8 ± 2.8 # * 2.8 ± 1.4 ‡ 2.4 ± 1.4
MTHFR TT677 19 (12%) 9 (8%) 32 (8%)
M/F: male/female, CVD: cardiovascular disease, BMI: body mass index, WHR: waist/hip ratio, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol, TG: triglycerides, HDL-C: 
high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, apo B: apolipoprotein 
B, K-value <0 reflects small dense LDL, HOMA: Homeostasis model assessment for insulin resistance 
defined by fasting plasma insulin x fasting plasma glucose / 22.5, MTHFR: methylenetetrahydrofolate 
reductase. Results are presented as mean values ± SD, #: statistical significant FCH compared to 
controls, *: statistical significant FCH compared to normolipidemic relatives, , ‡: statistical significant 
controls versus normolipidemic relatives, P<0.05= statistical significant 
FCH and plasma homocysteine 
The first aim of this study was to investigate whether subjects with FCH have 
higher plasma homocysteine levels than controls. The mean plasma homocysteine 
concentration (Table 2) in the FCH group was not significantly different from the 
control group with a mean difference of 0.9 µmol/l (CI 95% -0.5 to 2.3). After 
adjustment for age and sex, the mean difference in homocysteine levels between 
FCH and control subjects was 0.9 µmol/l (CI 95% -0.4 to 2.5). Figure 1 shows 
the individual fasting plasma homocysteine values for the subjects with FCH and 
control subjects. The cut-off point was defined as the 90th percentile in control 
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subjects (=18.9 µmol/l). Among the subjects with FCH, 16 (10 %) had fasting 
homocysteine concentrations above the cut-off point of 18.9 µmol/l, versus 10 (9 
%) in the control group (Table 2). 
Table 2 Plasma homocysteine concentration in subjects with familial combined hyperlipidemia 
(FCH) compared to controls 
FCH
n=161
Controls
n=109
Homocysteine (µmol/l)
>90th perc. (>18.9 µmol/l)
14.1 ± 6.5
16 (10)
13.2 ± 4.8
10 (9)
NS
NS
Values are mean ± SD and absolute numbers (percentages), NS: not significant, perc.: percentiles
Figure 1 Fasting homocysteine concentrations (µmol/l) in subjects with Familial Combined 
Hyperlipidemia (FCH) (n=161) and controls (n=109). The straight line indicates the 90th 
percentile of the homocysteine distribution in the control subjects.
Homocysteine and risk of cardiovascular disease 
Hyperhomocysteinemia is associated with CVD. Therefore, we stratified the 
subjects by the presence or absence of CVD (Table 3). Thirty-four (21%) of the 161 
subjects with FCH had CVD. The group of control subjects with CVD consisted of 
only 4 subjects. As FCH is not associated with hyperhomocysteinemia, we analysed 
normolipidemic relatives and non-related control subjects together in 1 group, 
defined as non-FCH. In this non-FCH group 28 (6%) of the 506 subjects had CVD.
In the non-FCH group increased levels of homocysteine, defined by levels above 
the 90th percentile (18.9 µmol/l), were associated with a 2.8 times increased risk 
of CVD compared to subjects with lower homocysteine levels (Table 3). In the FCH 
group increased levels of homocysteine were also associated with increased risk of 
CVD although the risk estimate was lower. 
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Table 3 Odds ratios for cardiovascular disease associated with hyperhomocysteinemia in subjects 
with familial combined hyperlipidemia (FCH) and non-FCH subjects 
FCH Non-FCH
CVD + 
n=34
CVD – 
n=127
OR CVD + 
n=28
CVD – 
N=478
OR
Homocysteine >90th perc. 5 
(15)
11 
(9)
1.8 
(0.7 to 4.6)
5 
(18)
35 
(7)
2.8 
(1.1 to 7.1)
Values are absolute numbers (percentages), OR: Odds ratios (95% CI), CVD: cardiovascular disease, 
perc.: percentiles
Effect of parameters of lipid and lipoprotein metabolism and insulin 
resistance on plasma homocysteine levels
Log transformed plasma homocysteine level showed significant correlations in 
the total group (n=667) with sex (r=0.246), age (r=0.08), CVD (r=0.123), WHR 
(r=0.131), SBP (r=0.158), TC (r=0.091), HDL-C (r=-0.099), LDL-C (r=0.116), apo 
B (r=0.079), but no significant correlations with the other measurements were 
found (Table 4). With the multiple regression model using log homocysteine as the 
dependent variable and sex, age, CVD, WHR, SBP, TC, HDL-C, LDL-C, apo B as the 
independent variables, only sex, age, WHR, SBP proved to correlate independently 
with plasma homocysteine level (Table 5).
Table 4 Pearson correlation coefficient between plasma homocysteine level (log transformed) and 
anthropometric and biochemical parameters in the total group (n=667).
    R p-value
Sex  0.246  <0.001
Age (yr)  0.08  0.039
Smoking (y/n)  -0.03  0.41
CVD (y/n)  0.123  0.001
BMI (kg/m2)  0.05  0.18
WHR  0.131  0.001
SBP (mm Hg)  0.158  <0.001
DBP (mm Hg)  0.105  0.07
Biochemical parameters
TC (mmol/l)  0.091  0.019
TG (mmol/l)  0.008  0.832
HDL-C (mmol/l)  -0.099  0.011
LDL-C (mmol/l)  0.116  0.003
Apo B (mg/l)  0.079  0.043
K-value  -0.040  0.296
Insulin (mU/ml)  -0.015  0.713
Glucose (mmol/l)  0.029  0.455
HOMA  0.004  0.918
R: Pearson’s correlation-coefficient, CVD: cardiovascular disease, BMI: body mass index, WHR: 
waist/hip ratio, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol, TG: 
triglycerides, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, 
apo B: apolipoprotein B, K-value <0 reflects small dense LDL, HOMA: Homeostasis model assessment 
for insulin resistance defined by fasting plasma insulin x fasting plasma glucose / 22.5. 
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Table 5 Multiple regression model for variables associated with homocysteine level (log 
transformed) in the total group (n=667)
Variable Unstandard. Coefficients B S.E. p-value
Sex  0.06 0.012  <0.001
Age  -0.001 0.00  0.003
CVD  0.03 0.018  0.079
WHR  -0.152 0.077  0.048
SBP  0.001 0.00  0.004
TC  0.09 0.014  0.485
HDL-C  0.003 0.021  0.160
LDL-C  0.016 0.010  0.114
ApoB  0.00008 0.00  0.142
CVD: cardiovascular disease, WHR: waist/hip ratio, SBP: systolic blood pressure, TC: total cholesterol, 
HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, apo B: 
apolipoprotein B.
Discussion
This study shows that subjects with FCH have no increased levels of plasma 
homocysteine compared to controls. In FCH, homocysteine does not contribute 
significantly to the increased risk of CVD. Furthermore plasma homocysteine level 
is not associated with parameters of lipid and lipoprotein metabolism, including 
small dense LDL, nor by an estimate of insulin resistance. 
FCH is a disorder in which multiple risk factors interact to increase the risk of 
CVD. Our interest in associations between plasma homocysteine concentration 
and FCH has been spurred by the search for novel metabolic factors accounting 
for the increased risk of CVD in FCH. Sofar, the relevance of plasma homocysteine 
concentration as risk factor in FCH has not been investigated. 
As described in the literature, oxidative modification of LDL is believed to 
constitute the link between increased cholesterol concentrations and atherosclerosis 
(23). Subjects with FCH have more small dense LDL, which are more susceptible to 
oxidative modification (24). According to Welch et al. high plasma homocysteine 
concentrations may exert an atherothrombotic effect through increasing oxidative 
stress (6), although not confirmed in other studies (25). So, it is unclear, if high plasma 
homocysteine concentrations could be even more harmful in this particular group. 
In our study we report that mean plasma homocysteine levels are not elevated 
in subjects with FCH compared to control subjects. The frequency of the 677C→
T mutation in the MTHFR gene, which is a determinant of elevated homocysteine 
levels (22), was quite similar between FCH patients, controls and normolipidemic 
relatives. Similar to the control group, 10% of the subjects with FCH had plasma 
homocysteine levels above the 90th percentile. The 90th percentile cut off point 
among the control subjects found in our population (Table 2) is comparable to 
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the cut-off point of 18.6 µmol/l found in another large cohort in the Netherlands 
(n=220) (26). 
Both the FCH and non-FCH subjects with a plasma homocysteine concentration 
>90th percentile showed an increased risk of CVD, although the risk estimates were 
lower in the FCH group (Table 3). So, there seems to be no synergism between 
hyperhomocysteinemia and FCH as risk factors for CVD. This is in line with data of 
the European Concerted Action Project demonstrating no more than an additional 
effect between elevated cholesterol and hyperhomocysteinemia (27). The odds 
ratios found in our cohort correspond to odds ratios found in other studies (28). 
In several studies the plasma homocysteine concentration is associated with 
different anthropometric and biochemical parameters. The correlations found in 
our study are in agreement with those found in literature. The modest correlations 
suggest that these parameters potentially account for some of the variation in 
homocysteine levels, although, most likely not resulting in clinically important 
elevations in homocysteine concentrations. A significant correlation was found 
between homocysteine concentration and sex. Sex proved to affect homocysteine 
level independently. It is well known that homocysteine levels of men are 
higher compared to women (29). Also age correlated with plasma homocysteine 
concentration but did not influence this parameter independently. In the Hordoland 
study, the plasma homocysteine level was positively associated with increased SBP 
and DBP (28). Like in our study, Sutton-Tyrell et al. (30) and Malinow et al. (31) 
found homocysteine to be strongly and independently associated with SBP. 
We found a positive correlation between plasma homocysteine concentration 
and TC, HDL-C, LDL-C and apo B, but none of the plasma lipid and lipoprotein 
levels (TC, TG, HDL-C, LDL-C but also apolipoprotein B and small dense LDL) 
was associated with the homocysteine level independently. There are no data 
earlier published whether small dense LDL, which is more susceptible to oxidative 
modification, is associated with homocysteine levels. A positive correlation between 
homocysteine concentration and total or LDL-C level has been demonstrated in a 
few previous reports (32-35). The Hordaland homocysteine study by Nygard et al. 
found a positive relation between homocysteine level and TC level, which was 
particularly strong in the younger age group (28). Other studies showed no significant 
correlations between homocysteine concentration and serum plasma lipids (36,37). 
Our data support the hypothesis that plasma homocysteine concentration and lipids 
and lipoproteins are independent parameters. 
Insulin resistance and hyperhomocysteinemia may both be associated with 
endothelial dysfunction and CVD. Plasma insulin levels could influence 
homocysteine metabolism, possibly through effects on glomerular filtration or by 
influencing activity of key enzymes in homocysteine metabolism (38). In agreement 
with previous reports (39), we show that subjects with FCH are more insulin 
resistant as reflected by a higher HOMA index. However, plasma homocysteine 
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concentration was not related with insulin resistance. This is in accordance with 
studies, which also found no relation between insulin resistance and homocysteine 
level (40,41). In some other previous studies hyperhomocysteinemia is associated 
with insulin resistance (29,34,42). In the Framingham Offspring study (n=2011) 
significant but low correlations between fasting glucose, insulin and homocysteine 
concentration were found (r=0.11 and r=0.07, respectively) (43). 
In conclusion, subjects with FCH have no increased levels of plasma homocysteine 
compared to controls and hyperhomocysteinemia does not disproportionally 
increase the risk of CVD in FCH subjects. No associations were observed between 
plasma homocysteine concentration and plasma lipid and lipoprotein levels, 
including small dense LDL, nor between homocysteine concentration and insulin 
resistance. 
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Abstract 
Objective: Insulin resistance is associated with increased triglyceride levels, low 
HDL cholesterol, small dense LDL and increased apoB levels, all characteristics 
of Familial Combined Hyperlipidemia (FCH). Therefore, we explored the role of 
insulin resistance in FCH lipid phenotype expression.
Methods and results: FCH was defined by traditional diagnostic criteria including 
plasma total cholesterol and/or triglyceride levels >90th percentile. Insulin resistance 
was assessed by the Homeostasis Model Assessment index (HOMA). In total 132 
subjects with FCH, 350 normolipidemic relatives and 81 spouses, who referenced 
as controls were studied. FCH subjects were significantly more insulin resistant 
compared to controls and normolipidemic relatives (HOMA index 2.9 (95% CI 
2.6-3.2), 2.2 (95% CI 2.0-2.5) and 2.0 (95% CI 1.9-2.2), respectively), even after 
correction for sex, age and BMI. The degree of insulin resistance was dependent 
on lipid phenotype expression and a change in lipid phenotype expression over 5 
year was associated with a change in insulin resistant-state. For any level of insulin 
resistance and degree of obesity, FCH subjects had increased levels of apoB and 
more small dense LDL compared to controls. 
Conclusion: Insulin resistance is a characteristic feature of FCH, which is not fully 
explained by their increased BMI and is associated with (change in) lipid phenotype 
expression. Furthermore, our results support the concept of genetic origin of high 
apoB and small dense LDL in FCH, which is modulated by insulin resistance and 
obesity.
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Introduction
Familial Combined Hyperlipidemia (FCH) is the most common familial form of 
hyperlipidemia with an estimated prevalence of 1 to 3% in the general population 
and up to 20% of patients with premature myocardial infarction (1). FCH was 
originally identified in the early 1970s as a new inherited lipid disorder, characterized 
by multiple phenotypes (2). The genetic and metabolic basis of the disorder has not 
yet been identified. In general FCH is thought to be caused by hepatic very low 
density lipoprotein (VLDL) overproduction with or without impaired clearance of 
triglyceride-rich lipoproteins (3). So, FCH is characterized by elevated apoB levels 
and high occurrence of small dense LDL, which are both attractive new candidates 
to redefine FCH, as recently described (4). Furthermore FCH has been associated 
with the presence of insulin resistance and obesity (5). 
Resistance to normal action of insulin is related to an excessive postprandial 
release of free fatty acids (FFA). An increased supply of FFA to liver cells is 
associated with VLDL overproduction. Furthermore, the normal insulin mediated 
activation of lipoprotein lipase (LPL) is diminished, resulting in a reduced clearance 
of triglyceride-rich lipoproteins (6). So, insulin resistance may coincide with 
alterations in lipid metabolism, such as hypertriglyceridemia, low HDL cholesterol, 
increased apoB levels and a predominance of small dense LDL particles (7). 
Because all these features are also characteristics of FCH, the presence of insulin 
resistance may be an important factor modulating FCH phenotypes. 
The aim of this study was to explore the role of insulin resistance in FCH lipid 
phenotype expression. Therefore, we studied in our large FCH cohort, FCH subjects 
with different lipid phenotypes and the effect of intra-individual changes in lipid 
phenotype on insulin resistance over a 5- year period. Furthermore, we investigated 
whether the elevated apoB levels and the presence of small dense LDL in FCH 
could be explained by the degree of insulin resistance and/or obesity.
Subjects and Methods
Study population
Recently, we performed a large study in FCH families (n=667 individuals), 
including a 5-year follow-up period (1994-1999), to investigate the metabolic and 
genetic aspects of FCH (4). For the current study we included all subjects with 
FCH, normolipidemic relatives and spouses of whom glucose and insulin levels 
were available in 1999, resulting in a study population of 132 FCH subjects, 350 
normolipidemic relatives and 81 spouses, who referenced as controls. Among the 
132 FCH subjects, data of lipids and glucose/insulin levels were also available in 
1994 in 76 subjects (58%). Fifty-five of these patients were affected FCH in both 
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1994 and 1999 (72%). These subjects were included in the follow-up to study 
the interdependence of change in lipid phenotype expression in time on insulin 
resistance. Among the 350 normolipidemic relatives data of lipids and glucose/
insulin levels were also available in 1994 in 180 subjects (51%). One hundred and 
fifty-six of the 180 subjects were normolipidemic relatives in both 1994 and 1999 
(87%). 
The relatives and spouses as described previously (4) were ascertained through 
probands exhibiting a combined hyperlipidemia, with both plasma TC and TG 
concentrations above the 90th percentile, adjusted for age and gender, as obtained 
from the Prospective Cardiovascular Munster (PROCAM) study (8). These values 
were confirmed by repeated measurement, on a lipid lowering diet and without 
lipid-lowering drugs. At least one first-degree relative of the proband had a multiple 
type hyperlipidemia with elevated levels of plasma TC and/or TG. Furthermore, 
at least the proband or one of the first-degree relatives should have premature 
CVD before the age of 60 years. All probands were tested for an underlying cause 
of hyperlipidemia (i.e., diabetes mellitus, hypothyroidism, and hepatic or renal 
impairment). The presence of one of these causes excluded the proband and 
his/her family from further analysis. None of the probands in these families were 
homozygous for the apo E2 allele and none of them and their first-degree relatives 
had tendon xanthomas. 
The subjects were classified affected FCH when plasma TC and/or TG levels 
exceeded the 90th percentile, based on the PROCAM study (8). These percentiles 
are age and gender adjusted. Normolipidemic relatives were defined by TC and 
TG levels <90th percentile. All individuals were Caucasian above the age of 12 
years. All subjects filled out a questionnaire about their previous medical history, 
especially cardiovascular status. Body mass index (BMI), waist/hip ratio (WHR) and 
blood pressure were determined in all subjects. After a withdrawal of four weeks 
of lipid-lowering medication and an overnight fast, venous blood was drawn by 
venipuncture. The study protocol was approved by the ethical committee of the 
University Medical Center Nijmegen. 
Plasma lipid, lipoprotein and apolipoprotein analysis
Plasma TC and TG concentrations were determined by enzymatic, commercially 
available reagents (Boehringer-Mannheim, Germany, catalog. No. 237574 and 
Sera Pak, Miles, Belgium, catalog. No. 6639, respectively). Total plasma apo B 
concentrations were determined by immunonephelometry as recently described in 
detail elsewhere (4,9).
Low density lipoprotein subfraction profile analysis
LDL subfractions were sepa rated by single spin density gradient ultracentrifugation(10). 
Each individual LDL subfraction profile was defined by a continuous variable K, as 
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described in detail previ ously (11,12). A negative value (K<0) reflected a more dense 
LDL subfracti on profile, and a positive K value (K>0) a more buoyant profile. 
Glucose, Insulin and Insulin resistance analysis
Glucose concentrations were measured in duplicate using the oxidation method 
(Beckman®, glucose Analyser2, Beckman instruments Inc., Fullerton, CA 92634 
USA). Plasma insulin concentrations were determined using a double antibody 
method with an interassay variability of 6%. Insulin resistance was assessed by the 
Homeostasis Model Assessment Index (HOMA) and calculated using the formula: 
HOMA = fasting serum insulin (mU/l) x fasting plasma glucose (mmol/l) / 22.5 (13).
Statistical analysis
Descriptive values were expressed as mean (95% CI) or absolute numbers with 
percentages. TG, HOMA, insulin and glucose were logarithmically transformed to 
obtain normal distributions before statistical analysis. Differences in characteristics 
between subjects with FCH, controls and normolipidemic relatives were tested by 
Generalized Estimating Equations (GEE) because of possible correlated values within 
families. Correlations between HOMA and variables were analyzed using Spearman 
correlation coefficients. The 90th percentile of HOMA, apoB concentration and K-
value were based on the group of controls. Multiple linear regression test was used 
to select the variables that contributed independently to HOMA. Probability values 
<0.05 were considered statistically significant. All analysis were computed using 
STATA 8.0 software.
Results
In total 563 subjects, including 132 subjects with FCH, 350 normolipidemic relatives 
and 81 controls, were included in the study. Table 1 shows the anthropometric 
and biochemical variables. The ratio women/men was not significantly different 
between the groups. The mean age of the group of subjects with FCH was 
significantly lower compared to controls and significantly higher compared to 
the normolipidemic relatives. The BMI was significantly higher in the FCH group 
compared to the control group and normolipidemic relatives. By definition the 
FCH group had significantly higher plasma TC and TG concentrations compared 
to controls and normolipidemic relatives. In addition, the subjects with FCH had 
a more atherogenic lipid and lipoprotein profile as reflected by increased LDL-C-, 
decreased HDL-C, increased apoB concentrations and a more small dense LDL 
subfraction profile as reflected by a more negative value of parameter K compared 
to the control group and normolipidemic relatives. The differences between the 
control group and normolipidemic relatives are indicated in Table 1. 
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Table 1 Anthropometric and biochemical parameters in subjects with familial combined 
hyperlipidemia (FCH) compared to controls and normolipidemic relatives (NL)
FCH
n=132
Controls
n=81
NL
N=350
Sex (%male) 58 (44%) 39 (48%) 168 (48%)
Age (years) 46.4 (43.6 – 49.2) # * 52.4 (48.9 – 56.0) + 38.4 (36.5 – 40.3)
BMI (kg/m2) 27.7 (27.0 – 28.4) # * 26.5 (25.6 – 27.3) + 24.2 (23.7 – 24.7)
WHR 0.88 (0.86 – 0.89) * 0.86 (0.84 – 0.87) + 0.83 (0.82 – 0.84)
TC (mmol/l) 6.3 (6.1 – 6.5) # * 5.2 (4.9 – 5.4) 5.0 (4.8 – 5.1)
TG (mmol/l) 2.8 (2.6 – 3.0) # * 1.1 (1.0 – 1.2) 1.1 (1.0 – 1.1)
LDL-C (mmol/l) 4.0 (3.8 – 4.2) # * 3.5 (3.2 – 3.7) 3.3 (3.2 – 3.4)
HDL-C (mmol/l) 0.95 (0.90 – 1.00) # * 1.29 (1.22 – 1.35) 1.22 (1.18 – 1.26)
Apo B (mg/l) 1328 (1285 – 1370) # * 993 (939 – 1047) 981 (954 – 1008)
K-value -0.26 (-0.31 - -0.22) # * 0.07 (0.02 – 0.12) 0.04 (0.01 – 0.07)
Values are estimated mean (95% CI) and absolute numbers for sex distribution, FCH: familial 
combined hyperlipidemia, NL: normolipidemic relatives, BMI: body mass index, WHR: waist hip ratio, 
TC: total cholesterol, TG: triglyceride, LDL-C: low density lipoprotein cholesterol, HDL-C: high density 
lipoprotein cholesterol, apoB: apolipoprotein B, K-value <0: reflecting small dense LDL, #: p<0.05 
FCH compared to controls, *:P<0.05 FCH compared to normolipidemic relatives, +: P<0.05 controls 
compared to normolipidemic relatives, p<0.05= statistical significant
FCH and insulin resistance
Subjects with FCH were more insulin resistant as assessed by the HOMA index, 
which was significantly higher in FCH subjects compared to the normolipidemic 
relatives and group of controls (Table 2) with a mean difference of 0.9 (CI 95%: 0.79 
to 0.92) between FCH subjects and controls. Even after adjustment for age, sex and 
BMI, subjects with FCH were still significantly more insulin resistant with a mean 
difference in HOMA of 0.9 (CI 95%: 0.83 to 0.95). Controls and normolipidemic 
relatives did not differ in HOMA. A significantly higher number of FCH subjects 
(18%) had a HOMA index above the 90th percentile compared to 6% in the group 
of normolipidemic relatives (Table 2). 
Table 2 Degree of insulin resistance (HOMA) in subjects with familial combined hyperlipidemia 
(FCH) compared to controls and normolipidemic relatives (NL)
FCH
n=132
Controls
n=81
NL
n=350
HOMA 2.9 (2.6 – 3.2) # * 2.2 (2.0 – 2.5) 2.0 (1.9 – 2.2)
HOMA >90th perc. 24 (18%) # * 8 (10%) 22 (6%)
Insulin (mU/l) 12.5 (11.4 – 13.7) # * 9.7 (8.6 – 10.8) 9.2 (8.6 – 9.8)
Glucose (mmol/l) 5.2 (5.1 – 5.3) * 5.2 (5.0 – 5.3) + 4.9 (4.9 – 5.0)
Values are estimated mean (95% CI) and absolute numbers (%) for homa >90th percentile (4.3), 
FCH: familial combined hyperlipidemia, NL: normolipidemic relatives, HOMA: homeostasis model 
assessment for insulin resistance defined by fasting plasma insulin x fasting plasma glucose / 22.5, #: 
p<0.05 FCH compared to controls, *: p<0.05 FCH compared to normolipidemic relatives, +: p<0.05 
controls compared to normolipidemic relatives, p<0.05= statistical significant 
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The glucose concentration was not significantly different between the FCH group 
and control group, whereas the subjects with FCH had significantly higher insulin 
levels compared to both other groups. HOMA was not statistically different between 
males and females in the three different groups (data not shown). We evaluated the 
effect of different variables on insulin resistance. The degree of insulin resistance 
(HOMA) had significant correlations with BMI (R=0.51, p<0.001), WHR (R=0.35, 
p<0.001), TG (R=0.32, p<0.001), HDL-C (R=-0.27, p<0.01), K-value (R=-0.19, 
p=0.02), systolic blood pressure (0.21, p=0.01) and diastolic blood pressure (0.30, 
p<0.001) evaluated in the FCH group (n= 132). With the linear regression model 
using log transformed HOMA as the dependent variable and sex, BMI, WHR, TG, 
HDL-C, K-value and blood pressure as the independent variables, only BMI and 
TG proved to contribute independently to the degree of insulin resistance. BMI 
alone explained 22% and the combination of BMI and TG explained 28% of the 
variance in HOMA. Similar results were found for the control group and the group 
of normolipidemic relatives (data not shown).
Lipid phenotype and insulin resistance in FCH
Of the 132 FCH subjects, 86 subjects were affected based on the presence of isolated 
hypertriglyceridemia (hyperTG: TG >90th percentile according to PROCAM(8)) , 24 
subjects based on the presence of combined hyperlipidemia (combined HLP: TC 
and TG >90th percentile) and 22 subjects based on isolated hypercholesterolemia 
(hyperTC: TC >90th percentile). Lipid and lipoprotein profiles are given in Table 3. 
Table 3 Anthropometric and biochemical parameters of FCH subjects with different lipid 
phenotypes compared to controls
Affected FCH based on
HyperTG
N=86
Combined HLP
N=24
HyperTC
N=22
Controls
N=81
Age (years) 46.7 (43.5-49.8) # 48.7 (42.9-54.6) 42.0 (35.9- 48.1) ⊥ 52.4 (49.2-55.7) 
BMI (kg/m2) 28.1 (27.2-29.0) # 27.8 (26.3-29.4) 26.7 (25.1-28.3) 26.3 (25.5-27.2)
TC (mmol/l) 5.7 (5.5-5.9) *‡# 7.8 (7.4-8.1) †¶ 7.2 (6.9-7.6) ⊥ 5.2 (5.0-5.4)
TG (mmol/l) 2.9 (2.8-3.1) *‡# 3.8 (3.3-4.4) †¶ 1.5 (1.3-1.8) ⊥ 1.1 (1.0-1.1) 
ApoB (mg/l) 1205 (1158-1252) *‡# 1629 (1543-1714) †¶ 1505 (1416-1594) ⊥ 999 (950-1048) 
K-value -0.30 (-0.36- -0.24) *# -0.39 (-0.49- -0.29) †¶ -0.03 (-0.13-0.07) 0.06 (0.003-0.12)
HOMA 3.0 (2.7 – 3.4) *# 3.3 (2.7 – 4.1) †¶ 2.3 (1.9– 2.9) 2.2 (2.0-2.5)
Values are estimated mean (95% CI), FCH: familial combined hyperlipidemia, BMI: body mass index, 
TC: total cholesterol, TG: triglycerides, apoB: apolipoprotein B, , K-value <0: reflecting small dense 
LDL , HOMA: homeostasis model assessment for insulin resistance defined by fasting plasma insulin 
x fasting plasma glucose / 22.5, hyperTC: FCH subjects based on TC >90th percentile, hyperTG: FCH 
subjects based on TG>90th percentile, combined HLP: FCH subjects based on TC and TG >90th 
percentile, * :p<0.05 hyperTG vs hyper TC, :‡: hyperTG vs combined HLP, #: p<0.05 hyperTG vs 
controls, †: p<0.05 combined vs hyperTC, ¶: p<0.05 combined HLP vs controls, ⊥: p<0.05 hyperTC 
vs controls, p<0.05= statistic significant
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The FCH subjects affected based on hyperTG or combined HLP have a significantly 
higher BMI, TC, TG, apoB level and more small dense LDL compared to controls. 
The HOMA index of FCH subjects who presented with hyperTG or combined HLP 
was significantly higher compared to controls even after correction for BMI. FCH 
subjects with combined HLP have higher TC, TG and apoB levels and more small 
dense LDL compared to hyperTG subjects but they do not differ in BMI or HOMA 
index. The FCH subjects affected based on hyperTC have higher TC, TG and apoB 
levels compared to controls. Strikingly, although all affected FCH subjects had higher 
apoB, TC and TG levels compared to controls, subjects with FCH based on hyperTC 
did not show a small dense LDL subfraction profile and were not insulin resistant. 
Lipid phenotype and insulin resistance over a period of 5 year
To evaluate the interdependence of change in lipid phenotype expression on insulin 
resistance we studied 55 subjects who were affected FCH in both 1994 and 1999, 
including 156 subjects who were normolipidemic in both 1994 and 1999 (Table 4). 
Table 4 Insulin resistance (HOMA) and obesity (BMI) in FCH subjects stratified by different lipid 
phenotype expression compared to normolipidemic relatives in 1994 and 1999. 
Affected FCH 1994 -- 1999 based on lipid 
phenotype expression
hyperTC – 
hyperTC 
(n=7)
hyperTC – 
hyperTG or 
combined HLP 
(n=8)
hyperTG or 
combined HLP –
hyperTG or 
combined HLP 
(n=39)
normolipidemic –
normolipidemic 
(n=156)
HOMA 1994 2.6 (1.7 – 4.1) # 1.9 (1.0 – 3.6) 2.6 (2.1 – 3.3) § 1.5 (1.4 – 1.7)
             1999 2.6 (2.0 – 3.4) # 3.8 (2.0 – 7.3) *¶ 3.0 (2.6 – 3.6) * § 1.9 (1.7 – 2.1) *
BMI       1994 27.6 (25.3 – 29.9) # 27.0 (23.6 – 30.4) ¶ 26.7 (25.5 – 28.0) § 22.8 (22.3 – 23.6)
             1999 28.5 (26.1 – 30.9) # 29.3 (24.8 – 33.7) *¶ 28.3 (26.5 – 30.1) § 24.2 (23.6 – 24.8) *
Values are mean (95% CI), TC: FCH based on hypercholesterolemia, TG: FCH based on hyper-
triglyceridemia, * : p<0.05 1994 versus 1999, # : p<0.05 hyperTC – hyperTC vs NL - NL, ¶ : p<0.05 
hyperTC – hyperTG or combined HLP vs NL – NL, § : p<0.05 hyperTG or combined HLP –
hyperTG or combined HLP vs NL – NL, p<0.05 = statistical significant 
Among the normolipidemic subjects the HOMA index and BMI increased 
significantly over 5 year, with a correlation between ∆BMI and ∆HOMA of 
r=0.24, p=0.001. Also among all FCH subjects an increase in BMI over 5 year was 
associated with an increase in HOMA index (r=0.47, p<0.001). Seven subjects 
were affected FCH based on hyperTC in both 1994 and 1999. BMI increased in 5 
year but this increase did not reach statistical significance. HOMA index did not 
change over this period. Both in 1994 and 1999, HOMA and BMI were significantly 
higher compared to NL subjects. Eight subjects were affected FCH in 1994 based on 
hyperTC and in 1999 based on combined HLP or hyperTG. Their BMI and HOMA 
index increased significantly over the 5- year period. Both in 1994 and 1999, BMI 
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and HOMA index were higher compared to the NL subjects, however, the HOMA 
in 1994 did not reach statistical significance. Among the 39 subjects who remained 
affected FCH based on hyperTG or combined HLP, BMI showed a trend of increase 
and the HOMA index increased significantly. Again, both BMI and HOMA, among 
these FCH subjects are significantly higher compared to the NL group. There was 
only one subject who changed from hyperTG to hyperTC; the HOMA index of 
this individual decreased from 1.96 in 1994 to 0.43 in 1999, whereas, the BMI 
increased slightly from 24.0 to 24.1 kg/m2. 
Can insulin resistance and/or obesity explain the elevated apo B levels and 
high occurrence of small dense LDL in FCH?
Scatter plots were generated to explore the relationship between insulin resistance / 
obesity and apoB levels / presence of small dense LDL in FCH and control subjects 
(Figure 1). Sixty-four percent of the subjects with FCH had an apoB level above the 
90th percentile, also 58% of the subjects with FCH had a K-value <-0.24. This figure 
shows that for any level of insulin resistance and/or degree of obesity most FCH 
subjects have higher apoB levels and more small dense LDL compared to controls. 
So, insulin resistance and/or obesity do not fully account for the increased plasma 
levels of apoB or high occurrence of small dense LDL in FCH. 
Insulin resistance and risk of cardiovascular disease 
Insulin resistance is related to cardiovascular risk. An HOMA index above the 90th 
percentile (>4.3) was associated with an increased risk for CVD in FCH subjects 
(OR=1.4 (95% CI: 0.49 to 3.93) and in non-FCH subjects (normolipidemic subjects 
and controls together) (OR=3.1 (95% CI: 0.97 to 9.83). The overall OR for the total 
group is 2.7 (95% CI:1.24 to 5.72) (Table 5). Thus, insulin resistance is associated 
with an increased risk of CVD. In the FCH group, the HOMA did not proportionally 
increase the OR. So insulin resistance does not appear to be an additional risk 
factor for CVD particularly in FCH subjects.
Table 5 Odds ratios for CVD associated with HOMA index above the 90th percentile
FCH Non-FCH  Total group
CVD + CVD – OR CVD + CVD - OR OR
n=27 n=105 [95%CI] N=23 n=408 [95%CI] [95%CI]
HOMA >90th 
percentile 
6 (22) 18 (17) 1.4 
[0.49-3.93]
4 (17) 26 (6) 3.1 
[0.97-9.83]
2.7 
[1.24-5.72]
Values are total numbers (percentages), FCH: familial combined hyperlipidemia, CVD: cardiovascular 
disease, CVD +: subjects with CVD, CVD -: subjects without CVD, OR: odds ratio CI: confidence 
interval, HOMA: homeostasis model assessment , Non-FCH includes both normolipidemic relatives 
and controls. The 90th percentile for HOMA as defined in controls was found at a level of >4.3
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Figure 1 Scatterplots to explore the relationship between insulin resistance (A) and degree of obesity 
(B) with apoB levels and the presence of small dense LDL.
HOMA: homeostasis model assessment for insulin resistance defined by fasting plasma insulin x 
fasting plasma glucose / 22.5, BMI:body mass index (kg/m2) , apoB: apolipoprotein B (mg/l), K-value 
<0: reflecting small dense LDL , blacksquares: FCH subjects, lightsquares : control subjects. The line 
indicates the 90th percentile for apoB levels ((>1200 mg/l) and the value of parameter K (<-0.24) as 
evaluated in the control group.
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Discussion
This study shows that subjects with FCH are more insulin resistant compared to 
controls, even after correction for sex, age and BMI. The insulin resistant state in 
FCH is dependent on lipid phenotype, as subjects with FCH based on hyperTG or 
combined HLP were more insulin resistant compared to FCH subjects based on 
hyperTC. For the first time we show in our 5 -year follow-up study that a change 
in lipid phenotype expression is associated with a change in insulin resistance. 
Moreover, insulin resistance does not fully account for the increased plasma levels 
of apoB or high occurrence of small dense LDL in FCH, both major characteristics 
of FCH. Thus, our results support the concept of genetic origin of high apoB and 
small dense LDL in FCH, which is modulated by BMI and insulin resistance.
Several groups including ourselves have demonstrated directly by hyperinsulinemic 
clamp technique the impaired insulin action in FCH patients (14-17). These studies 
were performed in a small number of subjects. In the present study we included a 
large population of 563 subjects, including 132 FCH subjects, 81 controls and 350 
normolipidemic relatives. Therefore the level of insulin resistance was determined 
by HOMA index. The accuracy and precision of the HOMA index as a measure of 
insulin resistance has been determined in literature by comparison with euglycemic 
and hyperglycemic clamps and the intravenous glucose tolerance test (13). In this 
large population we confirm that FCH subjects are more insulin resistant compared 
to controls. Pathofysiologically this could be related to the higher BMI in FCH 
subjects. However, we show that even after correction for BMI, FCH subjects are 
more insulin resistant compared to normolipidemic relatives and controls. So, our 
results suggest that a genetic component influences the degree of insulin resistance 
in FCH beside the traditional environmental influences such as BMI. Indeed, 
recently a major gene effect on insulin resistance in FCH has been suggested (18). 
FCH is characterized by multiple lipoprotein phenotype expression; in one 
family affected subjects may present with hyperTC, hyperTG or combined HLP. We 
demonstrate that insulin resistance depends on lipid phenotype as FCH subjects 
based on hyperTG or combined HLP, were more insulin resistant compared to 
FCH subjects based on hyperTC. This was previously also shown by Pihlajamaki 
et al. (16) and Vakkilainen et al. (19). This could be related to their increased BMI 
frequently reported in hyperTG subjects, however, even after correction for BMI, 
subjects with hyperTG or combined HLP were more insulin resistant compared to 
FCH subjects based on hyperTC. Thus, the degree of insulin resistance appears to 
depend on lipid phenotype expression. 
The main feature of FCH is the variability in lipid phenotype expression within an 
individual in time. Recently, we showed that 43% of the FCH patients had a change 
in lipid phenotype expression after 5 years (4). The effect of these intra-individual 
changes in lipid phenotype expression in time on insulin resistance has not been 
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addressed in literature. Twenty-four of the 55 FCH subjects (44%) in this study 
show an intra-individual change in lipid phenotype expression over the period of 
5 year. Independent of lipid phenotype expression is an increase in BMI in time 
associated with an increase in insulin resistance (r=0.47, p<0.001). A switch in 
lipid phenotype from hyperTC to hyperTG or combined HLP is associated with an 
increase in insulin resistance.
Thus, most strikingly, our data show that FCH defined by the traditional criteria 
(TC and/or TG levels >90th percentile) potentially comprise a heterogeneous 
group; subjects defined FCH by the presence of hyperTG or combined HLP are 
characterized by the presence of small dense LDL and insulin resistance whereas 
the FCH subjects based on hyperTC do not show these major characteristics of 
FCH. It appears that subjects with hyperTC comprise a distinct group within FCH. 
These results suggest that several metabolic pathways may contribute to the lipid 
phenotype expression in FCH. 
The diagnostic criteria for FCH have been debated in literature (4,20). Recently, 
we and others have shown that apoB and small dense LDL are important potential 
new diagnostic characteristics (4,21,22). Insulin resistance and obesity are also 
associated with increased levels of apoB and the presence of small dense LDL (6). 
Therefore, we explored whether insulin resistance and/or obesity can explain the 
increased apoB levels or high occurrence of small dense LDL in FCH. 
Purnell et al. examined this question for only apo B in a population of 11 FCH 
subjects (23). In our large cohort of 132 FCH subjects we confirmed that most FCH 
subjects had increased apo B levels for any level of insulin resistance (HOMA) or 
BMI compared to controls. In addition we show that FCH subjects have also more 
small dense LDL for any level of insulin resistance (HOMA) or BMI compared to 
controls. So, obesity and/or insulin resistance, do not fully account for the elevated 
levels of apoB but also not for the high prevalence of small dense LDL in FCH. 
These results support the physiological concept of separate, but additive, genetic 
determinants in the etiology of the FCH lipid phenotype with modulation by BMI 
and insulin resistance. We have reported previously that in our FCH families a 
major gene influences apoB levels and small, dense LDL (24), however, the gene 
has not been found yet. Recently, Pajukanta et al. published interesting data about 
association between FCH and upstream transcription factor 1 (USF1) (25). USF1 
encodes a transcription factor known to regulate several genes of glucose and lipid 
metabolism.
FCH subjects have increased risk of CVD, which can only to a certain extent be 
explained by the disturbed lipid profile. Insulin resistance is also associated with an 
increased risk of CVD (26). The question arise if the presence of insulin resistance in 
FCH subjects could be responsible for a part of the increased risk of CVD. We show 
that an HOMA index above the 90th percentile gives an increased risk of CVD in 
the total group but there was no proportionally increased risk in the FCH group 
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separately, however the number of subjects is small. So, insulin resistance does not 
appear to be an additional risk factor for CVD particularly in FCH subjects.
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Abstract
Familial Combined Hyperlipidemia (FCH) is characterized by hypercholesterolemia 
and/or hypertriglyceridemia and is associated with premature cardiovascular 
disease (CVD). Other features of FCH are obesity and insulin resistance. Serum 
leptin levels have been associated with obesity, insulin resistance and CVD. 
The aim of this study was to determine whether increased leptin levels contribute to 
the FCH phenotype and its increased risk for CVD. The study population comprised 
651 subjects, including 158 FCH patients. Leptin levels were determined, using 
a commercially available ELISA. For both males and females, the mean leptin 
level (ng/ml) was higher in FCH patients compared to normolipidemic relatives 
and spouses. However, after standardization for BMI and insulin resistance, these 
differences disappeared. The 90th percentile of the leptin level, standardized for 
BMI, insulin resistance and gender, was associated with an increased risk for CVD 
in FCH patients (OR = 3.4 [1.2-9.6]) and in non-FCH subjects (OR = 3.4 [1.3-9.3]). 
The overall OR on CVD was 3.5 [1.7-6.9]. 
We conclude that in patients with FCH, leptin levels are increased in proportion 
to their higher BMI and the presence of insulin resistance. These increased leptin 
levels are associated with an increased risk for CVD both in FCH patients and non-
FCH subjects, independent of BMI, insulin resistance and gender.
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Introduction
Familial combined hyperlipidemia (FCH) is the most common genetic 
hyperlipidemia in humans and affects 1 to 3% of the general population. It is 
characterized by multiple lipoprotein phenotypes and is strongly associated 
with premature cardiovascular disease (CVD). Of the survivors of a premature 
myocardial infarction, up to 20% are affected with FCH (1) FCH is characterized by 
hypercholesterolemia and/or hypertriglyceridemia. Other phenotypes of FCH are 
elevated levels of apolipoprotein B (apo B) and low-density lipoprotein cholesterol 
(LDLc), decreased levels of high-density lipoprotein cholesterol (HDLc) and the 
presence of small dense LDL (sdLDL). In addition, FCH is associated with obesity 
and insulin resistance (2).
Obesity results in an increase in number and size of adipocytes. These adipocytes 
secrete leptin, a hormone which is increased in obese subjects (3). Leptin is involved 
in the regulation of the energy expenditure and appetite via hypothalamic receptors 
(4). An increase of leptin level will lead to more energy expenditure and less 
appetite in normal persons via the hypothalamus. Obese persons have increased 
levels of leptin, but these high levels appear to fail to influence energy intake or 
expenditure to restore fat mass to normal. It is therefore believed that obesity is a 
state of leptin resistance. 
Leptin has direct effects on insulin secretion by inhibiting insulin gene transcription 
(5) and insulin secretion (6). On the other hand, insulin increases leptin production 
indirectly via its effects to increase glucose utilization and oxidative glucose 
metabolism in adipocytes at the transcriptional level (6,7). Thus high leptin levels 
are associated with insulin resistance (8).
Both obesity and insulin resistance are characteristics of FCH and therefore it is 
likely that leptin is elevated in persons with FCH. Furthermore, we hypothesize 
that leptin could be a marker for a disturbed adipocyte metabolism, one of the 
mechanisms proposed to play a role in the pathophysiology of FCH (2).
So far, only two small studies have studied the relationship between leptin 
concentrations and FCH, with conflicting results (9,10). Jacobson et al. found a 
significantly elevated leptin levels in young females with FCH (10), while Haluzik 
et al observed no differences in a group of males with and without FCH (9). 
The aim of this study was to investigate whether leptin levels in our large cohort 
of well-defined male and female patients with FCH were elevated, independent of 
their BMI, indicating that adipose tissue metabolism is disturbed in FCH. The second 
objective was to investigate whether leptin levels contribute to the increased risk for 
CVD in FCH. 
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Subjects and methods
Study population
The study population existed of 37 families, comprising 651 subjects, of whom 
158 subjects were diagnosed as FCH patients (11,12). The normolipidemic relatives 
(n=389) and spouses (n=97), also included in this study population, served as 
two independent reference groups. Eight subjects were not diagnosed because of 
missing values. We separated the normolipidemic relatives and the spouses into 
two different reference groups, because of the similar genetic background of the 
relatives with the FCH patients. All subjects filled out a questionnaire about their 
previous medical history, especially cardiovascular status, medication, smoking 
and drinking habits and hormonal status in women. CVD was defined by stroke, 
myocardial infarction, peripheral vascular disease and angina pectoris. After 
withdrawal of lipid-lowering medication for four weeks and an overnight fast, 
blood was drawn by venipuncture. The ethical committee of the University Medical 
Center Nijmegen approved the study protocol and the procedures followed were in 
accordance with institutional guidelines. All subjects gave informed consent. 
The diagnosis FCH was based on absolute apo B levels in combination with 
triglyceride and total cholesterol levels adjusted for age and gender, using a 
nomogram, as recently described (12). 
Body mass index (BMI) was calculated as body weight (in kilograms) divided by 
the square of height (in meters). 
Biochemical analyses
Plasma total cholesterol (TC) and total triglycerides (TG) were determined by 
enzymatic, commercially available reagents (Boehringer-Mannheim, Germany, 
catalog No. 237574 and Sera Pak, Miles, Belgium, catalog No. 6639, respectively). 
Total plasma apo B concentrations were determined by immunonephelometry 
as recently described in detail (13). Glucose concentrations were measured in 
duplicate using the oxidation method (Beckman®, Glucose Analyser2, Beckman 
Instruments Inc., Fullerton, CA 92634, USA). Plasma insulin concentrations were 
determined using a double antibody method. Insulin resistance was assessed by 
the Homeostasis model assessment (HOMA). The HOMA-index was calculated 
from the fasting concentrations of insulin and glucose using the following formula: 
HOMA-index = fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/L)/
22.5 (14).
Serum leptin levels
For measuring leptin levels, serum samples were assayed in duplicate using enzyme-
linked immunosorbent assay (R&D Systems, Minneapolis: Elisa Development 
System; Duoset® Human Leptin, Catalog no. DY398). This assay measured the total 
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amount of leptin present in a sample, independent of the presence of leptin-binding 
proteins. Inter- and intra-assay coefficients of variance were both approximately 
3%, the detection limit was 0.1 ng/ml. 
Statistical analyses
As it is well documented that, at a given BMI, females have a higher leptin levels 
than males (15,16), all analyses were stratified or standardized for gender. Variables 
with a skewed distribution, including leptin levels, triglyceride levels and the 
HOMA-index, were logarithmically transformed before analysis.
Descriptive statistics, expressed as means with 95% confidence intervals (95% 
CI), are presented separately for FCH patients, normolipidemic relatives and 
spouses. Differences in characteristics and leptin levels between subjects with 
FCH, normolipidemic relatives and spouses were tested by means of generalized 
estimating equations (GEE) because of possible correlated values within families. 
Also the odds ratios (OR) as an estimate of risk for CVD were calculated using 
GEE. Multiple linear regression analyses were performed to standardize leptin 
levels for BMI, HOMA-index and gender. The 90th percentile of the leptin levels, 
standardized for gender, BMI and HOMA-index, is based on the group of non-FCH 
subjects without CVD, including spouses. Differences were considered statistically 
significant at p-values <0.05. All analyses were computed using the STATA 8.0 
software. 
Results
Subject characteristics 
Descriptive statistics of anthropometric and metabolic characteristics of the study 
population are presented in table 1. FCH patients are older than normolipidemic 
relatives, but younger than the spouses. Evident is the higher incidence of CVD in 
patients with FCH, compared to normolipidemic relatives and the spouses. The 
mean BMI of patients with FCH is significantly higher compared to normolipidemic 
relatives. Compared to normolipidemic relatives and spouses, FCH patients have 
significant higher levels of total cholesterol, triglycerides and apo B and are more 
insulin resistant, as reflected by a higher HOMA-index. Normolipidemic relatives 
are younger, have a lower BMI, are less insulin resistant and have lower total 
cholesterol and apo B levels compared to the spouses (Table 1). 
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Table 1 Characteristics of patients with Familial Combined Hyperlipidemia, normolipidemic 
relatives and spouses
FCH patients
(n = 158)
NL relatives 
(n = 389)
Spouses
(n = 97)
 Mean (95% CI) Mean (95% CI) Mean (95% CI)
Gender (males) * 76 (48.1%) 175 (45.0%) 43 (44.3%)
Age (years) 47.1 (44.5-49.6) †‡ 37.8 (36.0-39.6) § 52.2 (49.0-55.4)
CVD * 32 (20.3%) †‡ 21 (5.4%) 3 (3.1%)
BMI (Kg/m2) 27.3 (26.6-28.0) † 24.2 (23.7-24.7) § 26.4 (25.6-27.2)
Total Cholesterol (mmol/L) 6.5 (6.3-6.6) †‡ 4.9 (4.7-5.0) § 5.3 (5.0-5.5)
Triglycerides (mmol/L) 2.7 (2.6-3.0) †‡ 1.1 (1.0-1.1) 1.2 (1.1-1.3)
Apo B (mg/L) 1370 (1333-1407) †‡ 961 (936-985) § 1018 (971-1065)
HOMA-index 2.9 (2.6-3.2) †‡ 2.0 (1.9-2.1) § 2.3 (2.0-2.6)
* Presented are number (%), FCH; familial combined hyperlipidemia, NL relatives; normolipidemic 
relatives, CVD; cardiovascular disease, BMI; body mass index, Apo B; apolipoprotein B, HOMA-index; 
homeostasis model assessment- index
† p <0.05; FCH patients compared to normolipidemic relatives
‡ p <0.05; FCH patients compared to spouses
§ p <0.05; Normolipidemic relatives compared to spouses
Leptin concentration and FCH
Both male and female FCH patients have higher mean leptin level compared to 
normolipidemic relatives and spouses, only not reaching statistical significance in 
female FCH patients versus female spouses (Table 2). 
Table 2  Mean serum leptin levels in patients with Familial Combined Hyperlipidemia, 
normolipidemic relatives and spouses
  FCH patients
 n = 158 (48.1%) *
NL relatives
n = 389 (45.0%) *
Spouses
n = 97 (44.3%) *
Leptin levels (ng/ml) Males
Females
8.9  (7.1-11.0) §† 
26.4  (22.3-31.4) §
3.9 (3.4-4.5) ‡
18.4 (16.4-20.7) ‡
5.4 (4.1-7.2)
23.9 (19.4-29.4)
Leptin levels (ng/ml) 
standardized for BMI
Males
Females
6.2  (5.3-7.2) §†
20.8  (18.5-23.5)
4.9 (4.4-5.4)
20.5 (19.0-22.2)
4.4 (3.6-5.4)
21.3 (18.5-24.7)
Leptin levels (ng/ml) 
standardized for BMI 
and HOMA-index
Males
Females
5.9  (5.0-6.9)
19.7  (17.5-22.2)
5.0 (4.5-5.6)
20.9 (19.3-22.7)
4.7 (3.9-5.8)
21.4 (18.6-24.6)
Values are means with 95% CI, FCH; Familial combined hyperlipidemia, NL relatives; Normolipidemic 
relatives, BMI; Body mass index, HOMA-index; homeostasis model assessment insulin resistance 
index, § P <0.05 between FCH patients and Normolipidemic (NL) relatives; † P <0.05 between FCH 
patients and spouses; ‡ P <0.05 between Normolipidemic (NL) relatives and spouses; * Percentage 
males
Leptin levels show a strong significant correlation with BMI in both males (r = 0.75) 
and females (r = 0.73). To determine whether the association of FCH with leptin 
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concentration is dependent on BMI, we standardized the leptin concentration for 
BMI. After standardization, no significant differences in leptin levels among females 
with FCH, normolipidemic relatives and spouses are found. However, male FCH 
patients still show significant higher leptin levels compared to normolipidemic 
relatives and spouses (Table 2). 
Patients with FCH are not only more obese than their normolipidemic relatives but 
they are also more insulin resistant. This is not completely contributable to their 
obesity, because after standardization of the HOMA-index for BMI, the differences 
in insulin resistance between patients with FCH and normolipidemic relatives and 
spouses remain significant in our FCH population (2). Because leptin levels show a 
strong correlation with the HOMA-index for both males (r = 0.59) and females (r = 
0.46), we also standardized leptin levels for the HOMA-index. After standardization 
of leptin levels for both BMI and HOMA-index, no significant differences in leptin 
levels are found among FCH patients, normolipidemic relatives and spouses, 
although among males a trend can be observed (Table 2). 
Leptin concentration in a multiple linear regression model
Multiple linear regression analyses showed that, in the total study population, the 
variation in leptin concentration could be explained for approximately 71% by the 
variables gender and BMI. When including the HOMA-index in the model, 74 % of 
the variation in leptin concentration could be explained. 
Leptin concentration and CVD
Next, we determined whether elevated serum leptin levels (standardized for 
gender, BMI and HOMA-index) are associated with an increased risk for CVD. A 
serum leptin concentration above the standardized 90th percentile of leptin was 
associated with an increased risk for CVD in FCH patients (OR = 3.4 [1.3-9.4]) and 
in non-FCH subjects (OR = 3.4 [1.3-9.2]. The overall OR for the total group is 3.5 
with confidence intervals ranging from 1.8 to 6.9 (Table 3). When performing the 
analysis with leptin levels as a continuous variable, we also obtained a significant 
increased risk on CVD associated with higher leptin levels (data not shown).
Table 3 Odds ratios for cardiovascular disease associated with serum leptin levels above the 90th 
percentile.
 FCH Non-FCH* Total Group
 CVD+ 
(n = 20)
CVD- 
(n = 84)
OR 
[95% CI]
CVD+ 
(n = 35)
CVD- 
(n = 497)
OR 
[95% CI]
OR 
[95% CI]
Leptin level >90th 
percentile
8 
(27.6%)
12 
(10.0%)
3.4 
[1.2-9.6]
6 
(27.3%)
40 
(9.9%)
3.4 
[1.3-9.3]
3.5 
[1.7 – 6.9]
* Non-FCH includes both normolipidemic relatives and spouses
Presented are total number (%) and the Odds Ratio’s. Serum leptin levels (ng/ml) are standardized 
for BMI, HOMA-index and gender. FCH; familial combined hyperlipidemia, CVD+; subjects with 
cardiovascular disease, CVD-; subjects without cardiovascular disease
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Discussion
In the present study we report higher leptin levels in both male and female patients 
with FCH compared to their normolipidemic relatives and spouses. The extent of 
increase in leptin levels is in proportion to the degree of overweight and insulin 
resistance in these FCH patients. In females, the increased leptin levels were 
completely attributable to BMI, whereas in male FCH patients increased leptin 
levels were only partially attributable to overweight, suggesting a defect in adipose 
tissue metabolism in male FCH patients. The remaining difference in leptin levels in 
male patients with FCH seemed related to insulin resistance, since after correction 
for HOMA-index, leptin levels were no longer significantly different. The increased 
leptin levels in FCH were found to contribute to the increased risk for CVD, 
independent of gender, BMI and insulin resistance. 
So far only two small studies investigated the relation of leptin concentrations 
and FCH. Haluzik et al. did not find any difference in the leptin concentration 
between male subjects with familial combined hyperlipidemia and controls (9). 
Another study, performed in a small group of women by Jacobson et al, did show an 
increased concentration of leptin in females with FCH (10). However, in this study 
they used subjects with familial hypercholesterolemia as a reference population 
and no healthy subjects. Our large study population, with both males and females, 
confirmed at first the results of Jacobson et al, but after standardization for BMI and 
insulin resistance, we report no difference in leptin levels of female FCH patients 
compared to their normolipidemic relatives and spouses, and only a non-significant 
trend for male FCH patients. 
Because we did not find a relation between FCH and leptin levels, independent 
of BMI and insulin resistance, adipose tissue metabolism with respect to leptin 
seems not disturbed in FCH. However, we cannot rule out the possibility of a 
disturbed adipose tissue metabolism in the pathophysiology of FCH, because leptin 
is just one of the many markers of adipose tissue metabolism. Other markers of the 
adipose tissue, such as adiponectin and resistin (17,18), need to be investigated 
before we can judge on involvement of disturbed adipose tissue metabolism in the 
pathophysiology of FCH indefinitely. 
The rate of leptin production is mainly determined by obesity (3,19-21), but 
there still is some inter-individual variability in plasma leptin concentration that is 
independent of body fatness. In our study 71 % of the individual variability in leptin 
levels could be accounted for by BMI and gender. However, after standardization 
of leptin levels for BMI only, we still found an association between FCH and leptin 
levels in men, not in women. Several studies have reported that leptin levels are 
also influenced by insulin resistance (22-26). Moreover, from literature it is known 
that, in men, but not in women, leptin levels correlate negatively with maximum 
glucose uptake rates and insulin sensitivity is related to serum leptin independently 
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of percent body fat (27). Indeed, in our population we observed a strong correlation 
between leptin levels and the HOMA-index, as a measure of insulin resistance. This 
indicates that leptin levels should not only be standardized for BMI, but also for 
HOMA-index, as a measure of insulin resistance. 
From literature it is known that leptin is an independent risk factor for CVD 
(20,24). So far, the relevance of high leptin concentrations as a risk factor for CVD 
associated with FCH has not been investigated. In the present study, we show that 
FCH subjects have elevated leptin levels, explained by the increased BMI and the 
presence of insulin resistance. Still it is possible that the elevated leptin levels 
contribute to the increased risk of CVD in FCH. Indeed, we demonstrate that leptin 
levels above the 90th percentile give an increased risk for CVD. Similar results were 
found among non-FCH subjects. This increased risk for CVD was not attributable 
to differences in gender, BMI and state of insulin resistance because the leptin 
level was standardized for these variables. Wallace et al found an increased risk of 
approximately 2-fold on CVD in the highest two quintiles of leptin concentration 
compared to the lowest quintile (20) in a prospective, nested, case control study 
of hypercholesterolemic men. Though our groups were not large enough to assess 
quintiles, the risk found for the 90th percentile in our study was comparable with 
the risks found for the highest two quintiles (60th and 80th percentile) by Wallace 
et al (20). Moreover, when performing the analyses with leptin as a continuous 
variable, we also obtained an increased risk for CVD to be associated with higher 
leptin levels. In another study by Couillard et al, no significant differences in serum 
leptin concentrations were observed between men with and without ischemic heart 
disease (21). This might be explained by the fact that obesity itself was not a risk 
factor for ischemic heart disease in this study.
Several mechanisms are hypothesized to explain how leptin may increase the 
risk for cardiovascular events. The fact that leptin and its receptor are expressed 
in atherosclerotic plaques (28,29) indicates that leptin may be involved in the 
development of CVD. Leptin has many potentially atherogenic effects, like 
stimulation of endothelial production of pro-atherosclerotic endothelin-1 (30), 
induction of migration and proliferation of vascular smooth muscle cells (31), 
stimulation of inflammatory cells (32) and induction of calcification of vascular 
cells (29). So, leptin is involved in the process of atherosclerosis, which can also 
be concluded from our results that increased leptin levels are associated with an 
increased risk for CVD 
So in summary, serum leptin levels are increased in patients with FCH in 
proportion to their obesity and state of insulin resistance. Elevated leptin levels are 
an independent risk factor for CVD in both FCH patients and in healthy controls.
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Summary
Familial Combined Hyperlipidemia (FCH) was originally identified in the early 
1970’s as a new inherited lipid disorder, characterized by multiple lipoprotein 
phenotypes and strongly associated with premature cardiovascular disease (CVD). 
At present, FCH is the most common inherited hyperlipidemia in humans, affecting 
1-3% of the population and up to 20% of patients with premature myocardial 
infarction. Subjects with FCH have a 2- to 5 fold increased risk of premature 
CVD. Therefore, it is of great importance to identify and treat subjects with FCH 
appropriately. For more than 30 years studies have been going on aiming to solve 
the metabolic background of FCH. Several metabolic abnormalities have been 
suggested, but the exact pathophysiology of FCH is still unknown. Also, the genetic 
basis for FCH has remained obscure. Because there is still no specific marker for 
FCH in clinical practice it demands time-consuming family investigation before the 
diagnosis can be established in individuals.    
The search for metabolic and genetic origin of this lipid disorder has some 
fundamental problems. Not all research groups use the same criteria to establish 
the diagnosis FCH, thereby the lipid phenotype can vary substantially within any 
individual. 
The main aim of this thesis was to evaluate this intra-individual variation in lipid 
phenotype over a period of 5 year and to come to more consistent and unequivocal 
diagnostic criteria for FCH which can be used in clinical practice. Furthermore, we 
investigated the contribution of other metabolic components and factors in relation 
to FCH phenotype and the increased risk of CVD.   
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Re-evaluation of diagnostic criteria of FCH
The most fundamental problem in the research of FCH is that the lipid phenotype 
can vary substantially within an individual. This has been suspected but was not 
convincingly demonstrated. In 1994, blood samples and required data of 687 
family members from 40 well-defined FCH families were collected. In 1999 
we collected again blood samples and required data of 299 of these 687 family 
members from 32 families.
In chapter 2 we evaluated the variability in lipid phenotype expression over this 5-
year period (1994-1999). A total of 32 families including 299 subjects were studied 
in 1994 and 1999. Subjects were classified affected FCH when total cholesterol (TC) 
and/or triglyceride (TG) levels exceeded the 90th percentile adjusted for age and 
gender. In 1994, 93 of the 299 subjects (31%) were affected, whereas 206 subjects 
(69%) were non-affected relatives. In 1999 the diagnosis FCH was consistent in 69 
of the 93 subjects (74%). So, 26% of the affected FCH subjects in 1994 showed 
a sporadic normolipidemic pattern (i.e. TC and/or TG < 90th percentile) in 1999. 
Among the 206 non-affected relatives in 1994, 178 subjects (86%) remained non-
affected in 1999 and 28 (14%) developed a FCH lipid phenotype. So, the diagnosis 
FCH, based on plasma TC and/or TG levels, is consistent in only 74% of the subjects 
over a 5-year period. Thereafter, we studied which characteristics of FCH are more 
consistent and show less intra-individual variability in time.
Two important characteristics of FCH are an elevated apolipoprotein B (apoB) 
concentration and the increased prevalence of small dense low-density lipoprotein 
(sdLDL). We reported that both the apoB concentration and the LDL subfraction 
profile show less variability in time and are more consistently associated with FCH. 
In conclusion, the results emphasize the need for re-evaluation of the diagnostic 
criteria for FCH. We demonstrated in chapter 2 that apoB and sdLDL are attractive 
new candidates to define FCH. Further studies are indicated to evaluate the role of 
apoB and sdLDL as diagnostic criteria for FCH (chapter 3). 
In chapter 3 we intended to define unequivocal diagnostic criteria for FCH based 
on our large FCH cohort with 5-year follow-up. We defined a subject ‘truly’-FCH 
when diagnosed FCH in 1994 and/or 1999 based on the traditional lipid criteria (TC 
and/or TG level above the 90th percentile). One hundred and twenty one of the 299 
subjects (40%) were affected ‘truly’-FCH. It appeared that the combination of TG 
level adjusted for age and gender in combination with absolute apoB and TC level 
adjusted for age and gender most adequately predict FCH. The TG concentration is 
well associated with the concentration of sdLDL. To facilitate the implementation of 
these new diagnostic criteria in clinical practice we provided a nomogram to simply 
and accurately diagnose FCH. In the literature a proposal to redefine FCH was 
undertaken based on hypertriglyceridemia (TG level>1.5 mmol/l) and hyperapoB 
(apoB concentration > 1200 mg/l). The choice of these cut-off points was tentative. 
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Now we showed for the first time that a cut-off point for apoB >1200 mg/l and for 
TG >1.5 mmol/l is justified, based on our large FCH cohort with 5 year follow-
up. So, our data provided evidence that the definition of FCH based on hyperTG 
and hyperapoB, as suggested in the literature, is an alternative when percentiles of 
TG and TC are not available. However, the diagnosis based on the absolute apoB 
value in combination with TG and TC concentrations, both adjusted for age and 
gender, better predicts ‘truly’-FCH compared to hyperTG and hyperapoB (R2 =69% 
versus 50%, respectively). Using the proposed new diagnostic criteria included in a 
nomogram will make it easier to identify patients and test relatives to diagnose FCH. 
Still, the diagnostic phenotype has to be present in more than one family member, 
and at least one individual in the family must have premature CVD to diagnose 
FCH. Confirmation of the relevance of this new definition of FCH in other large 
FCH cohorts is warranted to confirm the unequivocal diagnostic criteria for FCH.
Metabolic features of FCH and its increased risk of CVD
Several disturbances in metabolic pathways have been suggested to be 
pathophysiologically important for the FCH phenotype. The exact pathophysiology 
of FCH is unknown. FCH is, in general thought to be caused by hepatic 
overproduction of very low density lipoprotein (VLDL) particles with or without 
an impaired clearance of TG-rich lipoproteins. There is still more evidence that a 
primary defect in adipose tissue may be the culprit of FCH, resulting in reduced 
fatty acid (FA) trapping in adipose tissue and increased FA flux to the liver resulting 
in high apoB production and contributing to insulin resistance.
In chapter 4 we presented a review about the known pathogenesis of FCH with 
emphasis on the role of insulin resistance, adipose tissue metabolism and FA. 
Abnormalities in several metabolic pathways have been suggested to be important 
in causing the FCH phenotype. Figure 1 shows different possible metabolic 
disturbances in FCH.
The overproduction of VLDL in the liver (I) may result from an increased supply of 
FA to the liver. Thereby the impaired clearance of TG-rich lipoproteins is thought to 
be caused by the diminished lipoprotein lipase (LPL) activity (II) which is caused by 
LPL mutations, increased FFA concentrations, increased apoCIII concentration and/
or insulin resistance. A characteristic of FCH is the increased prevalence of sdLDL 
(III). This may be present due to an increased cholesteryl ester transfer protein (CETP) 
activity, a major gene effect or genetic defect, increased concentrations of precursor 
molecule VLDL, a change in hepatic lipase (HL) and/or LPL activity. The existence 
of insulin resistance (IV), which is a characteristic of FCH, and an important factor 
modulating the FCH phenotype may be caused by a genetic defect, obesity, defects in 
FA metabolism, activation of TNF-α system and an increased leptin concentration. 
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Figure 1 Different possible metabolic disturbances in Familial Combined Hyperlipidemia
Insulin resistance itself results in impaired suppression of hormone sensitive lipase 
(HSL) (V), increased FFA concentrations (VI) and diminished LPL activity (II). 
Over the past few years evidence has emerged to support the hypothesis that a 
primary defect in adipose tissue metabolism may be the culprit of FCH. The defects 
in adipose tissue metabolism (V) may result from a decreased activity of acylation 
stimulatory protein (ASP), a decreased activity of HSL, and/or an increased leptin 
concentration. These defects contribute to insulin resistance (IV) and an increased 
plasma FFA concentration (VI). Other recently proposed defects in adipose tissue 
metabolism are an increased adiponectin concentration or an altered adipocyte fatty 
acid-binding protein (A-FABP). A disturbed FA metabolism may play a central role 
in FCH (VI). Increased FFA may be caused by (genetic) defects in HSL, ASP or leptin 
(V), insulin resistan ce (IV), genetic defects, resistance to lipogenic hormones and 
TNF-α activation. The increased concentration of plasma FFA results in increased 
supply of FFA to the liver (I), insulin resistance (IV) and decreased LPL activity (II).
ApoB as risk predictor in FCH
Hyperlipidemia is strongly correlated with increased risk of CVD. The most 
commonly used approach to estimate CVD risk is based on the measurement 
of plasma TC, TG and HDL-chol with calculation of LDL-chol by means of the 
Friedewald formula. Recently apoB has been suggested to be a more accurate 
clinical measure of atherogenic risk than TC or LDL-chol. 
Metabolics pathways  
in familial combined  
hyperlipidemia
I
VLDL overproduction  
in liver
Fatty acids ↑
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TG + apoB + cholesterol
↓
VLDL overproduction
VI
Increased FFA  
concentration
a. HSL ↓ ASP ↓ leptin ↑
b. Insulin resistance
c. Genetic defects
d. Resistance to lipolitic 
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e. TNF activation
II 
Decreased lipoprotein  
lipase activity
a. LPL mutations
b. Free fatty acids ↑↑
c. APOCIII ↑↑
d. Insulin resistance
III 
Increase in small  
dense LDL
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b. Genetic defects
c. VLDL precursors ↑
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    activity
IV 
Insulin resistance
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V 
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tissue metabolism
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c. Increased leptin
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Therefore, we compared in chapter 5 the measurement of lipids and lipoproteins 
versus assay of apoB for estimation of CVD in our FCH cohort.  We compared in 
506 members of families with FCH these two approaches to select subjects with an 
apparent increased risk of CVD: assay of apoB versus measurement of plasma lipids 
and lipoproteins. When comparing both criteria, there was an overlap of 81.2% at 
apoB levels ≤ 1250 mg/l and of 86.9% at apoB levels > 1250 mg/l. At apoB ≤ 1250 
mg/l all subjects were normolipidemic. At apoB concentrations > 1250 mg/l we 
observed a group with normal plasma lipid levels  (13.1%). In this group, defined as 
normolipidemic hyperapobetalipoproteinemia, and considered to have an increased 
risk for CVD, apoB determination was thus most informative. The selection of the 
subgroup with “normolipidemic hyperapobetalipoproteinemia” on the basis of the 
conventional approach could be refined using a cut off limit for plasma TG < 1. 5 
mmol/l. This limit distinguished optimally between an atherogenic very dense LDL 
pattern versus a dense and buoyant LDL pattern.
Thus, based on the results of this study, the determination of apo B appeared to 
be, if not superior, at least as effective as the conventional lipid and lipoprotein 
parameters in classifying subjects at increased risk for CVD.
Homocysteine and FCH
FCH is associated with an increased risk of CVD. The plasma lipid and lipoprotein 
levels in subjects with FCH are relatively moderately elevated and do not fully 
explain the increased risk of CVD. Hyperhomocysteinemia, a disorder of methionine 
metabolism is also a well-known independent risk factor for CVD. 
In chapter 6 we investigated whether subjects with FCH have a higher plasma 
homocysteine concentration than controls and whether homocysteine contributes 
to the increased risk of CVD in FCH. In total 667 subjects, including 161 subjects 
with FCH, 109 spouses who referenced as control group and 397 normolipidemic 
relatives were studied. FCH was defined by the traditional accepted criteria: plasma 
TC and/or TG levels above the 90th percentile adjusted for age and gender. The 
mean plasma homocysteine concentration in the FCH group was not significantly 
different from the control group with a mean difference of 0.9 µmol/l (CI 95% 
-0.5 to 2.3). Also after adjustment for age and gender the mean difference in 
homocysteine levels between FCH subjects and controls was 0.9 µmol/l (CI 95% 
-0.4 to 2.5). So, the mean plasma homocysteine levels are not elevated in subjects 
with FCH compared to control subjects.  
Thirty-four (21%) of the 161 subjects with FCH had CVD. As FCH is not associated 
with hyperhomocysteinemia, we analyzed normolipidemic relatives and non-
related control subjects together in one group, defined as non-FCH. In this 
non-FCH group 28 (6%) of the 506 subjects had CVD and increased levels of 
homocysteine, defined by levels above the 90th percentile (18.9 µmol/l). They 
were associated with a 2.8 times increased risk of CVD compared to subjects with 
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lower homocysteine levels. In the FCH group increased levels of homocysteine 
were also associated with an increased risk of CVD although the risk estimator was 
lower (1.8 times). So, hyperhomocysteinemia does not disproportionally increase 
the risk of CVD in FCH subjects. We found a positive correlation between plasma 
homocysteine concentration and TC, HDL-chol, LDL-chol and apoB, but none of 
the plasma lipid and lipoprotein levels (TC, TG, HDL-chol, LDL-chol but also apoB 
and sdLDL) were independently associated with the homocysteine level. Our data 
support the hypothesis that plasma concentrations of homocysteine and lipids and 
lipoproteins are independent parameters. Also, insulin resistance was not related 
with plasma homocysteine concentration.
Insulin resistance and FCH
Insulin resistance is associated with a number of metabolic abnormalities, including 
increased TG levels, low HDL-chol, increased sdLDL and increased apoB levels, 
all characteristics of FCH. The presence of insulin resistance may be an important 
factor modulating FCH lipid phenotype expression.
In chapter 7 we explored the role of insulin resistance in FCH lipid phenotype 
expression and the effect of intra-individual changes in lipid phenotype on insulin 
resistance over a 5-year period. FCH was defined by the traditional diagnostic 
criteria including plasma TC and/or TG levels >90th percentile. Insulin resistance 
was assessed by the Homeostasis Model Assessment index (HOMA). For the current 
study we included all subjects with FCH, normolipidemic relatives and spouses 
of whom glucose and insulin levels were available in 1999, resulting in a study 
population of 132 FCH subjects, 350 normolipidemic relatives and 81 spouses, 
who referenced as controls. Among the 132 subjects with FCH, data of lipid and 
glucose/insulin levels were also available in 1994 in 76 subjects. These subjects were 
included in the follow-up to study the interdependence of change in lipid phenotype 
expression in time on insulin resistance. We showed that insulin resistance is a 
characteristic feature of FCH. FCH subjects were more insulin resistant compared 
to controls and normolipidemic relatives (HOMA index 2.9 (95% CI 2.7-3.2), 2.2 
(95% CI 2.0-2.5) and 2.0 (95% CI 1.9-2.2), respectively), even after correction for 
sex, age and BMI. The degree of insulin resistance is dependent on lipid phenotype 
expression. FCH subjects affected based on isolated hypertriglyceridemia or 
combined hyperlipidemia were more insulin resistant, whereas, FCH subjects 
based on isolated hypercholesterolemia were not more insulin resistant compared 
to controls. It appears that subjects with isolated hypercholesterolemia may 
comprise a distinct group within FCH. The mean feature of FCH is the variability in 
lipid phenotype expression within an individual in time. In our 5-year follow-up we 
studied the effect of these intra-individual changes in lipid phenotype expression 
in time on insulin resistance. A change in lipid phenotype expression over 5 year 
was associated with a change in insulin resistance, which is strongly related to the 
increase in BMI. 
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Increase of apoB and sdLDL are important characteristics of FCH. Insulin resistance 
and obesity are also associated with increased levels of apoB and increased 
prevalence of sdLDL. Therefore we explored whether insulin resistance and/or 
obesity could explain the increased apoB levels and high amount of sdLDL in 
FCH. In chapter 7 we showed that obesity and/or insulin resistance do not fully 
account for the elevated levels of apoB and the high prevalence of sdLDL in FCH. 
These results support the physiological concept of separate, but additive, genetic 
determinants in the etiology of the FCH lipid phenotype with modulation by BMI 
and insulin resistance.   
Leptin and FCH
The hormone leptin is involved in the regulation of the energy expenditure and 
appetite via hypothalamic receptors. Obese persons have increased levels of leptin 
and these high levels appear to fail to influence energy intake or expenditure to 
restore fat mass to normal. It is therefore believed that obesity is a state of leptin 
resistance. Elevated levels of leptin are also associated with insulin resistance. 
Both obesity and insulin resistance are characteristics of FCH and therefore leptin 
may be elevated in FCH subjects. So far, only two small studies have studied the 
relationship between leptin concentrations and FCH, with conflicting results. Leptin 
concentration is also associated with an increased risk of CVD. 
In chapter 8 we investigated whether leptin levels in subjects with FCH were 
elevated, independent of their BMI. The second objective was to investigate 
whether leptin levels contribute to the increased risk for CVD in FCH. The study 
population existed of 37 families, comprising 651 subjects, of whom 158 subjects 
were diagnosed as affected FCH, 389 as normolipidemic relatives and 97 subjects 
were spouses. The diagnosis FCH was in this study based on absolute apoB 
levels in combination with TG and TC levels adjusted for age and gender, using 
a nomogram, as described in chapter 3. We observed higher leptin levels in both 
male and female subjects with FCH compared to their normolipidemic relatives 
and controls, which is in proportion to the presence of overweight and insulin 
resistance in FCH subjects. In females, the increased leptin levels were completely 
attributable to BMI, whereas in male FCH subjects increased leptin levels were 
found, independent of overweight, suggesting a defect in adipose tissue metabolism 
in male subjects with FCH. After standardization of leptin levels for both BMI and 
HOMA, no significant difference in leptin levels were found among, subjects with 
FCH, normolipidemic relatives and controls, although the trend of male subjects 
with FCH having higher leptin levels was still present. Multiple linear regression 
analyses showed that the variation in leptin concentration could be explained 
for approximately 71% simply by the variables gender and BMI. When including 
the degree of insulin resistance (HOMA index) in the model, even 74% of the 
variation in leptin concentration could be explained. A serum leptin concentration 
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(standardized for gender and BMI) above the 90th percentile was associated with 
an increased risk of CVD in FCH subjects (OR=3.4 (95% CI: 1.3-9.4)) and in non-
FCH subjects (normolipidemic relatives and spouses together) (OR=3.4 (95% CI: 
1.3-9.2)). The overall OR for the total group was 3.5 (95% CI: 1.8-6.9). So, there is 
an increased risk for CVD associated with leptin levels (standardized for gender and 
BMI) above the 90th percentile in both subjects with FCH and in healthy controls. 
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Conclusions
1. The diagnosis FCH, based on plasma TC and/or TG levels above the 90th 
percentile adjusted for age and gender, is consistent in only 74% of 307 
subjects over a 5-year period. This emphasizes the need for more consistent 
diagnostic criteria for FCH.
2. Absolute apoB levels in combination with TG and TC levels, both adjusted for 
age and gender, are most predictive for diagnosing FCH. A nomogram can be 
used to simply and accurately calculate the probability to be affected FCH in 
clinical practice.
3. The definition of FCH based on hyperTG (TG levels > 1.5 mmol/l) hyperapoB 
(apoB>1200 mg/l) is an alternative when percentiles of TG and TC are not 
available.
4. The culprit of the pathophysiology of FCH may be a defect in adipose tissue 
metabolism and/or adipose tissue hormonal factors, resulting in reduced fatty 
acid (FA) trapping in adipose tissue and increased FA flux to the liver resulting 
in high apoB production and contributing to insulin resistance.
5. ApoB values are, if not superior, at least as effective as the conventional lipid 
and lipoprotein parameters in classifying subjects with FCH at increased risk 
for CVD.
6. Subjects with FCH have no increased levels of plasma homocysteine 
compared to controls. Plasma homocysteine concentration and lipids and 
lipoproteins are independent parameters. In FCH, plasma homocysteine does 
not disproportional contribute to the increased risk of CVD.
7. Insulin resistance is a characteristic feature of FCH, independent of BMI and 
dependent on lipid phenotype expression. 
8. The increased levels of apoB and the prevalence of small dense LDL in FCH 
are determined by genetic factors and are modulated by BMI and insulin 
resistance. 
9. Serum leptin levels are increased in subjects with FCH in proportion to their 
obesity and state of insulin resistance. Increased leptin levels in FCH contribute 
to the increased risk for CVD, independent of gender, BMI and insulin 
resistance. 
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Future perspectives
Confirmation of the new diagnostic criteria of FCH
FCH is a heterogeneous disorder with absence of a specific clinical, metabolic or 
genetic marker. A major step forward in the process of unravelling the metabolic 
and genetic background of this disease is the introduction of unequivocal diagnostic 
criteria, as we proposed using the nomogram. Confirmation of the relevance of the 
new definition of FCH in other large FCH cohorts is therefore warranted.
Genetic studies
After confirmation of the diagnostic criteria, re-evaluation of the genome-scans in 
all FCH cohorts should be performed, preferably by combining data sets to increase 
power. Recently, a genome scan was performed in our FCH cohort in collaboration 
with the NIH (USA). Currently, linkage analysis and quantitative trait analyses are 
in process.
Depending on the results of the linkage analysis, potential candidate genes in 
the regions of linkage can be further explored. Recently, the thioredoxin interacting 
protein (TXNIP) gene and the upstream transcription factor 1 (USF1) gene were 
found to be associated with FCH as a result of linkage analysis in the Finnish FCH 
cohort. However, in our FCH cohort we could exclude TXNIP to be involved in the 
pathogenesis of FCH. Again, differences in diagnostic criteria could be the culprit 
in the opposing results. 
Furthermore, the candidate gene approach can be used based on the 
pathophysiology of FCH. For example, evidence for a disturbed adipose tissue 
metabolism as the culprit of FCH accumulates. Therefore several genes of 
adipocytokines potentially involved in a disturbed adipose tissue metabolism are 
of interest, including leptin, adiponectin and resistin. Not only genetic variations 
in the promotor regions of the genes of adipocytokines but also mRNA expression 
studies in biopsies of adipose tissue should be performed to further evaluate the role 
of adipose tissue in the pathophysiology of FCH. 
Just recently, an exciting new type of genomic variation emerged, the so-called 
large-scale copy number variation (LCV), involving gain or loss of relatively large 
stretches of genomic DNA. It is anticipated that at least some of the LCVs may serve 
as predisposing factors for the development of human multifactorial diseases. So, 
systematic LCV studies will be of large interest in FCH populations. 
Metabolic studies
To further explore the role of adipose tissue in the pathophysiology of FCH it is of 
interest to measure several adipocytokines in plasma of FCH patients, including 
leptin, adiponectin and resistin in combination with in vivo turnover studies in 
adipose tissue. 
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FCH is characterised by a number of abnormalities which correspond with 
symptoms of the insulin resistance syndrome. Interventions purely aimed at 
improving insulin resistance should be performed to further evaluate the role of 
insulin resistance in the pathophysiology of FCH. Therefore, it is of interest to study 
the effect of thiazolidinediones, a class of drug which improves insulin sensitivity, 
on the FCH phenotype. 
FCH is the most common inherited lipid disorder with increased risk of CVD, 
which cannot only be explained by the relatively mildly elevated lipid levels. 
Additional risk factors contributing to the increased risk of CVD should be explored, 
including both pro-inflammatory and oxidative stress parameters. Interventions 
aimed at reducing these risk factors should be developed. 
Imaging of atherosclerosis 
To estimate the risk of CVD without the need to screen or know all potential risk 
factors it is necessary to be able to measure the burden of atherosclerosis. Non-
invasive measurements of atherosclerosis including both functional and structural 
changes in the arterial wall of FCH patients will be informative to calculate the risk 
of CVD and evaluate the effect of interventions aimed at eliminating risk factors.
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Samenvatting
Familiaire Gecombineerde Hyperlipidemie (FCH) werd voor het eerst beschreven 
in 1973 als een erfelijke vetstofwisselingsziekte. Deze ziekte wordt gekenmerkt 
door verhoogde plasmalipiden, dit wil zeggen een verhoogd totaal cholesterol-(TC) 
gehalte met of zonder een verhoogd triglyceride- (TG) gehalte en geeft een verhoogde 
kans op hart- en vaatziekten al op jonge leeftijd; patiënten met FCH hebben een 2 - 
5 maal verhoogde kans op hart- en vaatziekten voor het 60e levensjaar. Momenteel 
is FCH de meest voorkomende erfelijke vetstofwisselingsstoornis, 1-3% van de 
bevolking en 20% van de patiënten met een hartinfarct voor het 60e levensjaar zijn 
aangedaan. Daarom is het van groot belang patiënten met FCH zo vroeg mogelijk 
op te sporen en te behandelen. Al meer dan 30 jaar wordt er onderzoek verricht 
naar de oorzaak van FCH. Vele metabole stoornissen zijn gesuggereerd, maar de 
exacte oorzaak van FCH is nog steeds onbekend. Ook de genetische oorzaak van 
FCH is nog niet opgehelderd. Omdat er nog steeds geen specifieke marker voor 
FCH is in de klinische praktijk, is tijdrovend familieonderzoek nodig voor het 
stellen van de diagnose FCH in een individuele patiënt; om de diagnose FCH te 
stellen moet zowel bij de patiënt als bij tenminste 1 familielid een verhoogd TC- 
en/of TG-gehalte gemeten worden in combinatie met het voorkomen van hart- en 
vaatziekten voor het 60e levensjaar in de familie. 
Het onderzoek naar de metabole en genetische achtergrond van deze ziekte 
kent enkele belangrijke problemen. Ten eerste gebruiken de verschillende 
onderzoeksgroepen over de wereld die zich bezig houden met FCH niet altijd 
dezelfde diagnostische criteria. Daarnaast kunnen de TC- en TG-waarden  binnen 
een individu variëren in de tijd (wisselend lipidenfenotype).
Het doel van dit onderzoek was om de variatie in lipidenfenotype binnen een 
individu te evalueren over een periode van 5 jaar en daarmee te komen tot meer 
consistente en duidelijke diagnostische criteria voor FCH die gebruikt kunnen 
worden in de klinische praktijk. Daarnaast hebben we de bijdrage van diverse 
metabole variabelen onderzocht in relatie tot FCH en het verhoogde risico op hart- 
en vaatziekten.
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Her-evaluatie van de diagnostische criteria van FCH 
Het belangrijkste probleem bij het onderzoek naar FCH is het wisselende 
lipidenfenotype dat kan optreden binnen een individu. Dit  wisselende fenotype 
werd vermoed maar was nog niet overtuigend bewezen. In 1994 waren klinische 
gegevens en bloedmonsters van 687 familieleden van 40 FCH families verzameld. 
In 1999 hebben we opnieuw bloedmonsters en klinische gegevens verzameld bij 
299 van deze 687 personen uit 32 families.
In hoofdstuk 2 werd de variabiliteit in lipidenfenotype over een periode van 
5 jaar (1994-1999) geëvalueerd. In totaal 299 personen van 32 families werden 
bestudeerd. Personen werden geclassificeerd als aangedaan met FCH wanneer zij 
een TC- en/of TG-gehalte boven de 90e percentiel hadden, gecorrigeerd voor leeftijd 
en geslacht. In 1994, waren 93 (31%) van de 299 personen aangedaan, 206 (69%) 
waren niet aangedane familieleden. In 1999 bleken 69 (74%) van de 93 personen 
weer aangedaan te zijn. Dus, 26% van de met FCH aangedane personen in 1994 
waren niet aangedaan in 1999 (TC and/of TG <90e percentiel). Van de 206 niet 
aangedane familieleden in 1994 bleken 178 (86%) personen ook niet aangedaan 
te zijn in 1999 en 28 (14%) waren in 1999 wel aangedaan. Dus, de diagnose 
FCH, gebaseerd op plasma TC- and/of TG-concentratie was slechts consistent in 
74 % van de personen over een periode van 5 jaar. Hierna bestudeerden we welke 
andere karakteristieken van FCH potentieel meer betrouwbaar zijn en minder intra-
individuele variatie vertonen in de tijd. Twee belangrijke karakteristieken van FCH 
zijn een verhoogde apolipoproteine B- (apoB)  concentratie en de aanwezigheid 
van meer small dense low-density lipoprotein (sdLDL). We toonden aan dat deze 
beide karakteristieken minder variabel zijn in de tijd en consistenter geassocieerd 
met FCH. Als conclusie tonen de resultaten van deze studie de noodzaak aan tot 
her-evaluatie van de bestaande diagnostische criteria voor FCH. 
In hoofdstuk 3 stelden wij ons tot doel om te komen tot nieuwe, meer consistente 
diagnostische criteria voor FCH gebaseerd op ons grote FCH cohort met 5 jaar 
follow-up. We definieerden een persoon als hebbende FCH wanneer in 1994 dan 
wel in 1999 de diagnose FCH gesteld was gebaseerd op de traditionele criteria (TC 
en/of TG >90e  percentiel (gecorrigeerd voor leeftijd en geslacht)). Op basis van deze 
criteria hadden 121 (40%) van de 299 personen FCH. Vervolgens werd geëvalueerd 
welke (combinatie van) karakteristieken van FCH het meest betrouwbaar FCH 
voorspellen. De combinatie van TG-waarde (gecorrigeerd voor leeftijd en geslacht) 
met absoluut apoB- en TC-gehalte (gecorrigeerd voor leeftijd en geslacht) bleek het 
meest adequaat voor de diagnosestelling FCH. Om deze nieuwe definitie van FCH 
makkelijk toe te passen in de klinische praktijk werd een nomogram ontworpen 
waarmee op simpele en accurate wijze de diagnose FCH gesteld kan worden. 
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In de literatuur was een voorstel verschenen om FCH te definiëren op basis van 
hypertriglyceridemie (TG >1.5 mmol/l) en hyperapoB (apoB concentratie >1200 
mg/l). De keuze van deze afkappunten was tentatief. In onze studie tonen we aan 
dat de afkappunten voor apoB >1200 mg/l en TG >1.5 mmol/l gerechtvaardigd 
zijn. De definitie FCH gebaseerd op hyperTG en hyperapoB is dus een alternatief 
wanneer de percentielen voor TC en TG niet voorhanden zijn. Echter de diagnose 
FCH gebaseerd op de absolute apoB-concentratie in combinatie met TC- en 
TG-concentraties (beide gecorrigeerd voor leeftijd en geslacht) heeft een betere 
voorspelling voor de diagnose FCH vergeleken met hyperTG en hyperapoB (R2=69% 
versus 50%, respectievelijk). Het gebruik maken van de voorgestelde nieuwe 
criteria met behulp van het nomogram maakt het  makkelijker FCH patiënten te 
definiëren en familieleden te testen. Wel blijft de voorwaarde bestaan dat meer dan 
één familielid moet zijn aangedaan en  er hart- en vaatziekte moet voorkomen in de 
familie onder het 60e levensjaar voor men de diagnose FCH mag stellen.  
Metabole factoren bij FCH en het verhoogde risico op hart- en 
vaatziekten
Verschillende stoornissen in metabole processen dragen bij aan het ontstaan 
van FCH. De exacte pathofysiologie van FCH is echter nog steeds onbekend. 
Overproductie van TG-rijke very-low density lipoprotein (VLDL) deeltjes door 
de lever met of zonder een afgenomen afbraak van TG-rijke deeltjes zijn twee 
belangrijke stoornissen die leiden tot FCH. Er komt steeds meer bewijs dat een 
primaire stoornis in het vetweefsel mogelijk de belangrijkste oorzaak is voor 
FCH. Een gestoord vetweefselmetabolisme resulteert in een verlaagde opname 
van vetzuren in het vetweefsel en dus een verhoogde stroom van vetzuren naar 
de lever. Een verhoogd aanbod van vetzuren aan de lever leidt tot een verhoogde 
apoB-productie en draagt bij tot insulineresistentie, een ander belangrijk kenmerk 
van FCH.
In hoofdstuk 4 wordt een overzicht gegeven over de tot op heden bekende 
oorzaken van FCH met de nadruk op de rol van insulineresistentie, vetweefsel en 
vetzuren. Stoornissen in meerdere metabole processen dragen bij aan het ontstaan 
van FCH (Figuur 1).
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Figuur 1  Verschillende metabole stoornissen die mogelijk bijdragen aan het ontstaan van FCH.
(I) VLDL overproductie door de lever wordt veroorzaakt door verhoogde aanvoer van vrije vetzuren 
aan de lever. (II) Verminderde afbraak van TG-rijke deeltjes kan veroorzaakt worden door verminderde 
lipoproteine-lipase (LPL) activiteit hetgeen een gevolg kan zijn van (a) LPL mutaties, (b) verhoogde 
vrije-vetzuren-concentratie, (c) verhoogde apolipoprotein CIII-concentratie of (d) insulineresistentie. 
(III) Meer small dense LDL kan het gevolg zijn van (a) verhoogde cholesteryl ester transfer protein 
(CETP) activiteit, (b) verhoogde concentratie van precursor VLDL of (c) verandering in leverlipase (HL) 
en/of LPL-activiteit. (IV) Insulineresistentie kan het resultaat zijn van (a) overgewicht, (b) stoornissen 
in vetweefselmetabolisme, (c) activatie van tumor necrosis factor  (TNF) of (d) verhoogde leptine-
concentratie (V) stoornissen in het vetweefselmetabolisme kunnen het resultaat zijn van (a) verlaagde 
acylation-stimulatory-protein (ASP)-activiteit, (b) verlaagde hormone-sensitive lipase-(HSL) activiteit 
, (c) verhoogde leptine-concentratie of (d) verlaagde adiponectine-concentratie (VI) verhoogde 
concentratie van vrije vetzuren is potentieel het gevolg van verlaagde HSL, ASP activiteit, verhoogde 
leptine-concentratie, (b) insulineresistentie, (c) resistentie voor lipogene hormonen, (d) TNF activatie. 
Al deze metabole stoornissen (I – VI) kunnen ook berusten op genetische afwijkingen.
ApoB als risicovoorspeller voor hart- en vaatziekten in FCH
Hyperlipidemie is sterk geassocieerd met een verhoogd risico op hart- en 
vaatziekten. De meest gebruikte methode om het risico op hart- en vaatziekten 
te voorspellen is gebaseerd op de bepaling van plasma TC, TG en high-density 
lipoprotein cholesterol (HDL-c) met berekening van LDL-c met de Friedewald 
formule.  Recente studies laten zien dat apoB mogelijk de beste parameter is om 
het risico op hart- en vaatziekten te voorspellen.
Metabole stoornissen  
in Familiare Gecombineerde  
Hyperlipidemie
I
VLDL overproductie  
in de lever
Vetzuren ↑
↓ 
TG + apoB + TC
↓
VLDL overproductie
VI
Verhoogde vrije  
vetzuren concentratie
a. HSL ↓ ASP ↓ leptine ↑
b. Insulineresistentie
c. Resistentie voor 
    lipogene hormones
d. TNF activatie
II 
Vertraagde lipoproteine  
lipase activiteit
a. LPL mutaties
b. Vrije vetzuren ↑↑
c. APOCIII ↑↑
d. Insulineresistentie
III 
Verhoogde aanwezigheid  
van small dense LDL
a. CETP ↑
b. VLDL precursors ↑
c. Verandering in HL-LPL  
    activiteit
IV 
Insulineresistentie
a. Overgewicht
b. Vrije vetzuren concentratie ↑
c. Activatie van TNF 
d. Leptine-concentration ↑V 
Stoornis in   
vetweefsel metabolisme
a. ASP ↓ 
b. HSL ↓ 
c. Leptine ↑
d. Adiponectine ↓ 
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In hoofdstuk 5 is de bepaling van lipiden versus die van apoB in het classificeren 
van personen met een verhoogd risico op hart- en vaatziekten in onze FCH-
populatie bestudeerd. Bij het vergelijken van beide criteria bleken alle personen 
met een apoB-concentratie ≤1250 mg/l ook normale plasmalipidenwaarden te 
hebben. Echter bij een apoB concentratie >1250 mg/l bleek er een groep personen 
(13,1%) te zijn met normale plasmalipidenwaarden. Een verhoogde apoB-
concentratie >1250 mg/l is geassocieerd in de literatuur met een verhoogd risico op 
hart- en vaatziekten. Bij deze personen, die we definieerden als normolipidemisch 
hyperapoB, is de bepaling van apoB dus meer informatief dan de lipidenwaarden. 
Dus, gebaseerd op de resultaten van deze studie, blijkt de bepaling van apoB in 
ieder geval even effectief en mogelijk superieur te zijn boven de conventionele 
bepaling van lipiden bij het classificeren van personen met een verhoogd risico op 
hart- en vaatziekten.
Homocysteine en FCH
FCH is geassocieerd met een verhoogd risico op hart- en vaatziekten. De 
plasmalipiden en lipoproteinenconcentraties in patiënten met FCH zijn relatief 
slechts matig verhoogd en kunnen niet volledig het verhoogde risico op 
hart- en vaatziekten verklaren. Een te hoog homocysteinegehalte in het bloed 
(hyperhomocysteinemie) is ook een bekende onafhankelijke risicofactor voor 
hart- en vaatziekten. Hyperhomocysteinemie is het gevolg van een stoornis in het 
methionine metabolisme.
In hoofdstuk 6 werd onderzocht of patiënten met FCH een hogere plasma- 
homocysteineconcentratie hebben in vergelijking met controles, en of de 
homocysteineconcentratie bijdraagt tot een verhoogd risico op hart- en vaatziekten 
in FCH. In totaal werden 667 personen bestudeerd waaronder 161 patiënten met 
FCH, 109 partners (controle groep) en 397 normolipidemische familieleden.
FCH werd gedefinieerd op basis van de traditionele criteria (TC- en/of TG- 
concentratie boven het 90e percentiel gecorrigeerd voor leeftijd en geslacht). 
De gemiddelde plasmahomocysteineconcentratie in de FCH groep was niet 
significant verschillend van de controle groep met een gemiddeld verschil van 
0.9 µmol/l (CI 95% -0.5 tot 2.3). Ook na correctie voor leeftijd en geslacht bleef 
het gemiddelde verschil in homocysteineconcentratie 0.9 µmol/l (CI 95% -0.4 tot 
2.5). De gemiddelde plasmahomocysteineconcentratie is dus niet verhoogd in FCH 
patiënten vergeleken met controles.
Vier en dertig (21%) van de 161 patiënten met FCH hadden hart- en vaatziekten. 
Daar FCH niet is geassocieerd met hyperhomocysteinemie analyseerden we de 
normolipidemische familieleden en controles in één groep gedefinieerd als niet-
FCH. In deze niet-FCH groep hadden 28 (6%) van de 506 personen hart- en 
vaatziekten en een verhoogde homocysteineconcentratie, gedefinieerd als een 
concentratie boven het 90e percentiel (18.9 µmol/l). Dit was geassocieerd met 
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een 2.8 maal verhoogd risico op hart- en vaatziekten in vergelijking met personen 
van de niet-FCH groep met een homocysteineconcentratie <18.9 µmol/l. In de 
FCH groep waren verhoogde homocysteineconcentraties ook geassocieerd met 
verhoogd risico op hart- en vaatziekten ofschoon de risico schatting lager was 
(1.8 maal). Hyperhomocysteinemie verhoogt dus niet disproportioneel het risico 
op hart- en vaatziekten in FCH patiënten. Daarnaast vonden we een positieve 
correlatie tussen plasmahomocysteineconcentratie en TC, HDL-c, LDL-c en apoB, 
maar geen enkele van de plasmalipiden of lipoproteinen (TC, TG, HDL-c, LDL-c, 
apoB of sdLDL) was onafhankelijk geassocieerd met de homocysteineconcentratie. 
Onze gegevens ondersteunen dan ook de hypothese dat de plasmaconcentraties 
van homocysteine en lipiden en lipoproteinen onafhankelijke parameters zijn. Ook 
insulineresistentie was niet gerelateerd aan de plasmahomocysteineconcentratie.
Insulineresistentie en FCH
Insulineresistentie wordt geassocieerd met een aantal metabole afwijkingen, zoals 
een verhoogde concentratie van TG, verlaagde HDL-c-concentratie, meer sdLDL 
en een verhoogde apoB-concentratie, welke ook allen karakteristieken zijn van 
FCH. Insulineresistentie is dus een potentieel belangrijke factor die van invloed zou 
kunnen zijn op de expressie van het lipidenfenotype FCH.
In hoofdstuk 7 werd de rol van insulineresistentie op de expressie van het FCH 
lipidenfenotype en het effect van intra-individuele veranderingen in lipidenfenotype 
op insulineresistentie over een periode van 5 jaar bestudeerd. FCH werd gedefinieerd 
volgens de traditionele criteria (plasma TC en/of TG >90e percentiel, gecorrigeerd 
voor leeftijd en geslacht). Insulineresistentie werd bepaald met behulp van de 
Homeostasis Model Assessment Index (HOMA).  De studie populatie bestond uit 132 
FCH patiënten, 350 normolipidemische familieleden en 81 controles. Van 76 van de 
132 FCH patiënten waren ook gegevens van lipiden-, glucose- en insuline-waarden 
aanwezig uit 1994. Deze 76 personen werden opgenomen in de follow-up studie. 
Insulineresistentie bleek een karakteristiek van FCH te zijn. FCH patiënten waren 
meer insulineresistent vergeleken met controles en normolipidemische familieleden 
(HOMA index 2.9 (CI 95% 2.6 –3.2), 2.2 (CI 95% 2.0-2.5) en 2.0 (CI95% 1.9-2.2), 
respectievelijk), ook na correctie voor geslacht, leeftijd en body mass index (BMI). 
De ernst van insulineresistentie was geassocieerd met het lipidenfenotype; FCH 
patiënten aangedaan gebaseerd op een geïsoleerd verhoogd TG-gehalte of een 
combinatie van verhoogd TC- en TG-gehalte waren meer insulineresistent dan de 
controle personen, terwijl patiënten met FCH gebaseerd op een geïsoleerd verhoogd 
TC-gehalte niet meer insulineresistent waren dan controles. Deze data suggereren 
dat personen met een geïsoleerd verhoogd TC-gehalte mogelijk een aparte groep 
vormen binnen FCH. 
Een belangrijk kenmerk van FCH is de intra-individuele variabiliteit in 
lipidenfenotype in de tijd. In onze 5 jaar follow-up bestudeerden we de effecten van 
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deze intra-individuele veranderingen in lipidenfenotype op insulineresistentie. Een 
verandering in lipidenfenotype over 5 jaar was geassocieerd met een verandering 
in insulineresistentie, welke sterk gecorreleerd was aan BMI.
Toename van apoB en sdLDL zijn belangrijke karakteristieken van FCH. 
Insulineresistentie en overgewicht zijn ook geassocieerd met een verhoogde 
apoB-concentratie en een verhoogde prevalentie van sdLDL. We onderzochten 
of insulineresistentie en/of overgewicht de verhoogde apoB-concentratie en 
toegenomen prevalentie van sdLDL in FCH konden verklaren. In hoofdstuk 7 
toonden we aan dat overgewicht en/of insulineresistentie de verhoogde apoB- 
concentratie en de prevalentie van sdLDL niet konden verklaren. Deze resultaten 
ondersteunen het fysiologische concept dat afzonderlijke, genetische determinanten 
bijdragen aan het FCH lipidenfenotype, met modulatie door overgewicht en 
insulineresistentie.
Leptine en FCH
Het hormoon leptine is betrokken bij de regulatie van het energieverbruik en 
eetlust via hypothalame receptoren. Mensen met overgewicht hebben een 
verhoogde concentratie van leptine, echter deze verhoogde leptinewaarden leiden 
niet tot een normalisering van energieverbruik/opname dan wel herstel van de 
vetmassa. Overgewicht lijkt dus een toestand van leptineresistentie te zijn. Een 
verhoogde leptineconcentratie is ook geassocieerd met insulineresistentie en hart- 
en vaatziekten. Overgewicht en insulineresistentie zijn beide karakteristieken van 
FCH. Een verhoogd leptinegehalte zou dus potentieel aanwezig kunnen zijn in 
FCH. Tot dusver hadden slechts twee studies de relatie tussen leptineconcentratie 
en FCH onderzocht met tegengestelde resultaten. 
In hoofdstuk 8  onderzochten we of de leptineconcentratie verhoogd is bij 
patiënten met FCH, onafhankelijk van BMI en insulineresistentie. Ten tweede 
bestudeerden we of de leptineconcentratie bijdraagt tot het verhoogde risico 
op hart- en vaatziekten in patiënten met FCH. De studiepopulatie bestond 
uit 37 families, met in totaal 651 personen, 158 patiënten met FCH, 389 
normolipidemische familieleden en 97 controles. De diagnose FCH werd in deze 
studie gebaseerd op absolute apoB- concentratie in combinatie met TC- en TG-
concentraties, beide gecorrigeerd voor leeftijd en geslacht, gebruik makend van 
het nomogram, zoals beschreven in hoofdstuk 3. We vonden hogere concentraties 
van leptine in zowel mannen als vrouwen in de FCH groep vergeleken met de 
normolipidemische familieleden en controles, hetgeen was toe te schrijven aan 
het feit dat patiënten met FCH meer insulineresistent zijn en er sprake is van 
overgewicht. Bij de vrouwen was de verhoogde leptineconcentratie volledig toe 
te schrijven aan overgewicht, echter bij de mannen met FCH was de verhoogde 
concentratie leptine onafhankelijk van het overgewicht. Dit suggereert een defect 
in het vetweefselmetabolisme in mannelijke personen met FCH. Na correctie voor 
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beide, zowel overgewicht als insulineresistentie, werd er geen significant verschil 
meer in leptineconcentratie gevonden tussen de FCH groep, normolipidemische 
groep en controles, ofschoon de trend dat mannelijke patiënten met FCH een 
hogere concentratie leptine hebben nog aanwezig was. Multiple lineaire regressie 
toonde aan dat de variatie in leptineconcentratie voor bijna 71% verklaard kon 
worden door de variabelen, geslacht en overgewicht en 74% door de variabelen, 
geslacht, overgewicht en insulineresistentie. Een serumleptineconcentratie 
(gecorrigeerd voor geslacht en BMI) boven het 90e percentiel was geassocieerd met 
een verhoogd risico op hart- en vaatziekten in FCH patiënten (OR=3.4 (95%CI:
1.3-9.4)) en in niet-FCH personen (normolipidemische familieleden en controles) 
(OR=3.4 (95%CI: 1.3-9.2)). De OR voor de totale groep was 3.5 (95%CI: 1.8-6.9). 
Een verhoogde leptineconcentratie is dus geassocieerd met een verhoogd risico op 
hart- en vaatziekten in patiënten met FCH en in gezonde controles.
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Conclusies
1. De diagnose FCH, gebaseerd op plasma TC- en/of TG-concentratie >90e 
percentiel (gecorrigeerd voor leeftijd en geslacht), is consistent in slechts 74% 
van de 307 onderzochte personen over een periode van 5 jaar. Dit ondersteunt 
de noodzaak om te komen tot meer consistente diagnostische criteria voor 
FCH.
2. De absolute apoB-concentratie in combinatie met TC- en TG-concentraties, 
(beide gecorrigeerd voor leeftijd en geslacht) voorspellen het best de diagnose 
FCH. Het ontworpen nomogram kan gebruikt worden in de klinische praktijk 
om makkelijk en adequaat de kans te berekenen of iemand FCH heeft.
3. De diagnose FCH gebaseerd op hyperTG (TG concentratie >1.5 mmol/l) en 
hyperapoB (apoB >1200 mg/l) is een alternatief wanneer de percentielen van 
TC- en TG-waarden niet voorhanden zijn.
4. Een stoornis in het vetweefselmetabolisme is mogelijk een van de belangrijkste 
factoren in de pathofysiologie van FCH. Een gestoord vetweefselmetabolisme 
leidt tot een verlaagde opname van vetzuren in het vetweefsel en een 
verhoogde stroom van vetzuren naar de lever. Dit veroorzaakt een verhoogde 
apoB-aanmaak en draagt bij tot insulineresistentie, beiden belangrijke 
kenmerken van FCH. 
5. ApoB-waarden zijn, indien niet superieur, tenminste even effectief in 
vergelijking met de conventionele lipiden- en lipoproteinen-waarden in 
het classificeren van FCH patiënten met een verhoogd risico op hart- en 
vaatziekten.
6. Patiënten met FCH hebben geen verhoogde plasmahomocysteinespiegels 
vergeleken met controles. De plasmahomocysteineconcentratie en lipiden- en 
lipoproteinen-waarden zijn onafhankelijke parameters. In patiënten met FCH, 
draagt plasmahomocysteine niet disproportioneel bij aan het verhoogde risico 
op hart- en vaatziekten.
7. Insulineresistentie is een karakteristiek van FCH, onafhankelijk van overgewicht 
en afhankelijk van lipidenfenotype expressie.
8. De verhoogde concentratie van apoB en de prevalentie van sdLDL in FCH 
worden bepaald door genetische factoren en gemoduleerd door overgewicht 
en insulineresistentie.
9. De serumleptineconcentratie is verhoogd in patiënten met FCH evenredig met 
de mate van overgewicht en insulineresistentie. Verhoogde leptineconcentraties 
in FCH dragen bij tot het verhoogde risico op hart- en vaatziekten, onafhankelijk 
van geslacht, BMI en insulineresistentie. 
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Dankwoord
Een proefschrift schrijven doe je gelukkig niet alleen. Hierbij zou ik ook dan 
iedereen willen bedanken die een bijdrage heeft geleverd aan de totstandkoming 
hiervan. 
Allereerst alle patiënten en hun familieleden die bereid waren op nuchtere maag 
bloedmonsters af te staan, en speciale dank aan de 299 personen die dit 5 jaar 
geleden ook al eens hadden gedaan. 
Mijn co-promotor, beste Jacqueline, jij was de stuwende kracht achter dit 
onderzoek. Bedankt voor alle begeleiding, je snelle opbouwende kritiek op de 
diverse versies van de manuscripten en natuurlijk het gezellige reisgezelschap 
tijdens de buitenlandse congressen. 
Mijn promotor, beste Anton, bedankt dat je me de mogelijkheid gaf dit onderzoek 
te verrichten, het originele onderzoeksvoorstel zag er iets anders uit maar toch is 
het tot een promotie gekomen.
Beste Till, jij stond ‘s ochtends om 6.00 uur vaak al klaar om weer mee op stap 
te gaan om de verschillende families in den lande te gaan prikken. Ook de 
voorbereidingen hiervoor waren altijd piekfijn in orde. Hiervoor mijn dank. 
Ook de mensen van het lab interne wil ik hartelijk danken voor al het werk wat zij 
verricht hebben met alle bloedmonsters waarmee ik iedere keer weer aankwam.
Jan Hendriks ben ik veel dank verschuldigd voor de vele lastige statistische analyses 
van hoofdstuk 2 en 3 en voor het vervaardigen van het nomogram. 
Miranda Keijzer en Martin den Heijer, bedankt voor het uitvoeren van de GEE 
analyses van hoofdstuk 6 en 7. 
Mijn medeauteurs wil ik bedanken voor hun bijdrage aan de verschillende artikelen. 
Bas Bredie voor het beschikbaar stellen van de gegevens van de 299 personen uit 
zijn onderzoeksperiode. 
Gerly van der Vleuten en Ewoud ter Avest wens ik veel succes met het verdere 
onderzoek naar FCH.
Al mijn mede-onderzoekers uit deze periode bedankt voor de adviezen, de nodige 
afleiding, de lunches etc.. 
Speciale dank aan al mijn medebewoners van de buitenhoek. We hebben in die 
jaren heel wat leuke en minder leuke dingen van het (onderzoeks)leven mogen 
delen, bedankt voor jullie luisterend oor en de gezelligheid tijdens het werk.
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Marit en Lieke, fijn dat jullie mijn paranimfen wilden zijn. Hopelijk blijft onze 
vriendschap nog lang bestaan zoals deze nu is.
Lieve ouders, bedankt voor jullie altijd aanwezige steun. Mama, door het vele 
oppassen, zeker de laatste maanden leken de donderdag en vrijdag wel je vaste 
oppasdagen te zijn, kan het werk nu opgeleverd worden. Papa, een promotie is 
voor jou niets nieuws maar een dochter promoveren had je misschien toch niet 
verwacht. Bedankt voor al je begeleiding op de achtergrond.
Lieve familie en schoonfamilie, bedankt voor jullie interesse in mijn bezigheden en 
het “feestje” is er toch van gekomen!
Lieve Lieke en Bart, jullie zijn mijn mooiste geschenk. Lieve Guus, ik mocht je niet 
bedanken maar toch bedankt voor alles! De “promotiekamer” kan nu weer een 
andere bestemming krijgen.  
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Curriculum Vitae
Mario Veerkamp werd geboren op 8 november 1967 te Nijmegen. In 1986 
behaalde zij het VWO diploma aan het Canisius College te Nijmegen. Het jaar 
daarop volgend heeft zij de propedeuse fysiotherapie behaald. Zij startte met de 
studie geneeskunde in 1987 aan de Katholieke Universiteit Nijmegen. In 1991 
ontving zij haar doctoraal diploma geneeskunde en in 1994 haar arts diploma. 
Van augustus 1994 tot juli 1995 is zij werkzaam geweest als arts-assistent 
geneeskunde niet in opleiding op de afdeling interne geneeskunde van het 
Universitair Medisch Centrum St. Radboud, waarna zij startte met de opleiding tot 
internist in het St. Maartensgasthuis te Venlo (opleider Dr. J.J.J. Mattousch). Vanaf 
april 1997 vervolgde zij haar opleiding in het Universitair Medisch Centrum St. 
Radboud (opleider prof. dr. J.W.M. van der Meer). Van januari 1999 tot november 
2002 werkte zij deels fulltime, deels parttime aan het onderzoek waarvan de 
resultaten verwerkt zijn in dit proefschrift. In juli 2003 volgde de registratie tot 
internist. Vanaf januari 2004 is zij in opleiding tot reumatoloog in het Universitair 
Medisch Centrum St. Radboud (opleider prof. dr. P.L.C.M. van Riel). Zij is getrouwd 
met Guus Franssen en samen hebben zij twee kinderen, Lieke (2001), Bart (2003) 
en is er één op komst. 
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